id	sid	tid	token	lemma	pos
admet-496	1	1	the	the	DET
admet-496	1	2	role	role	NOUN
admet-496	1	3	of	of	ADP
admet-496	1	4	pharmacology	pharmacology	NOUN
admet-496	1	5	in	in	ADP
admet-496	1	6	anticancer	anticancer	NOUN
admet-496	1	7	drug	drug	PROPN
admet-496	1	8	development	development	PROPN
admet-496	1	9	doi	doi	PROPN
admet-496	1	10	:	:	PUNCT
admet-496	1	11	10.5599	10.5599	NUM
admet-496	1	12	/	/	SYM
admet-496	1	13	admet.6.1.496	admet.6.1.496	PROPN
admet-496	1	14	4	4	NUM
admet-496	1	15	admet	admet	X
admet-496	1	16	&	&	CCONJ
admet-496	1	17	dmpk	dmpk	PROPN
admet-496	1	18	6(1	6(1	NUM
admet-496	1	19	)	)	PUNCT
admet-496	1	20	(	(	PUNCT
admet-496	1	21	2018	2018	NUM
admet-496	1	22	)	)	PUNCT
admet-496	1	23	4	4	NUM
admet-496	1	24	-	-	SYM
admet-496	1	25	14	14	NUM
admet-496	1	26	;	;	PUNCT
admet-496	1	27	doi	doi	NOUN
admet-496	1	28	:	:	PUNCT
admet-496	1	29	http://dx.doi.org/10.5599/admet.6.1.496	http://dx.doi.org/10.5599/admet.6.1.496	NOUN
admet-496	1	30	open	open	ADJ
admet-496	1	31	access	access	NOUN
admet-496	1	32	:	:	PUNCT
admet-496	1	33	issn	issn	PROPN
admet-496	1	34	:	:	PUNCT
admet-496	1	35	1848	1848	NUM
admet-496	1	36	-	-	SYM
admet-496	1	37	7718	7718	NUM
admet-496	1	38	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-496	1	39	review	review	VERB
admet-496	1	40	the	the	DET
admet-496	1	41	role	role	NOUN
admet-496	1	42	of	of	ADP
admet-496	1	43	pharmacology	pharmacology	NOUN
admet-496	1	44	in	in	ADP
admet-496	1	45	anticancer	anticancer	NOUN
admet-496	1	46	drug	drug	NOUN
admet-496	1	47	development	development	PROPN
admet-496	1	48	godefridus	godefridus	PROPN
admet-496	1	49	j.	j.	PROPN
admet-496	1	50	peters1	peters1	PROPN
admet-496	1	51	,	,	PUNCT
admet-496	1	52	*	*	PROPN
admet-496	1	53	,	,	PUNCT
admet-496	1	54	anne	anne	PROPN
admet-496	1	55	-	-	PUNCT
admet-496	1	56	sophie	sophie	PROPN
admet-496	1	57	govaerts2	govaerts2	NOUN
admet-496	1	58	,	,	PUNCT
admet-496	1	59	hans	hans	PROPN
admet-496	1	60	r	r	PROPN
admet-496	1	61	hendriks3	hendriks3	PROPN
admet-496	1	62	,	,	PUNCT
admet-496	1	63	for	for	ADP
admet-496	1	64	the	the	DET
admet-496	1	65	eortc	eortc	ADJ
admet-496	1	66	pharmacology	pharmacology	NOUN
admet-496	1	67	and	and	CCONJ
admet-496	1	68	molecular	molecular	ADJ
admet-496	1	69	mechanism	mechanism	NOUN
admet-496	1	70	group	group	NOUN
admet-496	1	71	1	1	NUM
admet-496	1	72	dept	dept	NOUN
admet-496	1	73	of	of	ADP
admet-496	1	74	medical	medical	ADJ
admet-496	1	75	oncology	oncology	NOUN
admet-496	1	76	,	,	PUNCT
admet-496	1	77	vu	vu	PROPN
admet-496	1	78	university	university	PROPN
admet-496	1	79	medical	medical	ADJ
admet-496	1	80	center	center	NOUN
admet-496	1	81	,	,	PUNCT
admet-496	1	82	po	po	PROPN
admet-496	1	83	box	box	PROPN
admet-496	1	84	7057	7057	NUM
admet-496	1	85	,	,	PUNCT
admet-496	1	86	1007	1007	NUM
admet-496	1	87	mb	mb	ADP
admet-496	1	88	amsterdam	amsterdam	PROPN
admet-496	1	89	,	,	PUNCT
admet-496	1	90	the	the	DET
admet-496	1	91	netherlands	netherlands	PROPN
admet-496	1	92	2	2	NUM
admet-496	1	93	eortc	eortc	PROPN
admet-496	1	94	,	,	PUNCT
admet-496	1	95	avenue	avenue	PROPN
admet-496	1	96	e.	e.	PROPN
admet-496	1	97	mounier	mounier	PROPN
admet-496	1	98	83/11	83/11	PROPN
admet-496	1	99	,	,	PUNCT
admet-496	1	100	1200	1200	NUM
admet-496	1	101	brussels	brussel	NOUN
admet-496	1	102	,	,	PUNCT
admet-496	1	103	belgium	belgium	PROPN
admet-496	1	104	3	3	PROPN
admet-496	1	105	hendriks	hendriks	PROPN
admet-496	1	106	pharmaceutical	pharmaceutical	PROPN
admet-496	1	107	consulting	consulting	PROPN
admet-496	1	108	,	,	PUNCT
admet-496	1	109	j.	j.	PROPN
admet-496	1	110	wagenaarstraat	wagenaarstraat	PROPN
admet-496	1	111	67	67	NUM
admet-496	1	112	,	,	PUNCT
admet-496	1	113	1443	1443	NUM
admet-496	1	114	lr	lr	NOUN
admet-496	1	115	purmerend	purmerend	NOUN
admet-496	1	116	,	,	PUNCT
admet-496	1	117	the	the	DET
admet-496	1	118	netherlands	netherlands	PROPN
admet-496	1	119	*	*	PUNCT
admet-496	1	120	corresponding	correspond	VERB
admet-496	1	121	author	author	NOUN
admet-496	1	122	:	:	PUNCT
admet-496	1	123	e	e	NOUN
admet-496	1	124	-	-	NOUN
admet-496	1	125	mail	mail	NOUN
admet-496	1	126	:	:	PUNCT
admet-496	1	127	gj.peters@vumc.nl	gj.peters@vumc.nl	NOUN
admet-496	1	128	received	receive	VERB
admet-496	1	129	:	:	PUNCT
admet-496	1	130	january	january	PROPN
admet-496	1	131	11	11	NUM
admet-496	1	132	,	,	PUNCT
admet-496	1	133	2018	2018	NUM
admet-496	1	134	;	;	PUNCT
admet-496	1	135	revised	revise	VERB
admet-496	1	136	:	:	PUNCT
admet-496	1	137	march	march	PROPN
admet-496	1	138	07	07	NUM
admet-496	1	139	,	,	PUNCT
admet-496	1	140	2018	2018	NUM
admet-496	1	141	;	;	PUNCT
admet-496	1	142	published	publish	VERB
admet-496	1	143	:	:	PUNCT
admet-496	1	144	march	march	PROPN
admet-496	1	145	25	25	NUM
admet-496	1	146	,	,	PUNCT
admet-496	1	147	2018	2018	NUM
admet-496	1	148	abstract	abstract	ADJ
admet-496	1	149	drug	drug	NOUN
admet-496	1	150	development	development	NOUN
admet-496	1	151	consists	consist	VERB
admet-496	1	152	of	of	ADP
admet-496	1	153	many	many	ADJ
admet-496	1	154	sequential	sequential	ADJ
admet-496	1	155	and	and	CCONJ
admet-496	1	156	parallel	parallel	ADJ
admet-496	1	157	steps	step	NOUN
admet-496	1	158	;	;	PUNCT
admet-496	1	159	failure	failure	NOUN
admet-496	1	160	in	in	ADP
admet-496	1	161	one	one	NUM
admet-496	1	162	of	of	ADP
admet-496	1	163	the	the	DET
admet-496	1	164	steps	step	NOUN
admet-496	1	165	can	can	AUX
admet-496	1	166	lead	lead	VERB
admet-496	1	167	to	to	ADP
admet-496	1	168	discontinuation	discontinuation	NOUN
admet-496	1	169	of	of	ADP
admet-496	1	170	the	the	DET
admet-496	1	171	process	process	NOUN
admet-496	1	172	.	.	PUNCT
admet-496	2	1	the	the	DET
admet-496	2	2	process	process	NOUN
admet-496	2	3	is	be	AUX
admet-496	2	4	time	time	NOUN
admet-496	2	5	-	-	PUNCT
admet-496	2	6	consuming	consume	VERB
admet-496	2	7	and	and	CCONJ
admet-496	2	8	very	very	ADV
admet-496	2	9	expensive	expensive	ADJ
admet-496	2	10	,	,	PUNCT
admet-496	2	11	especially	especially	ADV
admet-496	2	12	the	the	DET
admet-496	2	13	clinical	clinical	ADJ
admet-496	2	14	phase	phase	NOUN
admet-496	2	15	.	.	PUNCT
admet-496	3	1	in	in	ADP
admet-496	3	2	order	order	NOUN
admet-496	3	3	to	to	PART
admet-496	3	4	enhance	enhance	VERB
admet-496	3	5	cancer	cancer	NOUN
admet-496	3	6	drug	drug	NOUN
admet-496	3	7	development	development	NOUN
admet-496	3	8	in	in	ADP
admet-496	3	9	the	the	DET
admet-496	3	10	1980s	1980	NOUN
admet-496	3	11	,	,	PUNCT
admet-496	3	12	the	the	DET
admet-496	3	13	national	national	PROPN
admet-496	3	14	cancer	cancer	PROPN
admet-496	3	15	institute	institute	PROPN
admet-496	3	16	(	(	PUNCT
admet-496	3	17	nci	nci	PROPN
admet-496	3	18	)	)	PUNCT
admet-496	3	19	adopted	adopt	VERB
admet-496	3	20	a	a	DET
admet-496	3	21	new	new	ADJ
admet-496	3	22	screening	screening	NOUN
admet-496	3	23	system	system	NOUN
admet-496	3	24	using	use	VERB
admet-496	3	25	60	60	NUM
admet-496	3	26	different	different	ADJ
admet-496	3	27	tumour	tumour	NOUN
admet-496	3	28	cell	cell	NOUN
admet-496	3	29	lines	line	NOUN
admet-496	3	30	from	from	ADP
admet-496	3	31	various	various	ADJ
admet-496	3	32	histologies	histology	NOUN
admet-496	3	33	.	.	PUNCT
admet-496	4	1	all	all	DET
admet-496	4	2	standard	standard	ADJ
admet-496	4	3	drugs	drug	NOUN
admet-496	4	4	were	be	AUX
admet-496	4	5	tested	test	VERB
admet-496	4	6	in	in	ADP
admet-496	4	7	this	this	DET
admet-496	4	8	panel	panel	NOUN
admet-496	4	9	and	and	CCONJ
admet-496	4	10	it	it	PRON
admet-496	4	11	is	be	AUX
admet-496	4	12	still	still	ADV
admet-496	4	13	open	open	ADJ
admet-496	4	14	for	for	ADP
admet-496	4	15	testing	testing	NOUN
admet-496	4	16	of	of	ADP
admet-496	4	17	new	new	ADJ
admet-496	4	18	chemical	chemical	NOUN
admet-496	4	19	entities	entity	NOUN
admet-496	4	20	(	(	PUNCT
admet-496	4	21	nce	nce	NOUN
admet-496	4	22	)	)	PUNCT
admet-496	4	23	of	of	ADP
admet-496	4	24	potential	potential	ADJ
admet-496	4	25	interest	interest	NOUN
admet-496	4	26	.	.	PUNCT
admet-496	5	1	the	the	DET
admet-496	5	2	european	european	PROPN
admet-496	5	3	nci	nci	PROPN
admet-496	5	4	compounds	compound	VERB
admet-496	5	5	initiative	initiative	NOUN
admet-496	5	6	,	,	PUNCT
admet-496	5	7	a	a	DET
admet-496	5	8	collaborative	collaborative	ADJ
admet-496	5	9	programme	programme	NOUN
admet-496	5	10	of	of	ADP
admet-496	5	11	the	the	DET
admet-496	5	12	nci	nci	PROPN
admet-496	5	13	,	,	PUNCT
admet-496	5	14	the	the	DET
admet-496	5	15	cancer	cancer	NOUN
admet-496	5	16	research	research	NOUN
admet-496	5	17	campaign	campaign	NOUN
admet-496	5	18	(	(	PUNCT
admet-496	5	19	crc	crc	NOUN
admet-496	5	20	;	;	PUNCT
admet-496	5	21	now	now	ADV
admet-496	5	22	cruk	cruk	NOUN
admet-496	5	23	)	)	PUNCT
admet-496	5	24	and	and	CCONJ
admet-496	5	25	the	the	DET
admet-496	5	26	pharmacology	pharmacology	NOUN
admet-496	5	27	and	and	CCONJ
admet-496	5	28	molecular	molecular	ADJ
admet-496	5	29	mechanism	mechanism	NOUN
admet-496	5	30	group	group	NOUN
admet-496	5	31	(	(	PUNCT
admet-496	5	32	pamm	pamm	PROPN
admet-496	5	33	)	)	PUNCT
admet-496	5	34	of	of	ADP
admet-496	5	35	the	the	DET
admet-496	5	36	eortc	eortc	ADJ
admet-496	5	37	(	(	PUNCT
admet-496	5	38	european	european	ADJ
admet-496	5	39	organization	organization	NOUN
admet-496	5	40	on	on	ADP
admet-496	5	41	research	research	NOUN
admet-496	5	42	and	and	CCONJ
admet-496	5	43	treatment	treatment	NOUN
admet-496	5	44	of	of	ADP
admet-496	5	45	cancer	cancer	NOUN
admet-496	5	46	)	)	PUNCT
admet-496	5	47	,	,	PUNCT
admet-496	5	48	was	be	AUX
admet-496	5	49	initiated	initiate	VERB
admet-496	5	50	in	in	ADP
admet-496	5	51	1993	1993	NUM
admet-496	5	52	.	.	PUNCT
admet-496	6	1	the	the	DET
admet-496	6	2	programme	programme	NOUN
admet-496	6	3	aimed	aim	VERB
admet-496	6	4	to	to	PART
admet-496	6	5	help	help	VERB
admet-496	6	6	the	the	DET
admet-496	6	7	nci	nci	NOUN
admet-496	6	8	reducing	reduce	VERB
admet-496	6	9	its	its	PRON
admet-496	6	10	backlog	backlog	NOUN
admet-496	6	11	of	of	ADP
admet-496	6	12	in	in	ADP
admet-496	6	13	vivo	vivo	NOUN
admet-496	6	14	testing	testing	NOUN
admet-496	6	15	by	by	ADP
admet-496	6	16	further	further	ADJ
admet-496	6	17	evaluation	evaluation	NOUN
admet-496	6	18	of	of	ADP
admet-496	6	19	interesting	interesting	ADJ
admet-496	6	20	european	european	ADJ
admet-496	6	21	compounds	compound	NOUN
admet-496	6	22	using	use	VERB
admet-496	6	23	a	a	DET
admet-496	6	24	pharmacologically	pharmacologically	ADV
admet-496	6	25	directed	direct	VERB
admet-496	6	26	approach	approach	NOUN
admet-496	6	27	.	.	PUNCT
admet-496	7	1	considerable	considerable	ADJ
admet-496	7	2	multidisciplinary	multidisciplinary	ADJ
admet-496	7	3	expertise	expertise	NOUN
admet-496	7	4	in	in	ADP
admet-496	7	5	drug	drug	NOUN
admet-496	7	6	development	development	NOUN
admet-496	7	7	was	be	AUX
admet-496	7	8	combined	combine	VERB
admet-496	7	9	by	by	ADP
admet-496	7	10	the	the	DET
admet-496	7	11	crc	crc	NOUN
admet-496	7	12	and	and	CCONJ
admet-496	7	13	eortc	eortc	ADJ
admet-496	7	14	-	-	PUNCT
admet-496	7	15	pamm	pamm	NOUN
admet-496	7	16	:	:	PUNCT
admet-496	7	17	chemists	chemist	NOUN
admet-496	7	18	,	,	PUNCT
admet-496	7	19	pharmacists	pharmacist	NOUN
admet-496	7	20	,	,	PUNCT
admet-496	7	21	biologists	biologist	NOUN
admet-496	7	22	,	,	PUNCT
admet-496	7	23	pharmacologists	pharmacologist	NOUN
admet-496	7	24	,	,	PUNCT
admet-496	7	25	oncologists	oncologist	NOUN
admet-496	7	26	.	.	PUNCT
admet-496	8	1	selection	selection	NOUN
admet-496	8	2	criteria	criterion	NOUN
admet-496	8	3	for	for	ADP
admet-496	8	4	european	european	PROPN
admet-496	8	5	nci	nci	PROPN
admet-496	8	6	compounds	compound	NOUN
admet-496	8	7	included	include	VERB
admet-496	8	8	novelty	novelty	NOUN
admet-496	8	9	of	of	ADP
admet-496	8	10	the	the	DET
admet-496	8	11	nce	nce	NOUN
admet-496	8	12	,	,	PUNCT
admet-496	8	13	in	in	ADP
admet-496	8	14	vitro	vitro	X
admet-496	8	15	activity	activity	NOUN
admet-496	8	16	,	,	PUNCT
admet-496	8	17	if	if	SCONJ
admet-496	8	18	available	available	ADJ
admet-496	8	19	in	in	ADP
admet-496	8	20	vivo	vivo	ADJ
admet-496	8	21	and	and	CCONJ
admet-496	8	22	hollow	hollow	ADJ
admet-496	8	23	fibre	fibre	NOUN
admet-496	8	24	activity	activity	NOUN
admet-496	8	25	,	,	PUNCT
admet-496	8	26	and	and	CCONJ
admet-496	8	27	compare	compare	VERB
admet-496	8	28	negativity	negativity	NOUN
admet-496	8	29	.	.	PUNCT
admet-496	9	1	over	over	ADP
admet-496	9	2	a	a	DET
admet-496	9	3	period	period	NOUN
admet-496	9	4	of	of	ADP
admet-496	9	5	more	more	ADJ
admet-496	9	6	than	than	ADP
admet-496	9	7	20	20	NUM
admet-496	9	8	years	year	NOUN
admet-496	9	9	95	95	NUM
admet-496	9	10	out	out	ADP
admet-496	9	11	of	of	ADP
admet-496	9	12	approximately	approximately	ADV
admet-496	9	13	2,000	2,000	NUM
admet-496	9	14	reviewed	review	VERB
admet-496	9	15	compounds	compound	NOUN
admet-496	9	16	were	be	AUX
admet-496	9	17	selected	select	VERB
admet-496	9	18	.	.	PUNCT
admet-496	10	1	these	these	DET
admet-496	10	2	compounds	compound	NOUN
admet-496	10	3	were	be	AUX
admet-496	10	4	put	put	VERB
admet-496	10	5	through	through	ADP
admet-496	10	6	a	a	DET
admet-496	10	7	series	series	NOUN
admet-496	10	8	of	of	ADP
admet-496	10	9	stepwise	stepwise	ADJ
admet-496	10	10	pharmacological	pharmacological	NOUN
admet-496	10	11	tests	test	NOUN
admet-496	10	12	comprising	comprise	VERB
admet-496	10	13	solubility	solubility	NOUN
admet-496	10	14	(	(	PUNCT
admet-496	10	15	suitable	suitable	ADJ
admet-496	10	16	formulation	formulation	NOUN
admet-496	10	17	to	to	PART
admet-496	10	18	administer	administer	VERB
admet-496	10	19	the	the	DET
admet-496	10	20	nce	nce	NOUN
admet-496	10	21	to	to	PART
admet-496	10	22	mice	mouse	NOUN
admet-496	10	23	)	)	PUNCT
admet-496	10	24	,	,	PUNCT
admet-496	10	25	feasibility	feasibility	NOUN
admet-496	10	26	to	to	PART
admet-496	10	27	develop	develop	VERB
admet-496	10	28	a	a	DET
admet-496	10	29	simple	simple	ADJ
admet-496	10	30	analytical	analytical	ADJ
admet-496	10	31	assay	assay	NOUN
admet-496	10	32	(	(	PUNCT
admet-496	10	33	usually	usually	ADV
admet-496	10	34	hplc	hplc	NOUN
admet-496	10	35	)	)	PUNCT
admet-496	10	36	,	,	PUNCT
admet-496	10	37	limited	limited	ADJ
admet-496	10	38	toxicology	toxicology	NOUN
admet-496	10	39	and	and	CCONJ
admet-496	10	40	angiogenic	angiogenic	ADJ
admet-496	10	41	properties	property	NOUN
admet-496	10	42	.	.	PUNCT
admet-496	11	1	this	this	DET
admet-496	11	2	paper	paper	NOUN
admet-496	11	3	provides	provide	VERB
admet-496	11	4	examples	example	NOUN
admet-496	11	5	to	to	PART
admet-496	11	6	illustrate	illustrate	VERB
admet-496	11	7	the	the	DET
admet-496	11	8	rigorousness	rigorousness	NOUN
admet-496	11	9	of	of	ADP
admet-496	11	10	the	the	DET
admet-496	11	11	elimination	elimination	NOUN
admet-496	11	12	process	process	NOUN
admet-496	11	13	of	of	ADP
admet-496	11	14	the	the	DET
admet-496	11	15	compounds	compound	NOUN
admet-496	11	16	and	and	CCONJ
admet-496	11	17	discusses	discuss	VERB
admet-496	11	18	the	the	DET
admet-496	11	19	way	way	NOUN
admet-496	11	20	to	to	PART
admet-496	11	21	improve	improve	VERB
admet-496	11	22	the	the	DET
admet-496	11	23	process	process	NOUN
admet-496	11	24	by	by	ADP
admet-496	11	25	inclusion	inclusion	NOUN
admet-496	11	26	of	of	ADP
admet-496	11	27	more	more	ADJ
admet-496	11	28	physico	physico	NOUN
admet-496	11	29	-	-	PUNCT
admet-496	11	30	chemical	chemical	NOUN
admet-496	11	31	parameters	parameter	NOUN
admet-496	11	32	.	.	PUNCT
admet-496	12	1	keywords	keyword	NOUN
admet-496	12	2	eortc	eortc	ADJ
admet-496	12	3	-	-	PUNCT
admet-496	12	4	pamm	pamm	NOUN
admet-496	12	5	;	;	PUNCT
admet-496	12	6	nci	nci	PROPN
admet-496	12	7	;	;	PUNCT
admet-496	12	8	cruk	cruk	NOUN
admet-496	12	9	;	;	PUNCT
admet-496	12	10	in	in	ADP
admet-496	12	11	vitro	vitro	X
admet-496	12	12	screen	screen	NOUN
admet-496	12	13	;	;	PUNCT
admet-496	12	14	pharmacological	pharmacological	ADJ
admet-496	12	15	approach	approach	NOUN
admet-496	12	16	;	;	PUNCT
admet-496	12	17	anticancer	anticancer	NOUN
admet-496	12	18	drug	drug	NOUN
admet-496	12	19	development	development	NOUN
admet-496	12	20	;	;	PUNCT
admet-496	12	21	european	european	PROPN
admet-496	12	22	nci	nci	PROPN
admet-496	12	23	compounds	compound	VERB
admet-496	12	24	introduction	introduction	NOUN
admet-496	12	25	anticancer	anticancer	NOUN
admet-496	12	26	drug	drug	NOUN
admet-496	12	27	development	development	NOUN
admet-496	12	28	is	be	AUX
admet-496	12	29	a	a	DET
admet-496	12	30	collaborative	collaborative	ADJ
admet-496	12	31	effort	effort	NOUN
admet-496	12	32	.	.	PUNCT
admet-496	13	1	when	when	SCONJ
admet-496	13	2	a	a	DET
admet-496	13	3	compound	compound	NOUN
admet-496	13	4	has	have	AUX
admet-496	13	5	been	be	AUX
admet-496	13	6	synthesised	synthesise	VERB
admet-496	13	7	chemically	chemically	ADV
admet-496	13	8	or	or	CCONJ
admet-496	13	9	isolated	isolate	VERB
admet-496	13	10	from	from	ADP
admet-496	13	11	a	a	DET
admet-496	13	12	specific	specific	ADJ
admet-496	13	13	source	source	NOUN
admet-496	13	14	,	,	PUNCT
admet-496	13	15	e.g.	e.g.	ADV
admet-496	13	16	a	a	DET
admet-496	13	17	natural	natural	ADJ
admet-496	13	18	product	product	NOUN
admet-496	13	19	,	,	PUNCT
admet-496	13	20	it	it	PRON
admet-496	13	21	will	will	AUX
admet-496	13	22	be	be	AUX
admet-496	13	23	characterised	characterise	VERB
admet-496	13	24	chemically	chemically	ADV
admet-496	13	25	,	,	PUNCT
admet-496	13	26	physically	physically	ADV
admet-496	13	27	,	,	PUNCT
admet-496	13	28	pharmacologically	pharmacologically	ADV
admet-496	13	29	,	,	PUNCT
admet-496	13	30	pharmaceutically	pharmaceutically	NOUN
admet-496	13	31	,	,	PUNCT
admet-496	13	32	toxicologically	toxicologically	ADV
admet-496	13	33	and	and	CCONJ
admet-496	13	34	biologically	biologically	ADV
admet-496	13	35	,	,	PUNCT
admet-496	13	36	requiring	require	VERB
admet-496	13	37	the	the	DET
admet-496	13	38	input	input	NOUN
admet-496	13	39	from	from	ADP
admet-496	13	40	various	various	ADJ
admet-496	13	41	disciplines	discipline	NOUN
admet-496	13	42	.	.	PUNCT
admet-496	14	1	when	when	SCONJ
admet-496	14	2	a	a	DET
admet-496	14	3	compound	compound	NOUN
admet-496	14	4	passes	pass	VERB
admet-496	14	5	all	all	DET
admet-496	14	6	these	these	DET
admet-496	14	7	steps	step	NOUN
admet-496	14	8	successfully	successfully	ADV
admet-496	14	9	it	it	PRON
admet-496	14	10	continues	continue	VERB
admet-496	14	11	to	to	ADP
admet-496	14	12	clinical	clinical	ADJ
admet-496	14	13	development	development	NOUN
admet-496	14	14	[	[	X
admet-496	14	15	1	1	NUM
admet-496	14	16	]	]	PUNCT
admet-496	14	17	.	.	PUNCT
admet-496	15	1	a	a	DET
admet-496	15	2	tightly	tightly	ADV
admet-496	15	3	controlled	control	VERB
admet-496	15	4	process	process	NOUN
admet-496	15	5	precedes	precede	VERB
admet-496	15	6	the	the	DET
admet-496	15	7	first	first	ADJ
admet-496	15	8	administration	administration	NOUN
admet-496	15	9	to	to	ADP
admet-496	15	10	a	a	DET
admet-496	15	11	patient	patient	NOUN
admet-496	15	12	.	.	PUNCT
admet-496	16	1	this	this	DET
admet-496	16	2	process	process	NOUN
admet-496	16	3	is	be	AUX
admet-496	16	4	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	PROPN
admet-496	16	5	mailto:gj.peters@vumc.nl	mailto:gj.peters@vumc.nl	PROPN
admet-496	16	6	admet	admet	PROPN
admet-496	16	7	&	&	CCONJ
admet-496	16	8	dmpk	dmpk	PROPN
admet-496	16	9	6(1	6(1	NUM
admet-496	16	10	)	)	PUNCT
admet-496	16	11	(	(	PUNCT
admet-496	16	12	2018	2018	NUM
admet-496	16	13	)	)	PUNCT
admet-496	16	14	4	4	NUM
admet-496	16	15	-	-	SYM
admet-496	16	16	14	14	NUM
admet-496	16	17	the	the	DET
admet-496	16	18	role	role	NOUN
admet-496	16	19	of	of	ADP
admet-496	16	20	pharmacology	pharmacology	NOUN
admet-496	16	21	in	in	ADP
admet-496	16	22	anticancer	anticancer	NOUN
admet-496	16	23	drug	drug	PROPN
admet-496	16	24	development	development	PROPN
admet-496	16	25	doi	doi	PROPN
admet-496	16	26	:	:	PUNCT
admet-496	16	27	10.5599	10.5599	NUM
admet-496	16	28	/	/	SYM
admet-496	16	29	admet.6.1.496	admet.6.1.496	VERB
admet-496	16	30	5	5	NUM
admet-496	16	31	subject	subject	ADJ
admet-496	16	32	to	to	ADP
admet-496	16	33	many	many	ADJ
admet-496	16	34	regulations	regulation	NOUN
admet-496	16	35	and	and	CCONJ
admet-496	16	36	requires	require	VERB
admet-496	16	37	approval	approval	NOUN
admet-496	16	38	by	by	ADP
admet-496	16	39	local	local	ADJ
admet-496	16	40	hospital	hospital	NOUN
admet-496	16	41	medical	medical	ADJ
admet-496	16	42	ethical	ethical	ADJ
admet-496	16	43	review	review	NOUN
admet-496	16	44	boards	board	NOUN
admet-496	16	45	and	and	CCONJ
admet-496	16	46	national	national	ADJ
admet-496	16	47	competent	competent	ADJ
admet-496	16	48	authorities	authority	NOUN
admet-496	16	49	.	.	PUNCT
admet-496	17	1	this	this	DET
admet-496	17	2	first	first	ADJ
admet-496	17	3	step	step	NOUN
admet-496	17	4	is	be	AUX
admet-496	17	5	the	the	DET
admet-496	17	6	phase	phase	NOUN
admet-496	17	7	i	i	PRON
admet-496	17	8	clinical	clinical	ADJ
admet-496	17	9	study	study	NOUN
admet-496	17	10	,	,	PUNCT
admet-496	17	11	in	in	ADP
admet-496	17	12	which	which	PRON
admet-496	17	13	the	the	DET
admet-496	17	14	safety	safety	NOUN
admet-496	17	15	,	,	PUNCT
admet-496	17	16	side	side	NOUN
admet-496	17	17	effects	effect	NOUN
admet-496	17	18	and	and	CCONJ
admet-496	17	19	best	good	ADJ
admet-496	17	20	dose	dose	NOUN
admet-496	17	21	of	of	ADP
admet-496	17	22	a	a	DET
admet-496	17	23	drug	drug	NOUN
admet-496	17	24	are	be	AUX
admet-496	17	25	determined	determine	VERB
admet-496	17	26	.	.	PUNCT
admet-496	18	1	the	the	DET
admet-496	18	2	latter	latter	ADJ
admet-496	18	3	can	can	AUX
admet-496	18	4	be	be	AUX
admet-496	18	5	the	the	DET
admet-496	18	6	maximum	maximum	ADJ
admet-496	18	7	tolerated	tolerate	VERB
admet-496	18	8	dose	dose	PROPN
admet-496	18	9	(	(	PUNCT
admet-496	18	10	mtd	mtd	PROPN
admet-496	18	11	)	)	PUNCT
admet-496	18	12	for	for	ADP
admet-496	18	13	cytotoxics	cytotoxic	NOUN
admet-496	18	14	or	or	CCONJ
admet-496	18	15	the	the	DET
admet-496	18	16	maximum	maximum	ADJ
admet-496	18	17	effective	effective	ADJ
admet-496	18	18	dose	dose	NOUN
admet-496	18	19	(	(	PUNCT
admet-496	18	20	usually	usually	ADV
admet-496	18	21	lower	low	ADJ
admet-496	18	22	than	than	ADP
admet-496	18	23	the	the	DET
admet-496	18	24	mtd	mtd	PROPN
admet-496	18	25	)	)	PUNCT
admet-496	18	26	for	for	ADP
admet-496	18	27	compounds	compound	NOUN
admet-496	18	28	affecting	affect	VERB
admet-496	18	29	signaling	signal	VERB
admet-496	18	30	pathways	pathway	NOUN
admet-496	18	31	.	.	PUNCT
admet-496	19	1	this	this	DET
admet-496	19	2	dose	dose	NOUN
admet-496	19	3	is	be	AUX
admet-496	19	4	used	use	VERB
admet-496	19	5	to	to	PART
admet-496	19	6	determine	determine	VERB
admet-496	19	7	the	the	DET
admet-496	19	8	antitumor	antitumor	PROPN
admet-496	19	9	activity	activity	NOUN
admet-496	19	10	of	of	ADP
admet-496	19	11	the	the	DET
admet-496	19	12	agent	agent	NOUN
admet-496	19	13	in	in	ADP
admet-496	19	14	a	a	DET
admet-496	19	15	phase	phase	NOUN
admet-496	19	16	ii	ii	NOUN
admet-496	19	17	study	study	NOUN
admet-496	19	18	[	[	X
admet-496	19	19	1	1	NUM
admet-496	19	20	-	-	SYM
admet-496	19	21	3	3	NUM
admet-496	19	22	]	]	PUNCT
admet-496	19	23	.	.	PUNCT
admet-496	20	1	in	in	ADP
admet-496	20	2	the	the	DET
admet-496	20	3	classical	classical	ADJ
admet-496	20	4	drug	drug	NOUN
admet-496	20	5	development	development	NOUN
admet-496	20	6	setting	setting	NOUN
admet-496	20	7	,	,	PUNCT
admet-496	20	8	an	an	DET
admet-496	20	9	active	active	ADJ
admet-496	20	10	compound	compound	NOUN
admet-496	20	11	(	(	PUNCT
admet-496	20	12	antitumor	antitumor	NOUN
admet-496	20	13	activity	activity	NOUN
admet-496	20	14	comparable	comparable	ADJ
admet-496	20	15	to	to	ADP
admet-496	20	16	that	that	PRON
admet-496	20	17	of	of	ADP
admet-496	20	18	standard	standard	ADJ
admet-496	20	19	therapy	therapy	NOUN
admet-496	20	20	)	)	PUNCT
admet-496	20	21	,	,	PUNCT
admet-496	20	22	will	will	AUX
admet-496	20	23	proceed	proceed	VERB
admet-496	20	24	to	to	ADP
admet-496	20	25	a	a	DET
admet-496	20	26	randomised	randomised	ADJ
admet-496	20	27	phase	phase	NOUN
admet-496	20	28	iii	iii	NUM
admet-496	20	29	study	study	NOUN
admet-496	20	30	in	in	ADP
admet-496	20	31	which	which	PRON
admet-496	20	32	the	the	DET
admet-496	20	33	new	new	ADJ
admet-496	20	34	drug	drug	NOUN
admet-496	20	35	will	will	AUX
admet-496	20	36	be	be	AUX
admet-496	20	37	compared	compare	VERB
admet-496	20	38	to	to	ADP
admet-496	20	39	the	the	DET
admet-496	20	40	standard	standard	ADJ
admet-496	20	41	therapy	therapy	NOUN
admet-496	20	42	or	or	CCONJ
admet-496	20	43	placebo	placebo	NOUN
admet-496	20	44	.	.	PUNCT
admet-496	21	1	however	however	ADV
admet-496	21	2	,	,	PUNCT
admet-496	21	3	with	with	ADP
admet-496	21	4	several	several	ADJ
admet-496	21	5	novel	novel	ADJ
admet-496	21	6	compounds	compound	NOUN
admet-496	21	7	in	in	ADP
admet-496	21	8	which	which	PRON
admet-496	21	9	a	a	DET
admet-496	21	10	target	target	NOUN
admet-496	21	11	is	be	AUX
admet-496	21	12	defined	define	VERB
admet-496	21	13	,	,	PUNCT
admet-496	21	14	a	a	DET
admet-496	21	15	phase	phase	NOUN
admet-496	21	16	i	i	PRON
admet-496	21	17	study	study	VERB
admet-496	21	18	may	may	AUX
admet-496	21	19	be	be	AUX
admet-496	21	20	expanded	expand	VERB
admet-496	21	21	to	to	PART
admet-496	21	22	include	include	VERB
admet-496	21	23	only	only	ADJ
admet-496	21	24	patients	patient	NOUN
admet-496	21	25	with	with	ADP
admet-496	21	26	predefined	predefine	VERB
admet-496	21	27	biomarkers	biomarker	NOUN
admet-496	21	28	[	[	X
admet-496	21	29	3	3	NUM
admet-496	21	30	]	]	PUNCT
admet-496	21	31	.	.	PUNCT
admet-496	22	1	drugs	drug	NOUN
admet-496	22	2	can	can	AUX
admet-496	22	3	obtain	obtain	VERB
admet-496	22	4	market	market	NOUN
admet-496	22	5	approval	approval	NOUN
admet-496	22	6	from	from	ADP
admet-496	22	7	medicines	medicine	NOUN
admet-496	22	8	agencies	agency	NOUN
admet-496	22	9	such	such	ADJ
admet-496	22	10	as	as	ADP
admet-496	22	11	the	the	DET
admet-496	22	12	ema	ema	PROPN
admet-496	22	13	and	and	CCONJ
admet-496	22	14	fda	fda	PROPN
admet-496	22	15	,	,	PUNCT
admet-496	22	16	based	base	VERB
admet-496	22	17	on	on	ADP
admet-496	22	18	an	an	DET
admet-496	22	19	extensive	extensive	ADJ
admet-496	22	20	risk	risk	NOUN
admet-496	22	21	/	/	SYM
admet-496	22	22	benefit	benefit	NOUN
admet-496	22	23	ratio	ratio	NOUN
admet-496	22	24	evaluation	evaluation	NOUN
admet-496	22	25	.	.	PUNCT
admet-496	23	1	an	an	DET
admet-496	23	2	increasing	increase	VERB
admet-496	23	3	understanding	understanding	NOUN
admet-496	23	4	of	of	ADP
admet-496	23	5	cancer	cancer	NOUN
admet-496	23	6	biology	biology	NOUN
admet-496	23	7	leads	lead	VERB
admet-496	23	8	to	to	ADP
admet-496	23	9	a	a	DET
admet-496	23	10	heterogeneity	heterogeneity	NOUN
admet-496	23	11	at	at	ADP
admet-496	23	12	multiple	multiple	ADJ
admet-496	23	13	levels	level	NOUN
admet-496	23	14	(	(	PUNCT
admet-496	23	15	genetic	genetic	ADJ
admet-496	23	16	,	,	PUNCT
admet-496	23	17	functional	functional	ADJ
admet-496	23	18	,	,	PUNCT
admet-496	23	19	tumour	tumour	ADJ
admet-496	23	20	components	component	NOUN
admet-496	23	21	,	,	PUNCT
admet-496	23	22	signalling	signal	VERB
admet-496	23	23	pathways	pathway	NOUN
admet-496	23	24	)	)	PUNCT
admet-496	23	25	,	,	PUNCT
admet-496	23	26	which	which	PRON
admet-496	23	27	translates	translate	VERB
admet-496	23	28	into	into	ADP
admet-496	23	29	an	an	DET
admet-496	23	30	increasing	increase	VERB
admet-496	23	31	number	number	NOUN
admet-496	23	32	of	of	ADP
admet-496	23	33	products	product	NOUN
admet-496	23	34	in	in	ADP
admet-496	23	35	the	the	DET
admet-496	23	36	pipeline	pipeline	NOUN
admet-496	23	37	of	of	ADP
admet-496	23	38	pharmaceutical	pharmaceutical	NOUN
admet-496	23	39	companies	company	NOUN
admet-496	23	40	.	.	PUNCT
admet-496	24	1	this	this	DET
admet-496	24	2	high	high	ADJ
admet-496	24	3	number	number	NOUN
admet-496	24	4	of	of	ADP
admet-496	24	5	compounds	compound	NOUN
admet-496	24	6	resulted	result	VERB
admet-496	24	7	in	in	ADP
admet-496	24	8	more	more	ADJ
admet-496	24	9	phase	phase	NOUN
admet-496	24	10	i	i	PRON
admet-496	24	11	,	,	PUNCT
admet-496	24	12	ii	ii	PROPN
admet-496	24	13	and	and	CCONJ
admet-496	24	14	iii	iii	NUM
admet-496	24	15	clinical	clinical	ADJ
admet-496	24	16	trials	trial	NOUN
admet-496	24	17	requiring	require	VERB
admet-496	24	18	even	even	ADV
admet-496	24	19	more	more	ADJ
admet-496	24	20	patients	patient	NOUN
admet-496	24	21	,	,	PUNCT
admet-496	24	22	which	which	PRON
admet-496	24	23	led	lead	VERB
admet-496	24	24	to	to	ADP
admet-496	24	25	extensively	extensively	ADV
admet-496	24	26	high	high	ADJ
admet-496	24	27	costs	cost	NOUN
admet-496	24	28	for	for	ADP
admet-496	24	29	pharmaceutical	pharmaceutical	NOUN
admet-496	24	30	industry	industry	NOUN
admet-496	24	31	and	and	CCONJ
admet-496	24	32	subsequently	subsequently	ADV
admet-496	24	33	health	health	NOUN
admet-496	24	34	care	care	NOUN
admet-496	24	35	in	in	ADP
admet-496	24	36	society	society	NOUN
admet-496	24	37	[	[	X
admet-496	24	38	4,5	4,5	NUM
admet-496	24	39	]	]	PUNCT
admet-496	24	40	.	.	PUNCT
admet-496	25	1	these	these	DET
admet-496	25	2	numbers	number	NOUN
admet-496	25	3	(	(	PUNCT
admet-496	25	4	costs	cost	NOUN
admet-496	25	5	and	and	CCONJ
admet-496	25	6	number	number	NOUN
admet-496	25	7	of	of	ADP
admet-496	25	8	patients	patient	NOUN
admet-496	25	9	)	)	PUNCT
admet-496	25	10	are	be	AUX
admet-496	25	11	increasing	increase	VERB
admet-496	25	12	in	in	ADP
admet-496	25	13	the	the	DET
admet-496	25	14	last	last	ADJ
admet-496	25	15	decades	decade	NOUN
admet-496	25	16	[	[	X
admet-496	25	17	6	6	NUM
admet-496	25	18	]	]	PUNCT
admet-496	25	19	,	,	PUNCT
admet-496	25	20	while	while	SCONJ
admet-496	25	21	the	the	DET
admet-496	25	22	rate	rate	NOUN
admet-496	25	23	of	of	ADP
admet-496	25	24	success	success	NOUN
admet-496	25	25	in	in	ADP
admet-496	25	26	oncology	oncology	NOUN
admet-496	25	27	drug	drug	NOUN
admet-496	25	28	development	development	NOUN
admet-496	25	29	is	be	AUX
admet-496	25	30	limited	limit	VERB
admet-496	25	31	,	,	PUNCT
admet-496	25	32	compared	compare	VERB
admet-496	25	33	to	to	ADP
admet-496	25	34	other	other	ADJ
admet-496	25	35	diseases	disease	NOUN
admet-496	25	36	[	[	X
admet-496	25	37	7	7	NUM
admet-496	25	38	]	]	PUNCT
admet-496	25	39	.	.	PUNCT
admet-496	26	1	in	in	ADP
admet-496	26	2	order	order	NOUN
admet-496	26	3	to	to	PART
admet-496	26	4	keep	keep	VERB
admet-496	26	5	the	the	DET
admet-496	26	6	costs	cost	NOUN
admet-496	26	7	as	as	ADV
admet-496	26	8	low	low	ADJ
admet-496	26	9	as	as	ADP
admet-496	26	10	possible	possible	ADJ
admet-496	26	11	it	it	PRON
admet-496	26	12	is	be	AUX
admet-496	26	13	important	important	ADJ
admet-496	26	14	that	that	SCONJ
admet-496	26	15	every	every	DET
admet-496	26	16	aspect	aspect	NOUN
admet-496	26	17	of	of	ADP
admet-496	26	18	the	the	DET
admet-496	26	19	development	development	NOUN
admet-496	26	20	process	process	NOUN
admet-496	26	21	is	be	AUX
admet-496	26	22	critically	critically	ADV
admet-496	26	23	reviewed	review	VERB
admet-496	26	24	,	,	PUNCT
admet-496	26	25	including	include	VERB
admet-496	26	26	optimisation	optimisation	NOUN
admet-496	26	27	of	of	ADP
admet-496	26	28	drug	drug	NOUN
admet-496	26	29	selection	selection	NOUN
admet-496	26	30	at	at	ADP
admet-496	26	31	an	an	DET
admet-496	26	32	early	early	ADJ
admet-496	26	33	stage	stage	NOUN
admet-496	26	34	.	.	PUNCT
admet-496	27	1	the	the	DET
admet-496	27	2	european	european	PROPN
admet-496	27	3	organization	organization	PROPN
admet-496	27	4	for	for	ADP
admet-496	27	5	research	research	NOUN
admet-496	27	6	and	and	CCONJ
admet-496	27	7	treatment	treatment	NOUN
admet-496	27	8	of	of	ADP
admet-496	27	9	cancer	cancer	NOUN
admet-496	27	10	(	(	PUNCT
admet-496	27	11	eortc	eortc	PROPN
admet-496	27	12	)	)	PUNCT
admet-496	27	13	is	be	AUX
admet-496	27	14	the	the	DET
admet-496	27	15	largest	large	ADJ
admet-496	27	16	european	european	ADJ
admet-496	27	17	organization	organization	NOUN
admet-496	27	18	coordinating	coordinate	VERB
admet-496	27	19	clinical	clinical	ADJ
admet-496	27	20	studies	study	NOUN
admet-496	27	21	in	in	ADP
admet-496	27	22	the	the	DET
admet-496	27	23	development	development	NOUN
admet-496	27	24	of	of	ADP
admet-496	27	25	new	new	ADJ
admet-496	27	26	cancer	cancer	NOUN
admet-496	27	27	therapies	therapy	NOUN
admet-496	27	28	[	[	X
admet-496	27	29	8	8	NUM
admet-496	27	30	]	]	PUNCT
admet-496	27	31	.	.	PUNCT
admet-496	28	1	the	the	DET
admet-496	28	2	national	national	PROPN
admet-496	28	3	cancer	cancer	PROPN
admet-496	28	4	institute	institute	PROPN
admet-496	28	5	(	(	PUNCT
admet-496	28	6	nci	nci	PROPN
admet-496	28	7	)	)	PUNCT
admet-496	28	8	in	in	ADP
admet-496	28	9	bethesda	bethesda	PROPN
admet-496	28	10	,	,	PUNCT
admet-496	28	11	md	md	PROPN
admet-496	28	12	,	,	PUNCT
admet-496	28	13	usa	usa	PROPN
admet-496	28	14	,	,	PUNCT
admet-496	28	15	developed	develop	VERB
admet-496	28	16	in	in	ADP
admet-496	28	17	the	the	DET
admet-496	28	18	2nd	2nd	ADJ
admet-496	28	19	half	half	NOUN
admet-496	28	20	of	of	ADP
admet-496	28	21	the	the	DET
admet-496	28	22	1980s	1980	NOUN
admet-496	28	23	a	a	DET
admet-496	28	24	60	60	NUM
admet-496	28	25	-	-	PUNCT
admet-496	28	26	cell	cell	NOUN
admet-496	28	27	line	line	NOUN
admet-496	28	28	panel	panel	NOUN
admet-496	28	29	(	(	PUNCT
admet-496	28	30	called	call	VERB
admet-496	28	31	nci-60	nci-60	PRON
admet-496	28	32	panel	panel	NOUN
admet-496	28	33	throughout	throughout	ADP
admet-496	28	34	this	this	DET
admet-496	28	35	paper	paper	NOUN
admet-496	28	36	)	)	PUNCT
admet-496	28	37	,	,	PUNCT
admet-496	28	38	consisting	consist	VERB
admet-496	28	39	of	of	ADP
admet-496	28	40	60	60	NUM
admet-496	28	41	cell	cell	NOUN
admet-496	28	42	lines	line	NOUN
admet-496	28	43	representative	representative	NOUN
admet-496	28	44	for	for	ADP
admet-496	28	45	the	the	DET
admet-496	28	46	9	9	NUM
admet-496	28	47	major	major	ADJ
admet-496	28	48	tumour	tumour	ADJ
admet-496	28	49	types	type	NOUN
admet-496	28	50	,	,	PUNCT
admet-496	28	51	with	with	ADP
admet-496	28	52	the	the	DET
admet-496	28	53	aim	aim	NOUN
admet-496	28	54	to	to	PART
admet-496	28	55	select	select	VERB
admet-496	28	56	compounds	compound	NOUN
admet-496	28	57	that	that	PRON
admet-496	28	58	show	show	VERB
admet-496	28	59	selective	selective	ADJ
admet-496	28	60	potency	potency	NOUN
admet-496	28	61	against	against	ADP
admet-496	28	62	one	one	NUM
admet-496	28	63	of	of	ADP
admet-496	28	64	these	these	DET
admet-496	28	65	malignancies	malignancy	NOUN
admet-496	28	66	[	[	X
admet-496	28	67	9	9	NUM
admet-496	28	68	]	]	PUNCT
admet-496	28	69	.	.	PUNCT
admet-496	29	1	this	this	DET
admet-496	29	2	nci-60	nci-60	PROPN
admet-496	29	3	panel	panel	NOUN
admet-496	29	4	was	be	AUX
admet-496	29	5	offered	offer	VERB
admet-496	29	6	to	to	ADP
admet-496	29	7	the	the	DET
admet-496	29	8	scientific	scientific	ADJ
admet-496	29	9	community	community	NOUN
admet-496	29	10	to	to	PART
admet-496	29	11	test	test	VERB
admet-496	29	12	the	the	DET
admet-496	29	13	potency	potency	NOUN
admet-496	29	14	of	of	ADP
admet-496	29	15	novel	novel	ADJ
admet-496	29	16	chemical	chemical	NOUN
admet-496	29	17	entities	entity	NOUN
admet-496	29	18	(	(	PUNCT
admet-496	29	19	nces	nce	NOUN
admet-496	29	20	)	)	PUNCT
admet-496	29	21	and	and	CCONJ
admet-496	29	22	since	since	SCONJ
admet-496	29	23	that	that	DET
admet-496	29	24	period	period	NOUN
admet-496	29	25	hundreds	hundred	NOUN
admet-496	29	26	of	of	ADP
admet-496	29	27	thousands	thousand	NOUN
admet-496	29	28	of	of	ADP
admet-496	29	29	compounds	compound	NOUN
admet-496	29	30	have	have	AUX
admet-496	29	31	been	be	AUX
admet-496	29	32	submitted	submit	VERB
admet-496	29	33	to	to	ADP
admet-496	29	34	the	the	DET
admet-496	29	35	nci	nci	PROPN
admet-496	29	36	screen	screen	NOUN
admet-496	29	37	,	,	PUNCT
admet-496	29	38	but	but	CCONJ
admet-496	29	39	not	not	PART
admet-496	29	40	all	all	PRON
admet-496	29	41	passed	pass	VERB
admet-496	29	42	the	the	DET
admet-496	29	43	initial	initial	ADJ
admet-496	29	44	nci	nci	PROPN
admet-496	29	45	selection	selection	NOUN
admet-496	29	46	procedure	procedure	NOUN
admet-496	29	47	and	and	CCONJ
admet-496	29	48	were	be	AUX
admet-496	29	49	not	not	PART
admet-496	29	50	tested	test	VERB
admet-496	29	51	.	.	PUNCT
admet-496	30	1	several	several	ADJ
admet-496	30	2	tested	test	VERB
admet-496	30	3	compounds	compound	NOUN
admet-496	30	4	showed	show	VERB
admet-496	30	5	an	an	DET
admet-496	30	6	interesting	interesting	ADJ
admet-496	30	7	profile	profile	NOUN
admet-496	30	8	and	and	CCONJ
admet-496	30	9	were	be	AUX
admet-496	30	10	candidates	candidate	NOUN
admet-496	30	11	for	for	ADP
admet-496	30	12	further	further	ADJ
admet-496	30	13	development	development	NOUN
admet-496	30	14	e.g.	e.g.	ADV
admet-496	30	15	in	in	ADP
admet-496	30	16	vivo	vivo	ADJ
admet-496	30	17	testing	testing	NOUN
admet-496	30	18	,	,	PUNCT
admet-496	30	19	but	but	CCONJ
admet-496	30	20	early	early	ADV
admet-496	30	21	in	in	ADP
admet-496	30	22	this	this	DET
admet-496	30	23	process	process	NOUN
admet-496	30	24	it	it	PRON
admet-496	30	25	was	be	AUX
admet-496	30	26	recognized	recognize	VERB
admet-496	30	27	that	that	SCONJ
admet-496	30	28	too	too	ADV
admet-496	30	29	many	many	ADJ
admet-496	30	30	compounds	compound	NOUN
admet-496	30	31	fulfilled	fulfil	VERB
admet-496	30	32	the	the	DET
admet-496	30	33	criteria	criterion	NOUN
admet-496	30	34	for	for	ADP
admet-496	30	35	in	in	ADP
admet-496	30	36	vivo	vivo	ADJ
admet-496	30	37	testing	testing	NOUN
admet-496	30	38	.	.	PUNCT
admet-496	31	1	in	in	ADP
admet-496	31	2	order	order	NOUN
admet-496	31	3	to	to	PART
admet-496	31	4	speed	speed	VERB
admet-496	31	5	up	up	ADP
admet-496	31	6	the	the	DET
admet-496	31	7	backlog	backlog	NOUN
admet-496	31	8	in	in	ADP
admet-496	31	9	this	this	DET
admet-496	31	10	development	development	NOUN
admet-496	31	11	and	and	CCONJ
admet-496	31	12	since	since	SCONJ
admet-496	31	13	many	many	ADJ
admet-496	31	14	compounds	compound	NOUN
admet-496	31	15	came	come	VERB
admet-496	31	16	from	from	ADP
admet-496	31	17	europe	europe	PROPN
admet-496	31	18	,	,	PUNCT
admet-496	31	19	an	an	DET
admet-496	31	20	international	international	ADJ
admet-496	31	21	academic	academic	ADJ
admet-496	31	22	collaboration	collaboration	NOUN
admet-496	31	23	between	between	ADP
admet-496	31	24	both	both	DET
admet-496	31	25	sides	side	NOUN
admet-496	31	26	of	of	ADP
admet-496	31	27	the	the	DET
admet-496	31	28	atlantic	atlantic	NOUN
admet-496	31	29	was	be	AUX
admet-496	31	30	initiated	initiate	VERB
admet-496	31	31	in	in	ADP
admet-496	31	32	1993	1993	NUM
admet-496	31	33	,	,	PUNCT
admet-496	31	34	between	between	ADP
admet-496	31	35	the	the	DET
admet-496	31	36	eortc	eortc	ADJ
admet-496	31	37	research	research	NOUN
admet-496	31	38	branch	branch	NOUN
admet-496	31	39	,	,	PUNCT
admet-496	31	40	the	the	DET
admet-496	31	41	cancer	cancer	NOUN
admet-496	31	42	research	research	NOUN
admet-496	31	43	campaign	campaign	NOUN
admet-496	31	44	(	(	PUNCT
admet-496	31	45	crc	crc	NOUN
admet-496	31	46	,	,	PUNCT
admet-496	31	47	now	now	ADV
admet-496	31	48	cruk	cruk	NOUN
admet-496	31	49	)	)	PUNCT
admet-496	31	50	and	and	CCONJ
admet-496	31	51	the	the	DET
admet-496	31	52	nci	nci	PROPN
admet-496	31	53	,	,	PUNCT
admet-496	31	54	the	the	DET
admet-496	31	55	so	so	ADV
admet-496	31	56	-	-	PUNCT
admet-496	31	57	called	call	VERB
admet-496	31	58	european	european	PROPN
admet-496	31	59	nci	nci	PROPN
admet-496	31	60	compounds	compound	VERB
admet-496	31	61	initiative	initiative	NOUN
admet-496	31	62	,	,	PUNCT
admet-496	31	63	which	which	PRON
admet-496	31	64	focused	focus	VERB
admet-496	31	65	on	on	ADP
admet-496	31	66	compounds	compound	NOUN
admet-496	31	67	synthesised	synthesise	VERB
admet-496	31	68	in	in	ADP
admet-496	31	69	europe	europe	PROPN
admet-496	31	70	and	and	CCONJ
admet-496	31	71	showing	show	VERB
admet-496	31	72	interesting	interesting	ADJ
admet-496	31	73	data	datum	NOUN
admet-496	31	74	in	in	ADP
admet-496	31	75	the	the	DET
admet-496	31	76	nci	nci	PROPN
admet-496	31	77	screen	screen	NOUN
admet-496	31	78	.	.	PUNCT
admet-496	32	1	crc	crc	NOUN
admet-496	32	2	and	and	CCONJ
admet-496	32	3	eortc	eortc	VERB
admet-496	32	4	set	set	VERB
admet-496	32	5	up	up	ADP
admet-496	32	6	a	a	DET
admet-496	32	7	review	review	NOUN
admet-496	32	8	committee	committee	NOUN
admet-496	32	9	to	to	PART
admet-496	32	10	select	select	VERB
admet-496	32	11	european	european	ADJ
admet-496	32	12	compounds	compound	NOUN
admet-496	32	13	for	for	ADP
admet-496	32	14	further	further	ADJ
admet-496	32	15	development	development	NOUN
admet-496	32	16	[	[	X
admet-496	32	17	10,11	10,11	NOUN
admet-496	32	18	]	]	X
admet-496	32	19	.	.	PUNCT
admet-496	33	1	about	about	ADV
admet-496	33	2	2,000	2,000	NUM
admet-496	33	3	compounds	compound	NOUN
admet-496	33	4	were	be	AUX
admet-496	33	5	evaluated	evaluate	VERB
admet-496	33	6	by	by	ADP
admet-496	33	7	the	the	DET
admet-496	33	8	crc	crc	PROPN
admet-496	33	9	-	-	PUNCT
admet-496	33	10	eortc	eortc	VERB
admet-496	33	11	review	review	PROPN
admet-496	33	12	committee	committee	NOUN
admet-496	33	13	in	in	ADP
admet-496	33	14	>	>	NUM
admet-496	33	15	20	20	NUM
admet-496	33	16	years	year	NOUN
admet-496	33	17	and	and	CCONJ
admet-496	33	18	95	95	NUM
admet-496	33	19	were	be	AUX
admet-496	33	20	selected	select	VERB
admet-496	33	21	for	for	ADP
admet-496	33	22	further	further	ADJ
admet-496	33	23	evaluation	evaluation	NOUN
admet-496	33	24	.	.	PUNCT
admet-496	34	1	further	further	ADJ
admet-496	34	2	details	detail	NOUN
admet-496	34	3	on	on	ADP
admet-496	34	4	this	this	DET
admet-496	34	5	process	process	NOUN
admet-496	34	6	and	and	CCONJ
admet-496	34	7	the	the	DET
admet-496	34	8	achievements	achievement	NOUN
admet-496	34	9	have	have	AUX
admet-496	34	10	recently	recently	ADV
admet-496	34	11	been	be	AUX
admet-496	34	12	summarised	summarise	VERB
admet-496	34	13	[	[	PUNCT
admet-496	34	14	10	10	NUM
admet-496	34	15	]	]	PUNCT
admet-496	34	16	.	.	PUNCT
admet-496	35	1	the	the	DET
admet-496	35	2	purpose	purpose	NOUN
admet-496	35	3	of	of	ADP
admet-496	35	4	this	this	DET
admet-496	35	5	paper	paper	NOUN
admet-496	35	6	is	be	AUX
admet-496	35	7	to	to	PART
admet-496	35	8	evaluate	evaluate	VERB
admet-496	35	9	mechanistic	mechanistic	ADJ
admet-496	35	10	details	detail	NOUN
admet-496	35	11	e.g.	e.g.	ADV
admet-496	35	12	adme	adme	NOUN
admet-496	35	13	(	(	PUNCT
admet-496	35	14	absorption	absorption	NOUN
admet-496	35	15	,	,	PUNCT
admet-496	35	16	distribution	distribution	NOUN
admet-496	35	17	,	,	PUNCT
admet-496	35	18	metabolism	metabolism	NOUN
admet-496	35	19	,	,	PUNCT
admet-496	35	20	excretion	excretion	NOUN
admet-496	35	21	)	)	PUNCT
admet-496	35	22	in	in	ADP
admet-496	35	23	this	this	DET
admet-496	35	24	process	process	NOUN
admet-496	35	25	by	by	ADP
admet-496	35	26	describing	describe	VERB
admet-496	35	27	the	the	DET
admet-496	35	28	development	development	NOUN
admet-496	35	29	of	of	ADP
admet-496	35	30	several	several	ADJ
admet-496	35	31	compounds	compound	NOUN
admet-496	35	32	that	that	PRON
admet-496	35	33	either	either	CCONJ
admet-496	35	34	failed	fail	VERB
admet-496	35	35	or	or	CCONJ
admet-496	35	36	were	be	AUX
admet-496	35	37	successful	successful	ADJ
admet-496	35	38	.	.	PUNCT
admet-496	36	1	successful	successful	ADJ
admet-496	36	2	means	mean	VERB
admet-496	36	3	moving	move	VERB
admet-496	36	4	into	into	ADP
admet-496	36	5	phase	phase	NOUN
admet-496	36	6	i	i	PRON
admet-496	36	7	or	or	CCONJ
admet-496	36	8	eventually	eventually	ADV
admet-496	36	9	phase	phase	VERB
admet-496	36	10	ii	ii	NOUN
admet-496	36	11	clinical	clinical	ADJ
admet-496	36	12	studies	study	NOUN
admet-496	36	13	.	.	PUNCT
admet-496	37	1	failure	failure	NOUN
admet-496	37	2	may	may	AUX
admet-496	37	3	have	have	AUX
admet-496	37	4	been	be	AUX
admet-496	37	5	caused	cause	VERB
admet-496	37	6	by	by	ADP
admet-496	37	7	obvious	obvious	ADJ
admet-496	37	8	parameters	parameter	NOUN
admet-496	37	9	,	,	PUNCT
admet-496	37	10	such	such	ADJ
admet-496	37	11	as	as	ADP
admet-496	37	12	lack	lack	NOUN
admet-496	37	13	of	of	ADP
admet-496	37	14	potency	potency	NOUN
admet-496	37	15	,	,	PUNCT
admet-496	37	16	poor	poor	ADJ
admet-496	37	17	solubility	solubility	NOUN
admet-496	37	18	,	,	PUNCT
admet-496	37	19	stability	stability	NOUN
admet-496	37	20	and	and	CCONJ
admet-496	37	21	other	other	ADJ
admet-496	37	22	physico	physico	NOUN
admet-496	37	23	-	-	PUNCT
admet-496	37	24	chemical	chemical	NOUN
admet-496	37	25	properties	property	NOUN
admet-496	37	26	.	.	PUNCT
admet-496	38	1	godefridus	godefridus	PROPN
admet-496	38	2	peters	peters	PROPN
admet-496	38	3	et	et	PROPN
admet-496	38	4	al	al	PROPN
admet-496	38	5	.	.	PROPN
admet-496	38	6	admet	admet	PROPN
admet-496	38	7	&	&	CCONJ
admet-496	38	8	dmpk	dmpk	PROPN
admet-496	38	9	6(1	6(1	NUM
admet-496	38	10	)	)	PUNCT
admet-496	38	11	(	(	PUNCT
admet-496	38	12	2018	2018	NUM
admet-496	38	13	)	)	PUNCT
admet-496	38	14	4	4	NUM
admet-496	38	15	-	-	SYM
admet-496	38	16	14	14	NUM
admet-496	38	17	6	6	NUM
admet-496	38	18	the	the	DET
admet-496	38	19	process	process	NOUN
admet-496	38	20	of	of	ADP
admet-496	38	21	european	european	PROPN
admet-496	38	22	nci	nci	PROPN
admet-496	38	23	compound	compound	PROPN
admet-496	38	24	evaluation	evaluation	NOUN
admet-496	38	25	in	in	ADP
admet-496	38	26	the	the	DET
admet-496	38	27	early	early	ADJ
admet-496	38	28	1990s	1990	NOUN
admet-496	38	29	,	,	PUNCT
admet-496	38	30	the	the	DET
admet-496	38	31	screening	screening	NOUN
admet-496	38	32	’s	’s	PART
admet-496	38	33	capacity	capacity	NOUN
admet-496	38	34	of	of	ADP
admet-496	38	35	the	the	DET
admet-496	38	36	nci-60	nci-60	PROPN
admet-496	38	37	panel	panel	NOUN
admet-496	38	38	was	be	AUX
admet-496	38	39	10,000	10,000	NUM
admet-496	38	40	compounds	compound	NOUN
admet-496	38	41	annually	annually	ADV
admet-496	38	42	.	.	PUNCT
admet-496	39	1	nces	nces	PROPN
admet-496	39	2	,	,	PUNCT
admet-496	39	3	submitted	submit	VERB
admet-496	39	4	by	by	ADP
admet-496	39	5	scientists	scientist	NOUN
admet-496	39	6	from	from	ADP
admet-496	39	7	all	all	ADV
admet-496	39	8	over	over	ADP
admet-496	39	9	the	the	DET
admet-496	39	10	world	world	NOUN
admet-496	39	11	,	,	PUNCT
admet-496	39	12	are	be	AUX
admet-496	39	13	selected	select	VERB
admet-496	39	14	for	for	ADP
admet-496	39	15	screening	screen	VERB
admet-496	39	16	based	base	VERB
admet-496	39	17	on	on	ADP
admet-496	39	18	structural	structural	ADJ
admet-496	39	19	diversity	diversity	NOUN
admet-496	39	20	and	and	CCONJ
admet-496	39	21	novelty	novelty	NOUN
admet-496	39	22	of	of	ADP
admet-496	39	23	the	the	DET
admet-496	39	24	compound	compound	NOUN
admet-496	39	25	.	.	PUNCT
admet-496	40	1	in	in	ADP
admet-496	40	2	the	the	DET
admet-496	40	3	initial	initial	ADJ
admet-496	40	4	program	program	NOUN
admet-496	40	5	selected	select	VERB
admet-496	40	6	nces	nce	NOUN
admet-496	40	7	were	be	AUX
admet-496	40	8	tested	test	VERB
admet-496	40	9	at	at	ADP
admet-496	40	10	5	5	NUM
admet-496	40	11	different	different	ADJ
admet-496	40	12	concentrations	concentration	NOUN
admet-496	40	13	(	(	PUNCT
admet-496	40	14	varying	vary	VERB
admet-496	40	15	over	over	ADP
admet-496	40	16	5	5	NUM
admet-496	40	17	logs	log	NOUN
admet-496	40	18	:	:	PUNCT
admet-496	40	19	10	10	NUM
admet-496	40	20	-	-	PUNCT
admet-496	40	21	4–10	4–10	NOUN
admet-496	40	22	-	-	PUNCT
admet-496	40	23	8	8	NUM
admet-496	40	24	or	or	CCONJ
admet-496	40	25	10	10	NUM
admet-496	40	26	-	-	PUNCT
admet-496	40	27	5–10	5–10	ADJ
admet-496	40	28	-	-	PUNCT
admet-496	40	29	9	9	NUM
admet-496	40	30	m	m	NOUN
admet-496	40	31	)	)	PUNCT
admet-496	40	32	and	and	CCONJ
admet-496	40	33	cells	cell	NOUN
admet-496	40	34	were	be	AUX
admet-496	40	35	exposed	expose	VERB
admet-496	40	36	for	for	ADP
admet-496	40	37	48	48	NUM
admet-496	40	38	hours	hour	NOUN
admet-496	40	39	to	to	ADP
admet-496	40	40	the	the	DET
admet-496	40	41	drug	drug	NOUN
admet-496	40	42	.	.	PUNCT
admet-496	41	1	three	three	NUM
admet-496	41	2	parameters	parameter	NOUN
admet-496	41	3	were	be	AUX
admet-496	41	4	determined	determine	VERB
admet-496	41	5	for	for	ADP
admet-496	41	6	each	each	DET
admet-496	41	7	drug	drug	NOUN
admet-496	41	8	:	:	PUNCT
admet-496	41	9	the	the	DET
admet-496	41	10	gi50	gi50	PROPN
admet-496	41	11	(	(	PUNCT
admet-496	41	12	or	or	CCONJ
admet-496	41	13	ic50	ic50	PROPN
admet-496	41	14	:	:	PUNCT
admet-496	41	15	50	50	NUM
admet-496	41	16	%	%	NOUN
admet-496	41	17	growth	growth	NOUN
admet-496	41	18	inhibition	inhibition	NOUN
admet-496	41	19	)	)	PUNCT
admet-496	41	20	,	,	PUNCT
admet-496	41	21	the	the	DET
admet-496	41	22	tgi	tgi	PROPN
admet-496	41	23	(	(	PUNCT
admet-496	41	24	total	total	ADJ
admet-496	41	25	growth	growth	NOUN
admet-496	41	26	inhibition	inhibition	NOUN
admet-496	41	27	)	)	PUNCT
admet-496	41	28	and	and	CCONJ
admet-496	41	29	the	the	DET
admet-496	41	30	lc50	lc50	PROPN
admet-496	41	31	(	(	PUNCT
admet-496	41	32	50	50	NUM
admet-496	41	33	%	%	NOUN
admet-496	41	34	cell	cell	NOUN
admet-496	41	35	kill	kill	NOUN
admet-496	41	36	or	or	CCONJ
admet-496	41	37	50	50	NUM
admet-496	41	38	%	%	NOUN
admet-496	41	39	lethal	lethal	ADJ
admet-496	41	40	concentration	concentration	NOUN
admet-496	41	41	)	)	PUNCT
admet-496	41	42	(	(	PUNCT
admet-496	41	43	figure	figure	NOUN
admet-496	41	44	1	1	NUM
admet-496	41	45	)	)	PUNCT
admet-496	42	1	[	[	X
admet-496	42	2	12	12	NUM
admet-496	42	3	]	]	PUNCT
admet-496	42	4	.	.	PUNCT
admet-496	43	1	the	the	DET
admet-496	43	2	results	result	NOUN
admet-496	43	3	of	of	ADP
admet-496	43	4	the	the	DET
admet-496	43	5	screen	screen	NOUN
admet-496	43	6	are	be	AUX
admet-496	43	7	reported	report	VERB
admet-496	43	8	as	as	ADP
admet-496	43	9	growth	growth	NOUN
admet-496	43	10	inhibition	inhibition	NOUN
admet-496	43	11	curves	curve	NOUN
admet-496	43	12	as	as	SCONJ
admet-496	43	13	shown	show	VERB
admet-496	43	14	in	in	ADP
admet-496	43	15	figure	figure	NOUN
admet-496	43	16	2	2	NUM
admet-496	43	17	for	for	ADP
admet-496	43	18	compound	compound	NOUN
admet-496	43	19	nsc-625492	nsc-625492	NOUN
admet-496	43	20	.	.	PUNCT
admet-496	44	1	many	many	ADJ
admet-496	44	2	current	current	ADJ
admet-496	44	3	drug	drug	NOUN
admet-496	44	4	sensitivity	sensitivity	NOUN
admet-496	44	5	tests	test	NOUN
admet-496	44	6	often	often	ADV
admet-496	44	7	denote	denote	VERB
admet-496	44	8	these	these	DET
admet-496	44	9	curves	curve	NOUN
admet-496	44	10	as	as	ADP
admet-496	44	11	viability	viability	NOUN
admet-496	44	12	curves	curve	NOUN
admet-496	44	13	.	.	PUNCT
admet-496	45	1	this	this	PRON
admet-496	45	2	is	be	AUX
admet-496	45	3	not	not	PART
admet-496	45	4	a	a	DET
admet-496	45	5	correct	correct	ADJ
admet-496	45	6	terminology	terminology	NOUN
admet-496	45	7	,	,	PUNCT
admet-496	45	8	because	because	SCONJ
admet-496	45	9	growth	growth	NOUN
admet-496	45	10	inhibition	inhibition	NOUN
admet-496	45	11	is	be	AUX
admet-496	45	12	measured	measure	VERB
admet-496	45	13	.	.	PUNCT
admet-496	46	1	the	the	DET
admet-496	46	2	nci	nci	PROPN
admet-496	46	3	data	datum	NOUN
admet-496	46	4	are	be	AUX
admet-496	46	5	summarized	summarize	VERB
admet-496	46	6	as	as	ADP
admet-496	46	7	mean	mean	ADJ
admet-496	46	8	graphs	graph	NOUN
admet-496	46	9	for	for	ADP
admet-496	46	10	gi50	gi50	PROPN
admet-496	46	11	,	,	PUNCT
admet-496	46	12	tgi	tgi	PROPN
admet-496	46	13	or	or	CCONJ
admet-496	46	14	lc50	lc50	PROPN
admet-496	46	15	values	value	NOUN
admet-496	46	16	.	.	PUNCT
admet-496	47	1	these	these	PRON
admet-496	47	2	mean	mean	ADJ
admet-496	47	3	graphs	graph	NOUN
admet-496	47	4	depict	depict	VERB
admet-496	47	5	whether	whether	SCONJ
admet-496	47	6	a	a	DET
admet-496	47	7	cell	cell	NOUN
admet-496	47	8	line	line	NOUN
admet-496	47	9	is	be	AUX
admet-496	47	10	more	more	ADV
admet-496	47	11	or	or	CCONJ
admet-496	47	12	less	less	ADV
admet-496	47	13	sensitive	sensitive	ADJ
admet-496	47	14	than	than	ADP
admet-496	47	15	the	the	DET
admet-496	47	16	gi50	gi50	PROPN
admet-496	47	17	/	/	SYM
admet-496	47	18	tgi	tgi	PROPN
admet-496	47	19	/	/	SYM
admet-496	47	20	lc50	lc50	PROPN
admet-496	47	21	mean	mean	NOUN
admet-496	47	22	of	of	ADP
admet-496	47	23	the	the	DET
admet-496	47	24	test	test	NOUN
admet-496	47	25	drug	drug	NOUN
admet-496	47	26	in	in	ADP
admet-496	47	27	the	the	DET
admet-496	47	28	nci-60	nci-60	PROPN
admet-496	47	29	panel	panel	NOUN
admet-496	47	30	.	.	PUNCT
admet-496	48	1	figure	figure	NOUN
admet-496	48	2	3	3	NUM
admet-496	48	3	shows	show	VERB
admet-496	48	4	the	the	DET
admet-496	48	5	mean	mean	ADJ
admet-496	48	6	graphs	graph	NOUN
admet-496	48	7	of	of	ADP
admet-496	48	8	compound	compound	NOUN
admet-496	48	9	nsc-710305	nsc-710305	NOUN
admet-496	49	1	[	[	X
admet-496	49	2	13	13	NUM
admet-496	49	3	]	]	PUNCT
admet-496	49	4	,	,	PUNCT
admet-496	49	5	also	also	ADV
admet-496	49	6	known	know	VERB
admet-496	49	7	as	as	ADP
admet-496	49	8	phortress	phortress	NOUN
admet-496	49	9	,	,	PUNCT
admet-496	49	10	and	and	CCONJ
admet-496	49	11	a	a	DET
admet-496	49	12	prodrug	prodrug	NOUN
admet-496	49	13	of	of	ADP
admet-496	49	14	phortress	phortress	NOUN
admet-496	49	15	5f-203	5f-203	NUM
admet-496	49	16	.	.	PUNCT
admet-496	50	1	these	these	DET
admet-496	50	2	mean	mean	ADJ
admet-496	50	3	graphs	graph	NOUN
admet-496	50	4	demonstrate	demonstrate	VERB
admet-496	50	5	a	a	DET
admet-496	50	6	tumour	tumour	NOUN
admet-496	50	7	specific	specific	ADJ
admet-496	50	8	sensitivity	sensitivity	NOUN
admet-496	50	9	for	for	ADP
admet-496	50	10	lung	lung	NOUN
admet-496	50	11	,	,	PUNCT
admet-496	50	12	ovarian	ovarian	ADJ
admet-496	50	13	,	,	PUNCT
admet-496	50	14	renal	renal	ADJ
admet-496	50	15	and	and	CCONJ
admet-496	50	16	breast	breast	NOUN
admet-496	50	17	cancer	cancer	NOUN
admet-496	50	18	(	(	PUNCT
admet-496	50	19	bars	bar	NOUN
admet-496	50	20	to	to	ADP
admet-496	50	21	the	the	DET
admet-496	50	22	right	right	NOUN
admet-496	50	23	)	)	PUNCT
admet-496	50	24	.	.	PUNCT
admet-496	51	1	subsequent	subsequent	ADJ
admet-496	51	2	mechanistic	mechanistic	ADJ
admet-496	51	3	studies	study	NOUN
admet-496	51	4	were	be	AUX
admet-496	51	5	performed	perform	VERB
admet-496	51	6	according	accord	VERB
admet-496	51	7	to	to	ADP
admet-496	51	8	the	the	DET
admet-496	51	9	guidelines	guideline	NOUN
admet-496	51	10	published	publish	VERB
admet-496	51	11	recently	recently	ADV
admet-496	51	12	[	[	X
admet-496	51	13	14	14	NUM
admet-496	51	14	]	]	PUNCT
admet-496	51	15	.	.	PUNCT
admet-496	52	1	figure	figure	NOUN
admet-496	52	2	1	1	NUM
admet-496	52	3	.	.	PUNCT
admet-496	52	4	example	example	NOUN
admet-496	52	5	growth	growth	NOUN
admet-496	52	6	inhibition	inhibition	VERB
admet-496	52	7	curves	curve	NOUN
admet-496	52	8	after	after	ADP
admet-496	52	9	48	48	NUM
admet-496	52	10	hours	hour	NOUN
admet-496	52	11	exposure	exposure	NOUN
admet-496	52	12	to	to	ADP
admet-496	52	13	a	a	DET
admet-496	52	14	hypothetical	hypothetical	ADJ
admet-496	52	15	drug	drug	NOUN
admet-496	52	16	tested	test	VERB
admet-496	52	17	at	at	ADP
admet-496	52	18	0.1	0.1	NUM
admet-496	52	19	to	to	ADP
admet-496	52	20	1000	1000	NUM
admet-496	52	21	nm	nm	NOUN
admet-496	52	22	in	in	ADP
admet-496	52	23	three	three	NUM
admet-496	52	24	lung	lung	NOUN
admet-496	52	25	cancer	cancer	NOUN
admet-496	52	26	cell	cell	NOUN
admet-496	52	27	lines	line	NOUN
admet-496	52	28	.	.	PUNCT
admet-496	53	1	three	three	NUM
admet-496	53	2	parameters	parameter	NOUN
admet-496	53	3	are	be	AUX
admet-496	53	4	shown	show	VERB
admet-496	53	5	:	:	PUNCT
admet-496	53	6	the	the	DET
admet-496	53	7	gi50	gi50	PROPN
admet-496	53	8	(	(	PUNCT
admet-496	53	9	the	the	DET
admet-496	53	10	concentration	concentration	NOUN
admet-496	53	11	that	that	PRON
admet-496	53	12	gives	give	VERB
admet-496	53	13	50	50	NUM
admet-496	53	14	%	%	NOUN
admet-496	53	15	growth	growth	NOUN
admet-496	53	16	inhibition	inhibition	NOUN
admet-496	53	17	,	,	PUNCT
admet-496	53	18	often	often	ADV
admet-496	53	19	also	also	ADV
admet-496	53	20	referred	refer	VERB
admet-496	53	21	to	to	ADP
admet-496	53	22	as	as	ADP
admet-496	53	23	ic50	ic50	PROPN
admet-496	53	24	)	)	PUNCT
admet-496	53	25	,	,	PUNCT
admet-496	53	26	the	the	DET
admet-496	53	27	tgi	tgi	PROPN
admet-496	53	28	(	(	PUNCT
admet-496	53	29	the	the	DET
admet-496	53	30	concentration	concentration	NOUN
admet-496	53	31	that	that	PRON
admet-496	53	32	gives	give	VERB
admet-496	53	33	a	a	DET
admet-496	53	34	total	total	ADJ
admet-496	53	35	growth	growth	NOUN
admet-496	53	36	inhibition	inhibition	NOUN
admet-496	53	37	meaning	mean	VERB
admet-496	53	38	that	that	SCONJ
admet-496	53	39	the	the	DET
admet-496	53	40	number	number	NOUN
admet-496	53	41	of	of	ADP
admet-496	53	42	cells	cell	NOUN
admet-496	53	43	at	at	ADP
admet-496	53	44	the	the	DET
admet-496	53	45	end	end	NOUN
admet-496	53	46	of	of	ADP
admet-496	53	47	the	the	DET
admet-496	53	48	exposure	exposure	NOUN
admet-496	53	49	is	be	AUX
admet-496	53	50	similar	similar	ADJ
admet-496	53	51	to	to	ADP
admet-496	53	52	that	that	PRON
admet-496	53	53	at	at	ADP
admet-496	53	54	the	the	DET
admet-496	53	55	beginning	beginning	NOUN
admet-496	53	56	)	)	PUNCT
admet-496	53	57	and	and	CCONJ
admet-496	53	58	the	the	DET
admet-496	53	59	lc50	lc50	PROPN
admet-496	53	60	(	(	PUNCT
admet-496	53	61	the	the	DET
admet-496	53	62	concentration	concentration	NOUN
admet-496	53	63	that	that	PRON
admet-496	53	64	gives	give	VERB
admet-496	53	65	50	50	NUM
admet-496	53	66	%	%	NOUN
admet-496	53	67	cell	cell	NOUN
admet-496	53	68	kill	kill	NOUN
admet-496	53	69	,	,	PUNCT
admet-496	53	70	meaning	mean	VERB
admet-496	53	71	that	that	SCONJ
admet-496	53	72	at	at	ADP
admet-496	53	73	the	the	DET
admet-496	53	74	end	end	NOUN
admet-496	53	75	the	the	DET
admet-496	53	76	number	number	NOUN
admet-496	53	77	of	of	ADP
admet-496	53	78	cells	cell	NOUN
admet-496	53	79	is	be	AUX
admet-496	53	80	50	50	NUM
admet-496	53	81	%	%	NOUN
admet-496	53	82	of	of	ADP
admet-496	53	83	the	the	DET
admet-496	53	84	number	number	NOUN
admet-496	53	85	of	of	ADP
admet-496	53	86	cells	cell	NOUN
admet-496	53	87	at	at	ADP
admet-496	53	88	the	the	DET
admet-496	53	89	beginning	beginning	NOUN
admet-496	53	90	)	)	PUNCT
admet-496	53	91	.	.	PUNCT
admet-496	54	1	values	value	NOUN
admet-496	54	2	are	be	AUX
admet-496	54	3	calculated	calculate	VERB
admet-496	54	4	according	accord	VERB
admet-496	54	5	to	to	ADP
admet-496	54	6	the	the	DET
admet-496	54	7	nci	nci	PROPN
admet-496	54	8	protocol	protocol	NOUN
admet-496	54	9	:	:	PUNCT
admet-496	54	10	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	PROPN
admet-496	54	11	when	when	SCONJ
admet-496	54	12	positive	positive	ADJ
admet-496	54	13	,	,	PUNCT
admet-496	54	14	such	such	ADJ
admet-496	54	15	as	as	ADP
admet-496	54	16	for	for	ADP
admet-496	54	17	phortress	phortress	NOUN
admet-496	54	18	,	,	PUNCT
admet-496	54	19	compounds	compound	NOUN
admet-496	54	20	were	be	AUX
admet-496	54	21	further	far	ADV
admet-496	54	22	screened	screen	VERB
admet-496	54	23	in	in	ADP
admet-496	54	24	a	a	DET
admet-496	54	25	human	human	ADJ
admet-496	54	26	tumour	tumour	NOUN
admet-496	54	27	xenograft	xenograft	NOUN
admet-496	54	28	(	(	PUNCT
admet-496	54	29	htx	htx	PROPN
admet-496	54	30	)	)	PUNCT
admet-496	54	31	panel	panel	NOUN
admet-496	54	32	.	.	PUNCT
admet-496	55	1	however	however	ADV
admet-496	55	2	,	,	PUNCT
admet-496	55	3	the	the	DET
admet-496	55	4	nci	nci	PROPN
admet-496	55	5	screen	screen	NOUN
admet-496	55	6	yielded	yield	VERB
admet-496	55	7	too	too	ADV
admet-496	55	8	many	many	ADJ
admet-496	55	9	potential	potential	ADJ
admet-496	55	10	compounds	compound	NOUN
admet-496	55	11	for	for	ADP
admet-496	55	12	htx	htx	PROPN
admet-496	55	13	testing	testing	NOUN
admet-496	55	14	,	,	PUNCT
admet-496	55	15	so	so	SCONJ
admet-496	55	16	that	that	SCONJ
admet-496	55	17	a	a	DET
admet-496	55	18	fast	fast	ADJ
admet-496	55	19	low	low	ADJ
admet-496	55	20	-	-	PUNCT
admet-496	55	21	cost	cost	NOUN
admet-496	55	22	preliminary	preliminary	NOUN
admet-496	55	23	in	in	ADP
admet-496	55	24	vivo	vivo	NOUN
admet-496	55	25	screen	screen	NOUN
admet-496	55	26	was	be	AUX
admet-496	55	27	developed	develop	VERB
admet-496	55	28	,	,	PUNCT
admet-496	55	29	the	the	DET
admet-496	55	30	so	so	ADV
admet-496	55	31	-	-	PUNCT
admet-496	55	32	called	call	VERB
admet-496	55	33	hollow	hollow	ADJ
admet-496	55	34	fibre	fibre	NOUN
admet-496	55	35	assay	assay	NOUN
admet-496	55	36	(	(	PUNCT
admet-496	55	37	hfa	hfa	NOUN
admet-496	55	38	)	)	PUNCT
admet-496	56	1	[	[	X
admet-496	56	2	15,16	15,16	NUM
admet-496	56	3	]	]	PUNCT
admet-496	56	4	.	.	PUNCT
admet-496	57	1	this	this	DET
admet-496	57	2	assay	assay	NOUN
admet-496	57	3	combines	combine	VERB
admet-496	57	4	advantages	advantage	NOUN
admet-496	57	5	of	of	ADP
admet-496	57	6	in	in	ADP
admet-496	57	7	vitro	vitro	X
admet-496	57	8	screens	screen	NOUN
admet-496	57	9	(	(	PUNCT
admet-496	57	10	relatively	relatively	ADV
admet-496	57	11	fast	fast	ADJ
admet-496	57	12	,	,	PUNCT
admet-496	57	13	several	several	ADJ
admet-496	57	14	tumour	tumour	ADJ
admet-496	57	15	types	type	NOUN
admet-496	57	16	together	together	ADV
admet-496	57	17	)	)	PUNCT
admet-496	57	18	and	and	CCONJ
admet-496	57	19	bypasses	bypass	VERB
admet-496	57	20	the	the	DET
admet-496	57	21	disadvantages	disadvantage	NOUN
admet-496	57	22	such	such	ADJ
admet-496	57	23	as	as	ADP
admet-496	57	24	the	the	DET
admet-496	57	25	poor	poor	ADJ
admet-496	57	26	predictive	predictive	ADJ
admet-496	57	27	capacity	capacity	NOUN
admet-496	57	28	for	for	ADP
admet-496	57	29	in	in	ADP
admet-496	57	30	vivo	vivo	ADJ
admet-496	57	31	activity	activity	NOUN
admet-496	57	32	and	and	CCONJ
admet-496	57	33	lack	lack	NOUN
admet-496	57	34	of	of	ADP
admet-496	57	35	information	information	NOUN
admet-496	57	36	on	on	ADP
admet-496	57	37	potential	potential	ADJ
admet-496	57	38	pharmacological	pharmacological	ADJ
admet-496	57	39	properties	property	NOUN
admet-496	57	40	.	.	PUNCT
admet-496	58	1	the	the	DET
admet-496	58	2	latter	latter	ADJ
admet-496	58	3	are	be	AUX
admet-496	58	4	important	important	ADJ
admet-496	58	5	to	to	PART
admet-496	58	6	determine	determine	VERB
admet-496	58	7	the	the	DET
admet-496	58	8	amount	amount	NOUN
admet-496	58	9	of	of	ADP
admet-496	58	10	drug	drug	NOUN
admet-496	58	11	to	to	PART
admet-496	58	12	be	be	AUX
admet-496	58	13	delivered	deliver	VERB
admet-496	58	14	[	[	X
admet-496	58	15	17	17	NUM
admet-496	58	16	]	]	PUNCT
admet-496	58	17	.	.	PUNCT
admet-496	59	1	the	the	DET
admet-496	59	2	hfa	hfa	NOUN
admet-496	59	3	appeared	appear	VERB
admet-496	59	4	to	to	PART
admet-496	59	5	predict	predict	VERB
admet-496	59	6	for	for	ADP
admet-496	59	7	htx	htx	NOUN
admet-496	59	8	activity	activity	NOUN
admet-496	59	9	[	[	X
admet-496	59	10	18,19	18,19	NUM
admet-496	59	11	]	]	PUNCT
admet-496	59	12	.	.	PUNCT
admet-496	60	1	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	PROPN
admet-496	60	2	admet	admet	PROPN
admet-496	60	3	&	&	CCONJ
admet-496	60	4	dmpk	dmpk	PROPN
admet-496	60	5	6(1	6(1	NUM
admet-496	60	6	)	)	PUNCT
admet-496	60	7	(	(	PUNCT
admet-496	60	8	2018	2018	NUM
admet-496	60	9	)	)	PUNCT
admet-496	60	10	4	4	NUM
admet-496	60	11	-	-	SYM
admet-496	60	12	14	14	NUM
admet-496	60	13	the	the	DET
admet-496	60	14	role	role	NOUN
admet-496	60	15	of	of	ADP
admet-496	60	16	pharmacology	pharmacology	NOUN
admet-496	60	17	in	in	ADP
admet-496	60	18	anticancer	anticancer	NOUN
admet-496	60	19	drug	drug	PROPN
admet-496	60	20	development	development	PROPN
admet-496	60	21	doi	doi	PROPN
admet-496	60	22	:	:	PUNCT
admet-496	60	23	10.5599	10.5599	NUM
admet-496	60	24	/	/	SYM
admet-496	60	25	admet.6.1.496	admet.6.1.496	VERB
admet-496	60	26	7	7	NUM
admet-496	60	27	figure	figure	NOUN
admet-496	60	28	2	2	NUM
admet-496	60	29	.	.	NOUN
admet-496	60	30	example	example	NOUN
admet-496	60	31	of	of	ADP
admet-496	60	32	a	a	DET
admet-496	60	33	typical	typical	ADJ
admet-496	60	34	nci-60	nci-60	PRON
admet-496	60	35	cell	cell	NOUN
admet-496	60	36	line	line	NOUN
admet-496	60	37	growth	growth	NOUN
admet-496	60	38	inhibition	inhibition	NOUN
admet-496	60	39	report	report	NOUN
admet-496	60	40	for	for	ADP
admet-496	60	41	compound	compound	NOUN
admet-496	60	42	nsc-625492	nsc-625492	NOUN
admet-496	60	43	.	.	PUNCT
admet-496	61	1	each	each	DET
admet-496	61	2	panel	panel	NOUN
admet-496	61	3	represents	represent	VERB
admet-496	61	4	cell	cell	NOUN
admet-496	61	5	lines	line	NOUN
admet-496	61	6	derived	derive	VERB
admet-496	61	7	from	from	ADP
admet-496	61	8	of	of	ADP
admet-496	61	9	a	a	DET
admet-496	61	10	particular	particular	ADJ
admet-496	61	11	type	type	NOUN
admet-496	61	12	of	of	ADP
admet-496	61	13	cancer	cancer	NOUN
admet-496	61	14	(	(	PUNCT
admet-496	61	15	left	leave	VERB
admet-496	61	16	to	to	ADP
admet-496	61	17	right	right	NOUN
admet-496	61	18	,	,	PUNCT
admet-496	61	19	top	top	ADJ
admet-496	61	20	to	to	ADP
admet-496	61	21	bottom	bottom	NOUN
admet-496	61	22	):	):	PUNCT
admet-496	61	23	5	5	NUM
admet-496	61	24	breast	breast	NOUN
admet-496	61	25	cancer	cancer	NOUN
admet-496	61	26	cell	cell	NOUN
admet-496	61	27	lines	line	NOUN
admet-496	61	28	)	)	PUNCT
admet-496	61	29	,	,	PUNCT
admet-496	61	30	8	8	NUM
admet-496	61	31	central	central	ADJ
admet-496	61	32	nervous	nervous	ADJ
admet-496	61	33	system	system	NOUN
admet-496	61	34	(	(	PUNCT
admet-496	61	35	cns	cns	NOUN
admet-496	61	36	)	)	PUNCT
admet-496	61	37	cell	cell	NOUN
admet-496	61	38	lines	line	NOUN
admet-496	61	39	,	,	PUNCT
admet-496	61	40	9	9	NUM
admet-496	61	41	colon	colon	NOUN
admet-496	61	42	cancer	cancer	NOUN
admet-496	61	43	cell	cell	NOUN
admet-496	61	44	lines	line	NOUN
admet-496	61	45	,	,	PUNCT
admet-496	61	46	6	6	NUM
admet-496	61	47	leukaemia	leukaemia	NOUN
admet-496	61	48	cell	cell	NOUN
admet-496	61	49	lines	line	NOUN
admet-496	61	50	,	,	PUNCT
admet-496	61	51	11	11	NUM
admet-496	61	52	melanoma	melanoma	NOUN
admet-496	61	53	cell	cell	NOUN
admet-496	61	54	lines	line	NOUN
admet-496	61	55	,	,	PUNCT
admet-496	61	56	11	11	NUM
admet-496	61	57	non	non	ADJ
admet-496	61	58	-	-	ADJ
admet-496	61	59	small	small	ADJ
admet-496	61	60	cell	cell	NOUN
admet-496	61	61	lung	lung	NOUN
admet-496	61	62	cancer	cancer	NOUN
admet-496	61	63	(	(	PUNCT
admet-496	61	64	nsclc	nsclc	NOUN
admet-496	61	65	)	)	PUNCT
admet-496	61	66	cell	cell	NOUN
admet-496	61	67	lines	line	NOUN
admet-496	61	68	,	,	PUNCT
admet-496	61	69	7	7	NUM
admet-496	61	70	ovarian	ovarian	ADJ
admet-496	61	71	cancer	cancer	NOUN
admet-496	61	72	cell	cell	NOUN
admet-496	61	73	lines	line	NOUN
admet-496	61	74	(	(	PUNCT
admet-496	61	75	including	include	VERB
admet-496	61	76	one	one	NUM
admet-496	61	77	with	with	ADP
admet-496	61	78	p	p	NOUN
admet-496	61	79	-	-	PUNCT
admet-496	61	80	glycoprotein	glycoprotein	NOUN
admet-496	61	81	overexpression	overexpression	NOUN
admet-496	61	82	)	)	PUNCT
admet-496	61	83	,	,	PUNCT
admet-496	61	84	2	2	NUM
admet-496	61	85	prostate	prostate	NOUN
admet-496	61	86	cancer	cancer	NOUN
admet-496	61	87	cell	cell	NOUN
admet-496	61	88	lines	line	NOUN
admet-496	61	89	,	,	PUNCT
admet-496	61	90	9	9	NUM
admet-496	61	91	renal	renal	ADJ
admet-496	61	92	cancer	cancer	NOUN
admet-496	61	93	cell	cell	NOUN
admet-496	61	94	lines	line	NOUN
admet-496	61	95	)	)	PUNCT
admet-496	61	96	.	.	PUNCT
admet-496	62	1	the	the	DET
admet-496	62	2	two	two	NUM
admet-496	62	3	small	small	ADJ
admet-496	62	4	cell	cell	NOUN
admet-496	62	5	lung	lung	NOUN
admet-496	62	6	cancer	cancer	NOUN
admet-496	62	7	cell	cell	NOUN
admet-496	62	8	lines	line	NOUN
admet-496	62	9	are	be	AUX
admet-496	62	10	not	not	PART
admet-496	62	11	shown	show	VERB
admet-496	62	12	.	.	PUNCT
admet-496	63	1	the	the	DET
admet-496	63	2	compound	compound	NOUN
admet-496	63	3	was	be	AUX
admet-496	63	4	tested	test	VERB
admet-496	63	5	at	at	ADP
admet-496	63	6	the	the	DET
admet-496	63	7	concentration	concentration	NOUN
admet-496	63	8	range	range	NOUN
admet-496	63	9	of	of	ADP
admet-496	63	10	10	10	NUM
admet-496	63	11	-8	-8	NOUN
admet-496	63	12	to	to	ADP
admet-496	63	13	10	10	NUM
admet-496	63	14	-4	-4	NOUN
admet-496	63	15	m	m	NOUN
admet-496	63	16	and	and	CCONJ
admet-496	63	17	cells	cell	NOUN
admet-496	63	18	were	be	AUX
admet-496	63	19	exposed	expose	VERB
admet-496	63	20	for	for	ADP
admet-496	63	21	48	48	NUM
admet-496	63	22	hr	hr	NOUN
admet-496	63	23	.	.	PROPN
admet-496	64	1	obtained	obtain	VERB
admet-496	64	2	from	from	ADP
admet-496	64	3	the	the	DET
admet-496	64	4	nci	nci	PROPN
admet-496	64	5	dtp	dtp	PROPN
admet-496	64	6	database	database	PROPN
admet-496	64	7	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	PROPN
admet-496	64	8	.	.	PUNCT
admet-496	65	1	in	in	ADP
admet-496	65	2	addition	addition	NOUN
admet-496	65	3	to	to	ADP
admet-496	65	4	the	the	DET
admet-496	65	5	potency	potency	NOUN
admet-496	65	6	of	of	ADP
admet-496	65	7	the	the	DET
admet-496	65	8	drugs	drug	NOUN
admet-496	65	9	(	(	PUNCT
admet-496	65	10	e.g.	e.g.	ADV
admet-496	65	11	figure	figure	NOUN
admet-496	65	12	2	2	NUM
admet-496	65	13	)	)	PUNCT
admet-496	65	14	,	,	PUNCT
admet-496	65	15	the	the	DET
admet-496	65	16	selectivity	selectivity	NOUN
admet-496	65	17	for	for	ADP
admet-496	65	18	a	a	DET
admet-496	65	19	certain	certain	ADJ
admet-496	65	20	tumour	tumour	NOUN
admet-496	65	21	type	type	NOUN
admet-496	65	22	in	in	ADP
admet-496	65	23	vitro	vitro	X
admet-496	65	24	(	(	PUNCT
admet-496	65	25	mean	mean	ADJ
admet-496	65	26	graph	graph	NOUN
admet-496	65	27	,	,	PUNCT
admet-496	65	28	figure	figure	NOUN
admet-496	65	29	3	3	NUM
admet-496	65	30	)	)	PUNCT
admet-496	65	31	,	,	PUNCT
admet-496	65	32	the	the	DET
admet-496	65	33	hfa	hfa	NOUN
admet-496	65	34	and	and	CCONJ
admet-496	65	35	if	if	SCONJ
admet-496	65	36	available	available	ADJ
admet-496	65	37	the	the	DET
admet-496	65	38	htx	htx	PROPN
admet-496	65	39	data	data	PROPN
admet-496	65	40	,	,	PUNCT
admet-496	65	41	another	another	DET
admet-496	65	42	important	important	ADJ
admet-496	65	43	selection	selection	NOUN
admet-496	65	44	criterion	criterion	NOUN
admet-496	65	45	for	for	ADP
admet-496	65	46	the	the	DET
admet-496	65	47	european	european	PROPN
admet-496	65	48	nci	nci	PROPN
admet-496	65	49	compounds	compound	NOUN
admet-496	65	50	were	be	AUX
admet-496	65	51	the	the	DET
admet-496	65	52	compare	compare	ADJ
admet-496	65	53	data	datum	NOUN
admet-496	65	54	[	[	X
admet-496	65	55	20	20	NUM
admet-496	65	56	]	]	PUNCT
admet-496	65	57	.	.	PUNCT
admet-496	66	1	compare	compare	NOUN
admet-496	66	2	is	be	AUX
admet-496	66	3	a	a	DET
admet-496	66	4	comparison	comparison	NOUN
admet-496	66	5	tool	tool	NOUN
admet-496	66	6	developed	develop	VERB
admet-496	66	7	by	by	ADP
admet-496	66	8	the	the	DET
admet-496	66	9	nci	nci	PROPN
admet-496	66	10	based	base	VERB
admet-496	66	11	on	on	ADP
admet-496	66	12	the	the	DET
admet-496	66	13	sensitivity	sensitivity	NOUN
admet-496	66	14	profile	profile	NOUN
admet-496	66	15	of	of	ADP
admet-496	66	16	an	an	DET
admet-496	66	17	nce	nce	NOUN
admet-496	66	18	compared	compare	VERB
admet-496	66	19	to	to	ADP
admet-496	66	20	the	the	DET
admet-496	66	21	whole	whole	ADJ
admet-496	66	22	database	database	NOUN
admet-496	66	23	.	.	PUNCT
admet-496	67	1	compare	compare	ADJ
admet-496	67	2	-	-	PUNCT
admet-496	67	3	positive	positive	ADJ
admet-496	67	4	compounds	compound	NOUN
admet-496	67	5	(	(	PUNCT
admet-496	67	6	pearson	pearson	NOUN
admet-496	67	7	correlation	correlation	NOUN
admet-496	67	8	coefficient	coefficient	NOUN
admet-496	67	9	≥0.8	≥0.8	VERB
admet-496	67	10	)	)	PUNCT
admet-496	67	11	often	often	ADV
admet-496	67	12	showed	show	VERB
admet-496	67	13	the	the	DET
admet-496	67	14	same	same	ADJ
admet-496	67	15	mechanism	mechanism	NOUN
admet-496	67	16	of	of	ADP
admet-496	67	17	action	action	NOUN
admet-496	67	18	;	;	PUNCT
admet-496	67	19	these	these	DET
admet-496	67	20	compounds	compound	NOUN
admet-496	67	21	could	could	AUX
admet-496	67	22	be	be	AUX
admet-496	67	23	structurally	structurally	ADV
admet-496	67	24	related	relate	VERB
admet-496	67	25	but	but	CCONJ
admet-496	67	26	also	also	ADV
admet-496	67	27	unrelated	unrelated	ADJ
admet-496	67	28	compounds	compound	NOUN
admet-496	67	29	[	[	X
admet-496	67	30	9,12	9,12	NUM
admet-496	67	31	]	]	PUNCT
admet-496	67	32	.	.	PUNCT
admet-496	68	1	since	since	SCONJ
admet-496	68	2	compare	compare	NOUN
admet-496	68	3	-	-	PUNCT
admet-496	68	4	negative	negative	ADJ
admet-496	68	5	compounds	compound	NOUN
admet-496	68	6	(	(	PUNCT
admet-496	68	7	pearson	pearson	NOUN
admet-496	68	8	correlation	correlation	NOUN
admet-496	68	9	coefficient	coefficient	NOUN
admet-496	68	10	<	<	X
admet-496	68	11	0.8	0.8	NUM
admet-496	68	12	)	)	PUNCT
admet-496	68	13	usually	usually	ADV
admet-496	68	14	did	do	AUX
admet-496	68	15	not	not	PART
admet-496	68	16	have	have	VERB
admet-496	68	17	close	close	ADJ
admet-496	68	18	matches	match	NOUN
admet-496	68	19	in	in	ADP
admet-496	68	20	the	the	DET
admet-496	68	21	compare	compare	NOUN
admet-496	68	22	programme	programme	NOUN
admet-496	68	23	,	,	PUNCT
admet-496	68	24	they	they	PRON
admet-496	68	25	might	might	AUX
admet-496	68	26	have	have	VERB
admet-496	68	27	a	a	DET
admet-496	68	28	novel	novel	ADJ
admet-496	68	29	mechanism	mechanism	NOUN
admet-496	68	30	of	of	ADP
admet-496	68	31	action	action	NOUN
admet-496	68	32	and	and	CCONJ
admet-496	68	33	were	be	AUX
admet-496	68	34	thought	think	VERB
admet-496	68	35	to	to	PART
admet-496	68	36	be	be	AUX
admet-496	68	37	most	most	ADV
admet-496	68	38	interesting	interesting	ADJ
admet-496	68	39	.	.	PUNCT
admet-496	69	1	for	for	ADP
admet-496	69	2	administration	administration	NOUN
admet-496	69	3	of	of	ADP
admet-496	69	4	drugs	drug	NOUN
admet-496	69	5	to	to	ADP
admet-496	69	6	animals	animal	NOUN
admet-496	69	7	often	often	ADV
admet-496	69	8	additional	additional	ADJ
admet-496	69	9	hurdles	hurdle	NOUN
admet-496	69	10	needed	need	VERB
admet-496	69	11	to	to	PART
admet-496	69	12	be	be	AUX
admet-496	69	13	solved	solve	VERB
admet-496	69	14	,	,	PUNCT
admet-496	69	15	such	such	ADJ
admet-496	69	16	as	as	ADP
admet-496	69	17	the	the	DET
admet-496	69	18	administration	administration	NOUN
admet-496	69	19	vehicle	vehicle	NOUN
admet-496	69	20	,	,	PUNCT
admet-496	69	21	which	which	PRON
admet-496	69	22	will	will	AUX
admet-496	69	23	be	be	AUX
admet-496	69	24	different	different	ADJ
admet-496	69	25	from	from	ADP
admet-496	69	26	formulations	formulation	NOUN
admet-496	69	27	used	use	VERB
admet-496	69	28	in	in	ADP
admet-496	69	29	vitro	vitro	X
admet-496	69	30	[	[	X
admet-496	69	31	14	14	NUM
admet-496	69	32	]	]	PUNCT
admet-496	69	33	.	.	PUNCT
admet-496	70	1	many	many	ADJ
admet-496	70	2	compounds	compound	NOUN
admet-496	70	3	were	be	AUX
admet-496	70	4	poorly	poorly	ADV
admet-496	70	5	soluble	soluble	ADJ
admet-496	70	6	and	and	CCONJ
admet-496	70	7	specific	specific	ADJ
admet-496	70	8	formulations	formulation	NOUN
admet-496	70	9	were	be	AUX
admet-496	70	10	used	use	VERB
admet-496	70	11	,	,	PUNCT
admet-496	70	12	dependent	dependent	ADJ
admet-496	70	13	on	on	ADP
admet-496	70	14	the	the	DET
admet-496	70	15	compound	compound	NOUN
admet-496	70	16	,	,	PUNCT
admet-496	70	17	but	but	CCONJ
admet-496	70	18	keeping	keep	VERB
admet-496	70	19	in	in	ADP
admet-496	70	20	mind	mind	NOUN
admet-496	70	21	what	what	PRON
admet-496	70	22	might	might	AUX
admet-496	70	23	be	be	AUX
admet-496	70	24	suitable	suitable	ADJ
admet-496	70	25	for	for	ADP
admet-496	70	26	future	future	ADJ
admet-496	70	27	administration	administration	NOUN
admet-496	70	28	to	to	ADP
admet-496	70	29	patients	patient	NOUN
admet-496	70	30	.	.	PUNCT
admet-496	71	1	hence	hence	ADV
admet-496	71	2	dimethyl	dimethyl	NOUN
admet-496	71	3	sulfoxide	sulfoxide	NOUN
admet-496	71	4	(	(	PUNCT
admet-496	71	5	dmso	dmso	NOUN
admet-496	71	6	)	)	PUNCT
admet-496	71	7	might	might	AUX
admet-496	71	8	be	be	AUX
admet-496	71	9	suitable	suitable	ADJ
admet-496	71	10	for	for	ADP
admet-496	71	11	in	in	ADP
admet-496	71	12	vitro	vitro	X
admet-496	71	13	and	and	CCONJ
admet-496	71	14	in	in	ADP
admet-496	71	15	vivo	vivo	NOUN
admet-496	71	16	to	to	ADP
admet-496	71	17	mice	mouse	NOUN
admet-496	71	18	,	,	PUNCT
admet-496	71	19	but	but	CCONJ
admet-496	71	20	not	not	PART
admet-496	71	21	for	for	ADP
admet-496	71	22	patients	patient	NOUN
admet-496	71	23	(	(	PUNCT
admet-496	71	24	table	table	NOUN
admet-496	71	25	1	1	NUM
admet-496	71	26	)	)	PUNCT
admet-496	71	27	.	.	PUNCT
admet-496	72	1	after	after	ADP
admet-496	72	2	this	this	DET
admet-496	72	3	pre	pre	ADJ
admet-496	72	4	-	-	ADJ
admet-496	72	5	formulation	formulation	ADJ
admet-496	72	6	step	step	NOUN
admet-496	72	7	,	,	PUNCT
admet-496	72	8	the	the	DET
admet-496	72	9	potential	potential	ADJ
admet-496	72	10	bioavailability	bioavailability	NOUN
admet-496	72	11	of	of	ADP
admet-496	72	12	a	a	DET
admet-496	72	13	compound	compound	NOUN
admet-496	72	14	was	be	AUX
admet-496	72	15	investigated	investigate	VERB
admet-496	72	16	.	.	PUNCT
admet-496	73	1	after	after	ADP
admet-496	73	2	the	the	DET
admet-496	73	3	development	development	NOUN
admet-496	73	4	of	of	ADP
admet-496	73	5	a	a	DET
admet-496	73	6	suitable	suitable	ADJ
admet-496	73	7	hplc	hplc	NOUN
admet-496	73	8	assay	assay	NOUN
admet-496	73	9	(	(	PUNCT
admet-496	73	10	or	or	CCONJ
admet-496	73	11	another	another	DET
admet-496	73	12	analytical	analytical	ADJ
admet-496	73	13	assay	assay	NOUN
admet-496	73	14	)	)	PUNCT
admet-496	73	15	and	and	CCONJ
admet-496	73	16	using	use	VERB
admet-496	73	17	a	a	DET
admet-496	73	18	proper	proper	ADJ
admet-496	73	19	formulation	formulation	NOUN
admet-496	73	20	,	,	PUNCT
admet-496	73	21	the	the	DET
admet-496	73	22	mtd	mtd	PROPN
admet-496	73	23	in	in	ADP
admet-496	73	24	mice	mouse	NOUN
admet-496	73	25	was	be	AUX
admet-496	73	26	determined	determine	VERB
admet-496	73	27	.	.	PUNCT
admet-496	74	1	the	the	DET
admet-496	74	2	mtd	mtd	PROPN
admet-496	74	3	was	be	AUX
admet-496	74	4	administered	administer	VERB
admet-496	74	5	and	and	CCONJ
admet-496	74	6	plasma	plasma	VERB
admet-496	74	7	pharmacokinetics	pharmacokinetic	NOUN
admet-496	74	8	determined	determine	VERB
admet-496	74	9	at	at	ADP
admet-496	74	10	various	various	ADJ
admet-496	74	11	time	time	NOUN
admet-496	74	12	points	point	NOUN
admet-496	74	13	to	to	PART
admet-496	74	14	ascertain	ascertain	VERB
admet-496	74	15	whether	whether	SCONJ
admet-496	74	16	the	the	DET
admet-496	74	17	drug	drug	NOUN
admet-496	74	18	would	would	AUX
admet-496	74	19	reach	reach	VERB
admet-496	74	20	plasma	plasma	NOUN
admet-496	74	21	concentrations	concentration	NOUN
admet-496	74	22	in	in	ADP
admet-496	74	23	the	the	DET
admet-496	74	24	range	range	NOUN
admet-496	74	25	of	of	ADP
admet-496	74	26	the	the	DET
admet-496	74	27	in	in	ADV
admet-496	74	28	vitro	vitro	X
admet-496	74	29	gi50	gi50	PROPN
admet-496	74	30	.	.	PUNCT
admet-496	75	1	subsequently	subsequently	ADV
admet-496	75	2	,	,	PUNCT
admet-496	75	3	this	this	DET
admet-496	75	4	dose	dose	NOUN
admet-496	75	5	and	and	CCONJ
admet-496	75	6	schedule	schedule	NOUN
admet-496	75	7	were	be	AUX
admet-496	75	8	used	use	VERB
admet-496	75	9	to	to	PART
admet-496	75	10	explore	explore	VERB
admet-496	75	11	whether	whether	SCONJ
admet-496	75	12	the	the	DET
admet-496	75	13	compound	compound	NOUN
admet-496	75	14	would	would	AUX
admet-496	75	15	have	have	VERB
admet-496	75	16	suitable	suitable	ADJ
admet-496	75	17	in	in	ADP
admet-496	75	18	vivo	vivo	ADJ
admet-496	75	19	antitumor	antitumor	NOUN
admet-496	75	20	activity	activity	NOUN
admet-496	75	21	.	.	PUNCT
admet-496	76	1	if	if	SCONJ
admet-496	76	2	so	so	ADV
admet-496	76	3	,	,	PUNCT
admet-496	76	4	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	https://dtp.cancer.gov/discovery_development/nci-60/methodology.htm	PROPN
admet-496	76	5	godefridus	godefridus	PROPN
admet-496	76	6	peters	peters	PROPN
admet-496	76	7	et	et	PROPN
admet-496	76	8	al	al	PROPN
admet-496	76	9	.	.	PROPN
admet-496	76	10	admet	admet	PROPN
admet-496	76	11	&	&	CCONJ
admet-496	76	12	dmpk	dmpk	PROPN
admet-496	76	13	6(1	6(1	NUM
admet-496	76	14	)	)	PUNCT
admet-496	76	15	(	(	PUNCT
admet-496	76	16	2018	2018	NUM
admet-496	76	17	)	)	PUNCT
admet-496	76	18	4	4	NUM
admet-496	76	19	-	-	SYM
admet-496	76	20	14	14	NUM
admet-496	76	21	8	8	NUM
admet-496	76	22	the	the	DET
admet-496	76	23	development	development	NOUN
admet-496	76	24	was	be	AUX
admet-496	76	25	continued	continue	VERB
admet-496	76	26	and	and	CCONJ
admet-496	76	27	if	if	SCONJ
admet-496	76	28	not	not	PART
admet-496	76	29	,	,	PUNCT
admet-496	76	30	stopped	stop	VERB
admet-496	76	31	.	.	PUNCT
admet-496	77	1	in	in	ADP
admet-496	77	2	the	the	DET
admet-496	77	3	next	next	ADJ
admet-496	77	4	section	section	NOUN
admet-496	77	5	,	,	PUNCT
admet-496	77	6	several	several	ADJ
admet-496	77	7	examples	example	NOUN
admet-496	77	8	of	of	ADP
admet-496	77	9	such	such	DET
admet-496	77	10	a	a	DET
admet-496	77	11	development	development	NOUN
admet-496	77	12	will	will	AUX
admet-496	77	13	be	be	AUX
admet-496	77	14	presented	present	VERB
admet-496	77	15	.	.	PUNCT
admet-496	78	1	figure	figure	VERB
admet-496	78	2	3	3	NUM
admet-496	78	3	.	.	NOUN
admet-496	78	4	example	example	NOUN
admet-496	78	5	report	report	NOUN
admet-496	78	6	of	of	ADP
admet-496	78	7	drug	drug	NOUN
admet-496	78	8	selectivity	selectivity	NOUN
admet-496	78	9	for	for	ADP
admet-496	78	10	5f-203	5f-203	NUM
admet-496	78	11	and	and	CCONJ
admet-496	78	12	its	its	PRON
admet-496	78	13	prodrug	prodrug	NOUN
admet-496	78	14	phortress	phortress	NOUN
admet-496	78	15	(	(	PUNCT
admet-496	78	16	source	source	NOUN
admet-496	78	17	nci	nci	PROPN
admet-496	78	18	dtp	dtp	PROPN
admet-496	78	19	)	)	PUNCT
admet-496	78	20	.	.	PUNCT
admet-496	79	1	values	value	NOUN
admet-496	79	2	are	be	AUX
admet-496	79	3	calculated	calculate	VERB
admet-496	79	4	relative	relative	ADJ
admet-496	79	5	to	to	ADP
admet-496	79	6	the	the	DET
admet-496	79	7	mean	mean	NOUN
admet-496	79	8	gi50	gi50	PROPN
admet-496	79	9	for	for	ADP
admet-496	79	10	each	each	DET
admet-496	79	11	compound	compound	NOUN
admet-496	79	12	.	.	PUNCT
admet-496	80	1	differences	difference	NOUN
admet-496	80	2	compared	compare	VERB
admet-496	80	3	to	to	ADP
admet-496	80	4	the	the	DET
admet-496	80	5	mean	mean	NOUN
admet-496	80	6	are	be	AUX
admet-496	80	7	given	give	VERB
admet-496	80	8	as	as	ADP
admet-496	80	9	a	a	DET
admet-496	80	10	log	log	NOUN
admet-496	80	11	10	10	NUM
admet-496	80	12	value	value	NOUN
admet-496	80	13	,	,	PUNCT
admet-496	80	14	with	with	ADP
admet-496	80	15	bars	bar	NOUN
admet-496	80	16	to	to	PART
admet-496	80	17	left	leave	VERB
admet-496	80	18	representing	represent	VERB
admet-496	80	19	less	less	ADV
admet-496	80	20	sensitive	sensitive	ADJ
admet-496	80	21	cell	cell	NOUN
admet-496	80	22	lines	line	NOUN
admet-496	80	23	(	(	PUNCT
admet-496	80	24	10	10	NUM
admet-496	80	25	3	3	NUM
admet-496	80	26	to	to	ADP
admet-496	80	27	0	0	NUM
admet-496	80	28	)	)	PUNCT
admet-496	80	29	and	and	CCONJ
admet-496	80	30	those	those	PRON
admet-496	80	31	to	to	ADP
admet-496	80	32	the	the	DET
admet-496	80	33	right	right	NOUN
admet-496	80	34	more	more	ADV
admet-496	80	35	sensitive	sensitive	ADJ
admet-496	80	36	cell	cell	NOUN
admet-496	80	37	lines	line	NOUN
admet-496	80	38	(	(	PUNCT
admet-496	80	39	0	0	NUM
admet-496	80	40	to	to	PART
admet-496	80	41	10	10	NUM
admet-496	80	42	-3	-3	PUNCT
admet-496	80	43	)	)	PUNCT
admet-496	80	44	.	.	PUNCT
admet-496	81	1	cell	cell	NOUN
admet-496	81	2	lines	line	NOUN
admet-496	81	3	from	from	ADP
admet-496	81	4	top	top	NOUN
admet-496	81	5	to	to	ADP
admet-496	81	6	bottom	bottom	NOUN
admet-496	81	7	represent	represent	VERB
admet-496	81	8	5	5	NUM
admet-496	81	9	leukaemia	leukaemia	NOUN
admet-496	81	10	cell	cell	NOUN
admet-496	81	11	lines	line	NOUN
admet-496	81	12	,	,	PUNCT
admet-496	81	13	9	9	NUM
admet-496	81	14	nsclc	nsclc	NOUN
admet-496	81	15	,	,	PUNCT
admet-496	81	16	7	7	NUM
admet-496	81	17	colon	colon	NOUN
admet-496	81	18	cancer	cancer	NOUN
admet-496	81	19	,	,	PUNCT
admet-496	81	20	6	6	NUM
admet-496	81	21	cns	cns	NOUN
admet-496	81	22	,	,	PUNCT
admet-496	81	23	8	8	NUM
admet-496	81	24	melanoma	melanoma	NOUN
admet-496	81	25	,	,	PUNCT
admet-496	81	26	6	6	NUM
admet-496	81	27	ovarian	ovarian	ADJ
admet-496	81	28	cancer	cancer	NOUN
admet-496	81	29	,	,	PUNCT
admet-496	81	30	8	8	NUM
admet-496	81	31	renal	renal	ADJ
admet-496	81	32	cancer	cancer	NOUN
admet-496	81	33	,	,	PUNCT
admet-496	81	34	2	2	NUM
admet-496	81	35	prostate	prostate	NOUN
admet-496	81	36	cancer	cancer	NOUN
admet-496	81	37	,	,	PUNCT
admet-496	81	38	8	8	NUM
admet-496	81	39	breast	breast	NOUN
admet-496	81	40	cancer	cancer	NOUN
admet-496	81	41	(	(	PUNCT
admet-496	81	42	including	include	VERB
admet-496	81	43	one	one	NUM
admet-496	81	44	with	with	ADP
admet-496	81	45	p	p	NOUN
admet-496	81	46	-	-	PUNCT
admet-496	81	47	glycoprotein	glycoprotein	NOUN
admet-496	81	48	overexpression	overexpression	NOUN
admet-496	81	49	)	)	PUNCT
admet-496	81	50	.	.	PUNCT
admet-496	82	1	please	please	INTJ
admet-496	82	2	note	note	VERB
admet-496	82	3	that	that	SCONJ
admet-496	82	4	the	the	DET
admet-496	82	5	composition	composition	NOUN
admet-496	82	6	of	of	ADP
admet-496	82	7	this	this	DET
admet-496	82	8	panel	panel	NOUN
admet-496	82	9	is	be	AUX
admet-496	82	10	different	different	ADJ
admet-496	82	11	from	from	ADP
admet-496	82	12	figure	figure	NOUN
admet-496	82	13	.	.	PUNCT
admet-496	83	1	2	2	X
admet-496	83	2	.	.	X
admet-496	83	3	the	the	DET
admet-496	83	4	most	most	ADV
admet-496	83	5	sensitive	sensitive	ADJ
admet-496	83	6	cell	cell	NOUN
admet-496	83	7	lines	line	NOUN
admet-496	83	8	are	be	AUX
admet-496	83	9	depicted	depict	VERB
admet-496	83	10	in	in	ADP
admet-496	83	11	a	a	DET
admet-496	83	12	larger	large	ADJ
admet-496	83	13	font	font	NOUN
admet-496	83	14	.	.	PUNCT
admet-496	84	1	the	the	DET
admet-496	84	2	non	non	ADJ
admet-496	84	3	-	-	ADJ
admet-496	84	4	responsive	responsive	ADJ
admet-496	84	5	in	in	ADP
admet-496	84	6	italics	italic	NOUN
admet-496	84	7	.	.	PUNCT
admet-496	85	1	examples	example	NOUN
admet-496	85	2	of	of	ADP
admet-496	85	3	selected	select	VERB
admet-496	85	4	compounds	compound	NOUN
admet-496	85	5	in	in	ADP
admet-496	85	6	one	one	NUM
admet-496	85	7	of	of	ADP
admet-496	85	8	the	the	DET
admet-496	85	9	early	early	ADJ
admet-496	85	10	selected	select	VERB
admet-496	85	11	series	series	NOUN
admet-496	85	12	of	of	ADP
admet-496	85	13	compounds	compound	NOUN
admet-496	85	14	,	,	PUNCT
admet-496	85	15	nsc-697786	nsc-697786	NOUN
admet-496	85	16	(	(	PUNCT
admet-496	85	17	figure	figure	NOUN
admet-496	85	18	4	4	NUM
admet-496	85	19	)	)	PUNCT
admet-496	85	20	showed	show	VERB
admet-496	85	21	an	an	DET
admet-496	85	22	interesting	interesting	ADJ
admet-496	85	23	profile	profile	NOUN
admet-496	85	24	in	in	ADP
admet-496	85	25	the	the	DET
admet-496	85	26	compare	compare	ADJ
admet-496	85	27	analysis	analysis	NOUN
admet-496	85	28	with	with	ADP
admet-496	85	29	a	a	DET
admet-496	85	30	compare	compare	ADJ
admet-496	85	31	coefficient	coefficient	NOUN
admet-496	85	32	of	of	ADP
admet-496	85	33	0.503	0.503	NUM
admet-496	85	34	for	for	ADP
admet-496	85	35	methotrexate	methotrexate	NOUN
admet-496	85	36	,	,	PUNCT
admet-496	85	37	0.498	0.498	NUM
admet-496	85	38	for	for	ADP
admet-496	85	39	dup785	dup785	PROPN
admet-496	85	40	(	(	PUNCT
admet-496	85	41	brequinar	brequinar	NOUN
admet-496	85	42	)	)	PUNCT
admet-496	85	43	,	,	PUNCT
admet-496	85	44	0.496	0.496	NUM
admet-496	85	45	for	for	ADP
admet-496	85	46	n	n	CCONJ
admet-496	85	47	-	-	PUNCT
admet-496	85	48	phosphon	phosphon	NOUN
admet-496	85	49	-	-	PUNCT
admet-496	85	50	acetyl	acetyl	NOUN
admet-496	85	51	-	-	PUNCT
admet-496	85	52	l	l	NOUN
admet-496	85	53	-	-	NOUN
admet-496	85	54	aspartate	aspartate	NOUN
admet-496	85	55	(	(	PUNCT
admet-496	85	56	pala	pala	NOUN
admet-496	85	57	)	)	PUNCT
admet-496	85	58	and	and	CCONJ
admet-496	85	59	0.474	0.474	NUM
admet-496	85	60	for	for	ADP
admet-496	85	61	trimetrexate	trimetrexate	NOUN
admet-496	85	62	.	.	PUNCT
admet-496	86	1	this	this	PRON
admet-496	86	2	indicates	indicate	VERB
admet-496	86	3	some	some	DET
admet-496	86	4	similarity	similarity	NOUN
admet-496	86	5	with	with	ADP
admet-496	86	6	antifolates	antifolate	NOUN
admet-496	86	7	(	(	PUNCT
admet-496	86	8	methotrexate	methotrexate	NOUN
admet-496	86	9	and	and	CCONJ
admet-496	86	10	trimetrexate	trimetrexate	NOUN
admet-496	86	11	)	)	PUNCT
admet-496	86	12	and	and	CCONJ
admet-496	86	13	pyrimidine	pyrimidine	NOUN
admet-496	86	14	de	de	X
admet-496	86	15	novo	novo	NOUN
admet-496	86	16	nucleotide	nucleotide	ADJ
admet-496	86	17	inhibitors	inhibitor	NOUN
admet-496	86	18	(	(	PUNCT
admet-496	86	19	dup785	dup785	PROPN
admet-496	86	20	and	and	CCONJ
admet-496	86	21	pala	pala	PROPN
admet-496	86	22	)	)	PUNCT
admet-496	86	23	.	.	PUNCT
admet-496	87	1	the	the	DET
admet-496	87	2	standard	standard	ADJ
admet-496	87	3	approach	approach	NOUN
admet-496	87	4	to	to	PART
admet-496	87	5	exclude	exclude	VERB
admet-496	87	6	this	this	PRON
admet-496	87	7	is	be	AUX
admet-496	87	8	a	a	DET
admet-496	87	9	comparison	comparison	NOUN
admet-496	87	10	in	in	ADP
admet-496	87	11	cell	cell	NOUN
admet-496	87	12	lines	line	NOUN
admet-496	87	13	with	with	ADP
admet-496	87	14	aberrations	aberration	NOUN
admet-496	87	15	in	in	ADP
admet-496	87	16	folate	folate	NOUN
admet-496	87	17	metabolism	metabolism	NOUN
admet-496	87	18	and	and	CCONJ
admet-496	87	19	to	to	PART
admet-496	87	20	perform	perform	VERB
admet-496	87	21	rescue	rescue	NOUN
admet-496	87	22	experiments	experiment	NOUN
admet-496	87	23	with	with	ADP
admet-496	87	24	normal	normal	ADJ
admet-496	87	25	pyrimidine	pyrimidine	NOUN
admet-496	87	26	nucleosides	nucleoside	NOUN
admet-496	87	27	,	,	PUNCT
admet-496	87	28	respectively	respectively	ADV
admet-496	87	29	.	.	PUNCT
admet-496	88	1	consequently	consequently	ADV
admet-496	88	2	,	,	PUNCT
admet-496	88	3	this	this	DET
admet-496	88	4	compound	compound	NOUN
admet-496	88	5	was	be	AUX
admet-496	88	6	tested	test	VERB
admet-496	88	7	in	in	ADP
admet-496	88	8	colon	colon	NOUN
admet-496	88	9	cancer	cancer	NOUN
admet-496	88	10	widr	widr	NOUN
admet-496	88	11	cells	cell	NOUN
admet-496	88	12	grown	grow	VERB
admet-496	88	13	in	in	ADP
admet-496	88	14	standard	standard	ADJ
admet-496	88	15	culture	culture	NOUN
admet-496	88	16	medium	medium	NOUN
admet-496	88	17	(	(	PUNCT
admet-496	88	18	which	which	PRON
admet-496	88	19	has	have	VERB
admet-496	88	20	a	a	DET
admet-496	88	21	high	high	ADJ
admet-496	88	22	folate	folate	NOUN
admet-496	88	23	concentration	concentration	NOUN
admet-496	88	24	)	)	PUNCT
admet-496	88	25	and	and	CCONJ
admet-496	88	26	widr	widr	ADJ
admet-496	88	27	cells	cell	NOUN
admet-496	88	28	that	that	PRON
admet-496	88	29	are	be	AUX
admet-496	88	30	adapted	adapt	VERB
admet-496	88	31	to	to	ADP
admet-496	88	32	a	a	DET
admet-496	88	33	low	low	ADJ
admet-496	88	34	physiological	physiological	NOUN
admet-496	88	35	(	(	PUNCT
admet-496	88	36	comparable	comparable	ADJ
admet-496	88	37	to	to	ADP
admet-496	88	38	human	human	ADJ
admet-496	88	39	plasma	plasma	NOUN
admet-496	88	40	;	;	PUNCT
admet-496	88	41	widr	widr	NOUN
admet-496	88	42	/	/	SYM
admet-496	88	43	f	f	X
admet-496	88	44	)	)	PUNCT
admet-496	88	45	folate	folate	NOUN
admet-496	88	46	concentration	concentration	NOUN
admet-496	89	1	[	[	X
admet-496	89	2	21	21	NUM
admet-496	89	3	]	]	PUNCT
admet-496	89	4	.	.	PUNCT
admet-496	90	1	a	a	DET
admet-496	90	2	similar	similar	ADJ
admet-496	90	3	ic50	ic50	PROPN
admet-496	90	4	was	be	AUX
admet-496	90	5	found	find	VERB
admet-496	90	6	in	in	ADP
admet-496	90	7	both	both	DET
admet-496	90	8	lines	line	NOUN
admet-496	90	9	(	(	PUNCT
admet-496	90	10	0.26	0.26	NUM
admet-496	90	11	±	±	NUM
admet-496	90	12	0.06	0.06	NUM
admet-496	90	13	and	and	CCONJ
admet-496	90	14	0.25	0.25	NUM
admet-496	90	15	±	±	NUM
admet-496	90	16	0.07	0.07	NUM
admet-496	90	17	µm	µm	NOUN
admet-496	90	18	,	,	PUNCT
admet-496	90	19	respectively	respectively	ADV
admet-496	90	20	;	;	PUNCT
admet-496	90	21	means	mean	VERB
admet-496	90	22	±	±	PROPN
admet-496	90	23	se	se	X
admet-496	90	24	of	of	ADP
admet-496	90	25	4	4	NUM
admet-496	90	26	-	-	SYM
admet-496	90	27	7	7	NUM
admet-496	90	28	experiments	experiment	NOUN
admet-496	90	29	;	;	PUNCT
admet-496	90	30	72	72	NUM
admet-496	90	31	-	-	PUNCT
admet-496	90	32	hour	hour	NOUN
admet-496	90	33	exposure	exposure	NOUN
admet-496	90	34	)	)	PUNCT
admet-496	90	35	.	.	PUNCT
admet-496	91	1	widr	widr	PROPN
admet-496	91	2	/	/	SYM
admet-496	91	3	f	f	PROPN
admet-496	91	4	cells	cell	NOUN
admet-496	91	5	are	be	AUX
admet-496	91	6	more	more	ADV
admet-496	91	7	sensitive	sensitive	ADJ
admet-496	91	8	to	to	ADP
admet-496	91	9	antifolates	antifolate	NOUN
admet-496	91	10	such	such	ADJ
admet-496	91	11	as	as	ADP
admet-496	91	12	methotrexate	methotrexate	NOUN
admet-496	91	13	.	.	PUNCT
admet-496	92	1	addition	addition	NOUN
admet-496	92	2	of	of	ADP
admet-496	92	3	1	1	NUM
admet-496	92	4	or	or	CCONJ
admet-496	92	5	5	5	NUM
admet-496	92	6	mm	mm	NOUN
admet-496	92	7	uridine	uridine	NOUN
admet-496	92	8	or	or	CCONJ
admet-496	92	9	cytidine	cytidine	NOUN
admet-496	92	10	did	do	AUX
admet-496	92	11	not	not	PART
admet-496	92	12	protect	protect	VERB
admet-496	92	13	the	the	DET
admet-496	92	14	cells	cell	NOUN
admet-496	92	15	,	,	PUNCT
admet-496	92	16	which	which	PRON
admet-496	92	17	would	would	AUX
admet-496	92	18	have	have	AUX
admet-496	92	19	been	be	AUX
admet-496	92	20	indicative	indicative	ADJ
admet-496	92	21	for	for	SCONJ
admet-496	92	22	a	a	DET
admet-496	92	23	pyrimidine	pyrimidine	NOUN
admet-496	92	24	de	de	X
admet-496	92	25	novo	novo	NOUN
admet-496	92	26	inhibition	inhibition	NOUN
admet-496	92	27	[	[	X
admet-496	92	28	22	22	NUM
admet-496	92	29	]	]	PUNCT
admet-496	92	30	.	.	PUNCT
admet-496	93	1	fma3	fma3	ADJ
admet-496	93	2	wild	wild	ADJ
admet-496	93	3	type	type	NOUN
admet-496	93	4	and	and	CCONJ
admet-496	93	5	fma3	fma3	NOUN
admet-496	93	6	/	/	SYM
admet-496	93	7	tk(thymidine	tk(thymidine	PROPN
admet-496	93	8	kinase	kinase	NOUN
admet-496	93	9	deficient	deficient	ADJ
admet-496	93	10	)	)	PUNCT
admet-496	94	1	[	[	X
admet-496	94	2	23	23	NUM
admet-496	94	3	]	]	PUNCT
admet-496	94	4	were	be	AUX
admet-496	94	5	similarly	similarly	ADV
admet-496	94	6	sensitive	sensitive	ADJ
admet-496	94	7	(	(	PUNCT
admet-496	94	8	ic50	ic50	PROPN
admet-496	94	9	values	value	NOUN
admet-496	94	10	for	for	ADP
admet-496	94	11	nsc-697786	nsc-697786	NOUN
admet-496	94	12	3.2	3.2	NUM
admet-496	94	13	±	±	NUM
admet-496	94	14	0.2	0.2	NUM
admet-496	94	15	and	and	CCONJ
admet-496	94	16	2.0	2.0	NUM
admet-496	94	17	±	±	NUM
admet-496	94	18	0.8	0.8	NUM
admet-496	94	19	µm	µm	NOUN
admet-496	94	20	)	)	PUNCT
admet-496	94	21	,	,	PUNCT
admet-496	94	22	which	which	PRON
admet-496	94	23	excluded	exclude	VERB
admet-496	94	24	a	a	DET
admet-496	94	25	role	role	NOUN
admet-496	94	26	for	for	ADP
admet-496	94	27	thymidine	thymidine	ADJ
admet-496	94	28	kinase	kinase	PROPN
admet-496	94	29	.	.	PUNCT
admet-496	95	1	it	it	PRON
admet-496	95	2	was	be	AUX
admet-496	95	3	concluded	conclude	VERB
admet-496	95	4	that	that	SCONJ
admet-496	95	5	this	this	DET
admet-496	95	6	compound	compound	NOUN
admet-496	95	7	is	be	AUX
admet-496	95	8	a	a	DET
admet-496	95	9	not	not	PART
admet-496	95	10	acting	act	VERB
admet-496	95	11	as	as	ADP
admet-496	95	12	an	an	DET
admet-496	95	13	antimetabolite	antimetabolite	NOUN
admet-496	95	14	,	,	PUNCT
admet-496	95	15	and	and	CCONJ
admet-496	95	16	had	have	VERB
admet-496	95	17	possibly	possibly	ADV
admet-496	95	18	unique	unique	ADJ
admet-496	95	19	mechanism	mechanism	NOUN
admet-496	95	20	of	of	ADP
admet-496	95	21	action	action	NOUN
admet-496	95	22	.	.	PUNCT
admet-496	96	1	however	however	ADV
admet-496	96	2	,	,	PUNCT
admet-496	96	3	it	it	PRON
admet-496	96	4	was	be	AUX
admet-496	96	5	discontinued	discontinue	VERB
admet-496	96	6	due	due	ADP
admet-496	96	7	to	to	ADP
admet-496	96	8	lack	lack	NOUN
admet-496	96	9	of	of	ADP
admet-496	96	10	in	in	ADP
admet-496	96	11	vivo	vivo	NOUN
admet-496	96	12	activity	activity	NOUN
admet-496	96	13	,	,	PUNCT
admet-496	96	14	possibly	possibly	ADV
admet-496	96	15	because	because	SCONJ
admet-496	96	16	of	of	ADP
admet-496	96	17	poor	poor	ADJ
admet-496	96	18	pharmacokinetics	pharmacokinetic	NOUN
admet-496	96	19	.	.	PUNCT
admet-496	97	1	admet	admet	PROPN
admet-496	97	2	&	&	CCONJ
admet-496	97	3	dmpk	dmpk	PROPN
admet-496	97	4	6(1	6(1	NUM
admet-496	97	5	)	)	PUNCT
admet-496	97	6	(	(	PUNCT
admet-496	97	7	2018	2018	NUM
admet-496	97	8	)	)	PUNCT
admet-496	97	9	4	4	NUM
admet-496	97	10	-	-	SYM
admet-496	97	11	14	14	NUM
admet-496	97	12	the	the	DET
admet-496	97	13	role	role	NOUN
admet-496	97	14	of	of	ADP
admet-496	97	15	pharmacology	pharmacology	NOUN
admet-496	97	16	in	in	ADP
admet-496	97	17	anticancer	anticancer	NOUN
admet-496	97	18	drug	drug	PROPN
admet-496	97	19	development	development	PROPN
admet-496	97	20	doi	doi	PROPN
admet-496	97	21	:	:	PUNCT
admet-496	97	22	10.5599	10.5599	NUM
admet-496	97	23	/	/	SYM
admet-496	97	24	admet.6.1.496	admet.6.1.496	VERB
admet-496	97	25	9	9	NUM
admet-496	97	26	table	table	NOUN
admet-496	97	27	1	1	NUM
admet-496	97	28	.	.	PUNCT
admet-496	97	29	acceptable	acceptable	ADJ
admet-496	97	30	solvents	solvent	NOUN
admet-496	97	31	for	for	ADP
admet-496	97	32	in	in	ADP
admet-496	97	33	vitro	vitro	X
admet-496	97	34	drug	drug	NOUN
admet-496	97	35	solutions	solution	NOUN
admet-496	97	36	or	or	CCONJ
admet-496	97	37	in	in	ADP
admet-496	97	38	vivo	vivo	ADJ
admet-496	97	39	administration	administration	NOUN
admet-496	97	40	of	of	ADP
admet-496	97	41	drugs	drug	NOUN
admet-496	97	42	to	to	PART
admet-496	97	43	mice	mouse	NOUN
admet-496	97	44	or	or	CCONJ
admet-496	97	45	rats	rat	NOUN
admet-496	97	46	.	.	PUNCT
admet-496	98	1	solvent	solvent	ADJ
admet-496	98	2	maximal	maximal	ADJ
admet-496	98	3	concentration	concentration	NOUN
admet-496	98	4	maximal	maximal	ADJ
admet-496	98	5	dose	dose	NOUN
admet-496	98	6	species	specie	NOUN
admet-496	98	7	maximal	maximal	ADJ
admet-496	98	8	final	final	ADJ
admet-496	98	9	concentration	concentration	NOUN
admet-496	98	10	in	in	ADP
admet-496	98	11	vivo	vivo	NOUN
admet-496	98	12	in	in	ADP
admet-496	98	13	vitro	vitro	X
admet-496	98	14	culture	culture	PROPN
admet-496	98	15	medium	medium	PROPN
admet-496	98	16	dmem	dmem	PROPN
admet-496	98	17	,	,	PUNCT
admet-496	98	18	rpmi	rpmi	NOUN
admet-496	98	19	(	(	PUNCT
admet-496	98	20	1	1	NUM
admet-496	98	21	st	st	PROPN
admet-496	98	22	choice	choice	NOUN
admet-496	98	23	)	)	PUNCT
admet-496	98	24	water	water	NOUN
admet-496	98	25	10	10	NUM
admet-496	98	26	%	%	NOUN
admet-496	98	27	(	(	PUNCT
admet-496	98	28	final	final	ADJ
admet-496	98	29	)	)	PUNCT
admet-496	98	30	0.9	0.9	NUM
admet-496	98	31	%	%	NOUN
admet-496	98	32	saline	saline	NOUN
admet-496	98	33	ph	ph	NOUN
admet-496	98	34	7.4	7.4	NUM
admet-496	98	35	0.5	0.5	NUM
admet-496	98	36	ml	ml	NOUN
admet-496	98	37	mice	mouse	NOUN
admet-496	98	38	;	;	PUNCT
admet-496	98	39	rats	rat	NOUN
admet-496	98	40	2	2	NUM
admet-496	98	41	nd	nd	NUM
admet-496	98	42	choice	choice	NOUN
admet-496	98	43	saline	saline	NOUN
admet-496	98	44	ph	ph	VERB
admet-496	98	45	2.0	2.0	NUM
admet-496	98	46	saline	saline	NOUN
admet-496	98	47	ph	ph	NOUN
admet-496	98	48	11	11	NUM
admet-496	98	49	0.5	0.5	NUM
admet-496	98	50	ml	ml	NUM
admet-496	98	51	0.5	0.5	NUM
admet-496	98	52	ml	ml	NOUN
admet-496	98	53	rats	rat	NOUN
admet-496	98	54	(	(	PUNCT
admet-496	98	55	dx5	dx5	NOUN
admet-496	98	56	)	)	PUNCT
admet-496	98	57	rats	rat	NOUN
admet-496	98	58	(	(	PUNCT
admet-496	98	59	dx5	dx5	NOUN
admet-496	98	60	)	)	PUNCT
admet-496	98	61	not	not	PART
admet-496	98	62	acceptable	acceptable	ADJ
admet-496	98	63	not	not	PART
admet-496	98	64	acceptable	acceptable	ADJ
admet-496	98	65	ethanol	ethanol	NOUN
admet-496	98	66	10	10	NUM
admet-496	98	67	%	%	NOUN
admet-496	98	68	10	10	NUM
admet-496	98	69	ml	ml	NOUN
admet-496	98	70	/	/	SYM
admet-496	98	71	kg	kg	NOUN
admet-496	98	72	mice	mouse	NOUN
admet-496	98	73	(	(	PUNCT
admet-496	98	74	i.v	i.v	X
admet-496	98	75	.	.	PUNCT
admet-496	98	76	)	)	PUNCT
admet-496	99	1	1	1	NUM
admet-496	99	2	%	%	NOUN
admet-496	99	3	dimethylsulfoxide	dimethylsulfoxide	NOUN
admet-496	99	4	(	(	PUNCT
admet-496	99	5	dmso	dmso	NOUN
admet-496	99	6	)	)	PUNCT
admet-496	99	7	10	10	NUM
admet-496	99	8	%	%	NOUN
admet-496	99	9	in	in	ADP
admet-496	99	10	water	water	NOUN
admet-496	99	11	1	1	NUM
admet-496	99	12	%	%	NOUN
admet-496	99	13	in	in	ADP
admet-496	99	14	water	water	NOUN
admet-496	99	15	70	70	NUM
admet-496	99	16	%	%	NOUN
admet-496	99	17	in	in	ADP
admet-496	99	18	saline	saline	NOUN
admet-496	99	19	10	10	NUM
admet-496	99	20	ml	ml	NOUN
admet-496	99	21	/	/	SYM
admet-496	99	22	kg	kg	PROPN
admet-496	99	23	10	10	NUM
admet-496	99	24	ml	ml	NOUN
admet-496	99	25	/	/	SYM
admet-496	99	26	kg	kg	PROPN
admet-496	99	27	0.2	0.2	NUM
admet-496	99	28	ml	ml	NOUN
admet-496	99	29	mice	mouse	NOUN
admet-496	99	30	(	(	PUNCT
admet-496	99	31	i.v	i.v	X
admet-496	99	32	.	.	PUNCT
admet-496	99	33	;	;	PUNCT
admet-496	99	34	p.o	p.o	PROPN
admet-496	99	35	.	.	PROPN
admet-496	99	36	)	)	PUNCT
admet-496	99	37	mice	mouse	NOUN
admet-496	99	38	(	(	PUNCT
admet-496	99	39	i.p	i.p	PROPN
admet-496	99	40	.	.	PROPN
admet-496	99	41	)	)	PUNCT
admet-496	100	1	rats	rat	NOUN
admet-496	100	2	(	(	PUNCT
admet-496	100	3	dx5	dx5	NOUN
admet-496	100	4	)	)	PUNCT
admet-496	100	5	0.25	0.25	NUM
admet-496	100	6	%	%	NOUN
admet-496	100	7	(	(	PUNCT
admet-496	100	8	0.1	0.1	NUM
admet-496	100	9	%	%	NOUN
admet-496	100	10	preferable	preferable	ADJ
admet-496	100	11	)	)	PUNCT
admet-496	100	12	dimethylformamide	dimethylformamide	NOUN
admet-496	100	13	0.125	0.125	NUM
admet-496	100	14	%	%	NOUN
admet-496	100	15	(	(	PUNCT
admet-496	100	16	upper	upper	ADJ
admet-496	100	17	limit	limit	NOUN
admet-496	100	18	)	)	PUNCT
admet-496	100	19	tween	tween	NOUN
admet-496	100	20	80	80	NUM
admet-496	100	21	10	10	NUM
admet-496	100	22	%	%	NOUN
admet-496	100	23	in	in	ADP
admet-496	100	24	water	water	NOUN
admet-496	100	25	25	25	NUM
admet-496	100	26	%	%	NOUN
admet-496	100	27	in	in	ADP
admet-496	100	28	saline	saline	NOUN
admet-496	100	29	10	10	NUM
admet-496	100	30	ml	ml	NOUN
admet-496	100	31	/	/	SYM
admet-496	100	32	kg	kg	PROPN
admet-496	100	33	0.2	0.2	NUM
admet-496	100	34	ml	ml	NOUN
admet-496	100	35	mice	mouse	NOUN
admet-496	100	36	(	(	PUNCT
admet-496	100	37	i.v	i.v	X
admet-496	100	38	.	.	PUNCT
admet-496	100	39	)	)	PUNCT
admet-496	100	40	rats	rat	NOUN
admet-496	100	41	(	(	PUNCT
admet-496	100	42	dx5	dx5	NOUN
admet-496	100	43	)	)	PUNCT
admet-496	100	44	propylene	propylene	NOUN
admet-496	100	45	glycol	glycol	NOUN
admet-496	100	46	50	50	NUM
admet-496	100	47	%	%	NOUN
admet-496	100	48	25	25	NUM
admet-496	100	49	%	%	NOUN
admet-496	100	50	10	10	NUM
admet-496	100	51	ml	ml	NOUN
admet-496	100	52	/	/	SYM
admet-496	100	53	kg	kg	PROPN
admet-496	100	54	10	10	NUM
admet-496	100	55	ml	ml	NOUN
admet-496	100	56	/	/	SYM
admet-496	100	57	kg	kg	NOUN
admet-496	100	58	mice	mouse	NOUN
admet-496	100	59	(	(	PUNCT
admet-496	100	60	i.v	i.v	X
admet-496	100	61	.	.	PROPN
admet-496	100	62	,	,	PUNCT
admet-496	100	63	slow	slow	ADJ
admet-496	100	64	)	)	PUNCT
admet-496	100	65	mice	mouse	NOUN
admet-496	100	66	(	(	PUNCT
admet-496	100	67	i.p	i.p	NOUN
admet-496	100	68	)	)	PUNCT
admet-496	100	69	50%/25	50%/25	NUM
admet-496	100	70	%	%	NOUN
admet-496	100	71	0.2	0.2	NUM
admet-496	100	72	ml	ml	NOUN
admet-496	100	73	rats	rat	NOUN
admet-496	100	74	(	(	PUNCT
admet-496	100	75	dx5	dx5	NOUN
admet-496	100	76	)	)	PUNCT
admet-496	100	77	n	n	CCONJ
admet-496	100	78	-	-	PUNCT
admet-496	100	79	methyl	methyl	NOUN
admet-496	100	80	glucamine	glucamine	NOUN
admet-496	100	81	1	1	NUM
admet-496	100	82	%	%	NOUN
admet-496	100	83	in	in	ADP
admet-496	100	84	water	water	NOUN
admet-496	100	85	10	10	NUM
admet-496	100	86	ml	ml	NOUN
admet-496	100	87	/	/	SYM
admet-496	100	88	kg	kg	NOUN
admet-496	100	89	mice	mouse	NOUN
admet-496	100	90	(	(	PUNCT
admet-496	100	91	p.o	p.o	PROPN
admet-496	100	92	.	.	PROPN
admet-496	100	93	)	)	PUNCT
admet-496	100	94	carboxymethyl	carboxymethyl	NOUN
admet-496	100	95	cellulose	cellulose	NOUN
admet-496	100	96	1	1	NUM
admet-496	100	97	%	%	NOUN
admet-496	100	98	in	in	ADP
admet-496	100	99	water	water	NOUN
admet-496	100	100	10	10	NUM
admet-496	100	101	ml	ml	NOUN
admet-496	100	102	/	/	SYM
admet-496	100	103	kg	kg	NOUN
admet-496	100	104	mice	mouse	NOUN
admet-496	100	105	(	(	PUNCT
admet-496	100	106	i.p	i.p	PROPN
admet-496	100	107	)	)	PUNCT
admet-496	100	108	cremophor	cremophor	NOUN
admet-496	100	109	el	el	PROPN
admet-496	100	110	5	5	NUM
admet-496	100	111	%	%	NOUN
admet-496	100	112	in	in	ADP
admet-496	100	113	water	water	NOUN
admet-496	100	114	10	10	NUM
admet-496	100	115	ml	ml	NOUN
admet-496	100	116	/	/	SYM
admet-496	100	117	kg	kg	NOUN
admet-496	100	118	mice	mouse	NOUN
admet-496	100	119	(	(	PUNCT
admet-496	100	120	i.v	i.v	X
admet-496	100	121	.	.	PUNCT
admet-496	100	122	)	)	PUNCT
admet-496	100	123	nahco3	nahco3	ADJ
admet-496	100	124	5	5	NUM
admet-496	100	125	%	%	NOUN
admet-496	100	126	in	in	ADP
admet-496	100	127	water	water	NOUN
admet-496	100	128	10	10	NUM
admet-496	100	129	ml	ml	NOUN
admet-496	100	130	/	/	SYM
admet-496	100	131	kg	kg	NOUN
admet-496	100	132	mice	mouse	NOUN
admet-496	100	133	(	(	PUNCT
admet-496	100	134	i.v	i.v	X
admet-496	100	135	.	.	PUNCT
admet-496	100	136	)	)	PUNCT
admet-496	100	137	n	n	CCONJ
admet-496	100	138	,	,	PUNCT
admet-496	100	139	n	n	CCONJ
admet-496	100	140	-	-	PUNCT
admet-496	100	141	dimethylacetamide	dimethylacetamide	ADJ
admet-496	100	142	(	(	PUNCT
admet-496	100	143	dma	dma	NOUN
admet-496	100	144	)	)	PUNCT
admet-496	100	145	10	10	NUM
admet-496	100	146	%	%	NOUN
admet-496	100	147	in	in	ADP
admet-496	100	148	water	water	NOUN
admet-496	100	149	10	10	NUM
admet-496	100	150	ml	ml	NOUN
admet-496	100	151	/	/	SYM
admet-496	100	152	kg	kg	NOUN
admet-496	100	153	mice	mouse	NOUN
admet-496	100	154	(	(	PUNCT
admet-496	101	1	i.p	i.p	PROPN
admet-496	101	2	.	.	PUNCT
admet-496	101	3	)	)	PUNCT
admet-496	101	4	dma	dma	NOUN
admet-496	101	5	10	10	NUM
admet-496	101	6	%	%	NOUN
admet-496	101	7	in	in	ADP
admet-496	101	8	arachis	arachis	PRON
admet-496	101	9	oil	oil	NOUN
admet-496	101	10	10	10	NUM
admet-496	101	11	ml	ml	NOUN
admet-496	101	12	/	/	SYM
admet-496	101	13	kg	kg	NOUN
admet-496	101	14	mice	mouse	NOUN
admet-496	101	15	(	(	PUNCT
admet-496	101	16	i.p	i.p	PROPN
admet-496	101	17	.	.	PROPN
admet-496	101	18	)	)	PUNCT
admet-496	102	1	guidelines	guideline	NOUN
admet-496	102	2	developed	develop	VERB
admet-496	102	3	by	by	ADP
admet-496	102	4	the	the	DET
admet-496	102	5	joint	joint	ADJ
admet-496	102	6	formulation	formulation	NOUN
admet-496	102	7	working	work	VERB
admet-496	102	8	party	party	NOUN
admet-496	102	9	of	of	ADP
admet-496	102	10	the	the	DET
admet-496	102	11	screening	screening	NOUN
admet-496	102	12	and	and	CCONJ
admet-496	102	13	pharmacology	pharmacology	NOUN
admet-496	102	14	group	group	NOUN
admet-496	102	15	(	(	PUNCT
admet-496	102	16	spg	spg	PROPN
admet-496	102	17	)	)	PUNCT
admet-496	102	18	which	which	PRON
admet-496	102	19	was	be	AUX
admet-496	102	20	continued	continue	VERB
admet-496	102	21	as	as	ADP
admet-496	102	22	a	a	DET
admet-496	102	23	pamm	pamm	NOUN
admet-496	102	24	sub	sub	NOUN
admet-496	102	25	-	-	NOUN
admet-496	102	26	committee	committee	NOUN
admet-496	102	27	and	and	CCONJ
admet-496	102	28	renamed	rename	VERB
admet-496	102	29	into	into	ADP
admet-496	102	30	:	:	PUNCT
admet-496	102	31	drug	drug	NOUN
admet-496	102	32	discovery	discovery	PROPN
admet-496	102	33	committee	committee	PROPN
admet-496	102	34	(	(	PUNCT
admet-496	102	35	ddc	ddc	PROPN
admet-496	102	36	)	)	PUNCT
admet-496	103	1	[	[	X
admet-496	103	2	11	11	NUM
admet-496	103	3	]	]	PUNCT
admet-496	103	4	a	a	DET
admet-496	103	5	completely	completely	ADV
admet-496	103	6	different	different	ADJ
admet-496	103	7	compound	compound	NOUN
admet-496	103	8	,	,	PUNCT
admet-496	103	9	nsc-625492	nsc-625492	NOUN
admet-496	103	10	was	be	AUX
admet-496	103	11	selected	select	VERB
admet-496	103	12	for	for	ADP
admet-496	103	13	its	its	PRON
admet-496	103	14	unique	unique	ADJ
admet-496	103	15	molecular	molecular	ADJ
admet-496	103	16	structure	structure	NOUN
admet-496	103	17	being	be	AUX
admet-496	103	18	a	a	DET
admet-496	103	19	bismuth	bismuth	NOUN
admet-496	103	20	analogue	analogue	NOUN
admet-496	103	21	(	(	PUNCT
admet-496	103	22	figure	figure	NOUN
admet-496	103	23	4	4	NUM
admet-496	103	24	)	)	PUNCT
admet-496	103	25	.	.	PUNCT
admet-496	104	1	the	the	DET
admet-496	104	2	gi50	gi50	PROPN
admet-496	104	3	was	be	AUX
admet-496	104	4	low	low	ADJ
admet-496	104	5	(	(	PUNCT
admet-496	104	6	0.3	0.3	NUM
admet-496	104	7	µm	µm	NOUN
admet-496	104	8	)	)	PUNCT
admet-496	104	9	with	with	ADP
admet-496	104	10	activity	activity	NOUN
admet-496	104	11	in	in	ADP
admet-496	104	12	many	many	ADJ
admet-496	104	13	tumour	tumour	ADJ
admet-496	104	14	types	type	NOUN
admet-496	104	15	(	(	PUNCT
admet-496	104	16	colon	colon	NOUN
admet-496	104	17	,	,	PUNCT
admet-496	104	18	ovarian	ovarian	ADJ
admet-496	104	19	,	,	PUNCT
admet-496	104	20	non	non	ADJ
admet-496	104	21	-	-	ADJ
admet-496	104	22	small	small	ADJ
admet-496	104	23	cell	cell	NOUN
admet-496	104	24	lung	lung	NOUN
admet-496	104	25	cancer	cancer	NOUN
admet-496	104	26	and	and	CCONJ
admet-496	104	27	leukaemia	leukaemia	NOUN
admet-496	104	28	;	;	PUNCT
admet-496	104	29	figure	figure	NOUN
admet-496	104	30	2	2	NUM
admet-496	104	31	)	)	PUNCT
admet-496	104	32	.	.	PUNCT
admet-496	105	1	it	it	PRON
admet-496	105	2	was	be	AUX
admet-496	105	3	thought	think	VERB
admet-496	105	4	that	that	SCONJ
admet-496	105	5	it	it	PRON
admet-496	105	6	might	might	AUX
admet-496	105	7	form	form	VERB
admet-496	105	8	dna	dna	PROPN
admet-496	105	9	adducts	adduct	NOUN
admet-496	105	10	,	,	PUNCT
admet-496	105	11	because	because	SCONJ
admet-496	105	12	of	of	ADP
admet-496	105	13	its	its	PRON
admet-496	105	14	similarity	similarity	NOUN
admet-496	105	15	to	to	ADP
admet-496	105	16	other	other	ADJ
admet-496	105	17	heavy	heavy	ADJ
admet-496	105	18	metals	metal	NOUN
admet-496	105	19	(	(	PUNCT
admet-496	105	20	e.g.	e.g.	ADV
admet-496	105	21	platinum	platinum	NOUN
admet-496	105	22	)	)	PUNCT
admet-496	105	23	.	.	PUNCT
admet-496	106	1	using	use	VERB
admet-496	106	2	this	this	DET
admet-496	106	3	property	property	NOUN
admet-496	106	4	,	,	PUNCT
admet-496	106	5	an	an	DET
admet-496	106	6	assay	assay	NOUN
admet-496	106	7	using	use	VERB
admet-496	106	8	flameless	flameless	NOUN
admet-496	106	9	atom	atom	NOUN
admet-496	106	10	absorption	absorption	NOUN
admet-496	106	11	spectroscopy	spectroscopy	NOUN
admet-496	106	12	(	(	PUNCT
admet-496	106	13	faas	faas	NOUN
admet-496	106	14	)	)	PUNCT
admet-496	106	15	as	as	SCONJ
admet-496	106	16	used	use	VERB
admet-496	106	17	for	for	ADP
admet-496	106	18	cisplatin	cisplatin	NOUN
admet-496	106	19	[	[	X
admet-496	106	20	24	24	NUM
admet-496	106	21	]	]	PUNCT
admet-496	106	22	,	,	PUNCT
admet-496	106	23	was	be	AUX
admet-496	106	24	set	set	VERB
admet-496	106	25	up	up	ADP
admet-496	106	26	to	to	PART
admet-496	106	27	determine	determine	VERB
admet-496	106	28	its	its	PRON
admet-496	106	29	in	in	ADP
admet-496	106	30	vivo	vivo	ADJ
admet-496	106	31	pharmacokinetics	pharmacokinetic	NOUN
admet-496	106	32	.	.	PUNCT
admet-496	107	1	the	the	DET
admet-496	107	2	compound	compound	NOUN
admet-496	107	3	indeed	indeed	ADV
admet-496	107	4	showed	show	VERB
admet-496	107	5	interaction	interaction	NOUN
admet-496	107	6	with	with	ADP
admet-496	107	7	dna	dna	PROPN
admet-496	107	8	,	,	PUNCT
admet-496	107	9	but	but	CCONJ
admet-496	107	10	was	be	AUX
admet-496	107	11	not	not	PART
admet-496	107	12	cross	cross	ADJ
admet-496	107	13	-	-	ADJ
admet-496	107	14	resistant	resistant	ADJ
admet-496	107	15	against	against	ADP
admet-496	107	16	cisplatin	cisplatin	NOUN
admet-496	107	17	resistant	resistant	ADJ
admet-496	107	18	cell	cell	NOUN
admet-496	107	19	lines	line	NOUN
admet-496	107	20	and	and	CCONJ
admet-496	107	21	was	be	AUX
admet-496	107	22	active	active	ADJ
admet-496	107	23	in	in	ADP
admet-496	107	24	p	p	NOUN
admet-496	107	25	-	-	PUNCT
admet-496	107	26	glycoprotein	glycoprotein	NOUN
admet-496	107	27	expressing	express	VERB
admet-496	107	28	cell	cell	NOUN
admet-496	107	29	lines	line	NOUN
admet-496	107	30	.	.	PUNCT
admet-496	108	1	using	use	VERB
admet-496	108	2	a	a	DET
admet-496	108	3	formulation	formulation	NOUN
admet-496	108	4	of	of	ADP
admet-496	108	5	10	10	NUM
admet-496	108	6	%	%	NOUN
admet-496	108	7	dma	dma	NOUN
admet-496	108	8	and	and	CCONJ
admet-496	108	9	arachis	arachis	PRON
admet-496	108	10	oil	oil	NOUN
admet-496	108	11	,	,	PUNCT
admet-496	108	12	the	the	DET
admet-496	108	13	mtd	mtd	PROPN
admet-496	108	14	was	be	AUX
admet-496	108	15	30	30	NUM
admet-496	108	16	mg	mg	NUM
admet-496	108	17	/	/	SYM
admet-496	108	18	kg	kg	PROPN
admet-496	108	19	(	(	PUNCT
admet-496	108	20	8	8	NUM
admet-496	108	21	%	%	NOUN
admet-496	108	22	weight	weight	NOUN
admet-496	108	23	loss	loss	NOUN
admet-496	108	24	)	)	PUNCT
admet-496	108	25	,	,	PUNCT
admet-496	108	26	which	which	PRON
admet-496	108	27	was	be	AUX
admet-496	108	28	used	use	VERB
admet-496	108	29	to	to	PART
admet-496	108	30	determine	determine	VERB
admet-496	108	31	its	its	PRON
admet-496	108	32	plasma	plasma	NOUN
admet-496	108	33	pharmacokinetics	pharmacokinetic	NOUN
admet-496	108	34	(	(	PUNCT
admet-496	108	35	figure	figure	NOUN
admet-496	108	36	5	5	NUM
admet-496	108	37	)	)	PUNCT
admet-496	108	38	and	and	CCONJ
admet-496	108	39	potential	potential	ADJ
admet-496	108	40	antitumor	antitumor	PROPN
admet-496	108	41	activity	activity	NOUN
admet-496	108	42	.	.	PUNCT
admet-496	109	1	nsc-625492	nsc-625492	PROPN
admet-496	109	2	did	do	AUX
admet-496	109	3	not	not	PART
admet-496	109	4	show	show	VERB
admet-496	109	5	a	a	DET
admet-496	109	6	typical	typical	ADJ
admet-496	109	7	bell	bell	NOUN
admet-496	109	8	-	-	PUNCT
admet-496	109	9	shaped	shape	VERB
admet-496	109	10	plasma	plasma	NOUN
admet-496	109	11	profile	profile	NOUN
admet-496	109	12	curve	curve	NOUN
admet-496	109	13	,	,	PUNCT
admet-496	109	14	but	but	CCONJ
admet-496	109	15	the	the	DET
admet-496	109	16	concentrations	concentration	NOUN
admet-496	109	17	remained	remain	VERB
admet-496	109	18	relatively	relatively	ADV
admet-496	109	19	constant	constant	ADJ
admet-496	109	20	over	over	ADP
admet-496	109	21	a	a	DET
admet-496	109	22	24	24	NUM
admet-496	109	23	-	-	PUNCT
admet-496	109	24	hr	hr	NOUN
admet-496	109	25	period	period	NOUN
admet-496	109	26	,	,	PUNCT
admet-496	109	27	possibly	possibly	ADV
admet-496	109	28	indicating	indicate	VERB
admet-496	109	29	a	a	DET
admet-496	109	30	lack	lack	NOUN
admet-496	109	31	of	of	ADP
admet-496	109	32	metabolism	metabolism	NOUN
admet-496	109	33	.	.	PUNCT
admet-496	110	1	although	although	SCONJ
admet-496	110	2	sufficiently	sufficiently	ADV
admet-496	110	3	high	high	ADJ
admet-496	110	4	plasma	plasma	NOUN
admet-496	110	5	concentration	concentration	NOUN
admet-496	110	6	(	(	PUNCT
admet-496	110	7	>	>	X
admet-496	110	8	gi50	gi50	PROPN
admet-496	110	9	)	)	PUNCT
admet-496	110	10	were	be	AUX
admet-496	110	11	found	find	VERB
admet-496	110	12	,	,	PUNCT
admet-496	110	13	a	a	DET
admet-496	110	14	long	long	ADJ
admet-496	110	15	retention	retention	NOUN
admet-496	110	16	and	and	CCONJ
admet-496	110	17	no	no	DET
admet-496	110	18	protein	protein	NOUN
admet-496	110	19	binding	bind	VERB
admet-496	110	20	(	(	PUNCT
admet-496	110	21	in	in	ADP
admet-496	110	22	contrast	contrast	NOUN
admet-496	110	23	to	to	ADP
admet-496	110	24	cisplatin	cisplatin	NOUN
admet-496	110	25	)	)	PUNCT
admet-496	110	26	,	,	PUNCT
admet-496	110	27	there	there	PRON
admet-496	110	28	was	be	VERB
admet-496	110	29	no	no	PRON
admet-496	110	30	in	in	ADP
admet-496	110	31	vivo	vivo	ADJ
admet-496	110	32	activity	activity	NOUN
admet-496	110	33	against	against	ADP
admet-496	110	34	godefridus	godefridus	NOUN
admet-496	110	35	peters	peters	PROPN
admet-496	110	36	et	et	PROPN
admet-496	110	37	al	al	PROPN
admet-496	110	38	.	.	PROPN
admet-496	110	39	admet	admet	PROPN
admet-496	110	40	&	&	CCONJ
admet-496	110	41	dmpk	dmpk	PROPN
admet-496	110	42	6(1	6(1	NUM
admet-496	110	43	)	)	PUNCT
admet-496	110	44	(	(	PUNCT
admet-496	110	45	2018	2018	NUM
admet-496	110	46	)	)	PUNCT
admet-496	110	47	4	4	NUM
admet-496	110	48	-	-	SYM
admet-496	110	49	14	14	NUM
admet-496	110	50	10	10	NUM
admet-496	110	51	various	various	ADJ
admet-496	110	52	tumour	tumour	NOUN
admet-496	110	53	models	model	NOUN
admet-496	110	54	.	.	PUNCT
admet-496	111	1	the	the	DET
admet-496	111	2	development	development	NOUN
admet-496	111	3	of	of	ADP
admet-496	111	4	the	the	DET
admet-496	111	5	compound	compound	NOUN
admet-496	111	6	was	be	AUX
admet-496	111	7	therefore	therefore	ADV
admet-496	111	8	discontinued	discontinue	VERB
admet-496	111	9	.	.	PUNCT
admet-496	112	1	nsc-637828	nsc-637828	PROPN
admet-496	112	2	also	also	ADV
admet-496	112	3	showed	show	VERB
admet-496	112	4	an	an	DET
admet-496	112	5	interesting	interesting	ADJ
admet-496	112	6	compare	compare	NOUN
admet-496	112	7	negative	negative	ADJ
admet-496	112	8	profile	profile	NOUN
admet-496	112	9	(	(	PUNCT
admet-496	112	10	correlation	correlation	NOUN
admet-496	112	11	coefficients	coefficient	VERB
admet-496	112	12	<	<	X
admet-496	112	13	0.625	0.625	NUM
admet-496	112	14	)	)	PUNCT
admet-496	112	15	with	with	ADP
admet-496	112	16	rifamycin	rifamycin	PROPN
admet-496	112	17	and	and	CCONJ
admet-496	112	18	the	the	DET
admet-496	112	19	nitrogen	nitrogen	NOUN
admet-496	112	20	mustard	mustard	PROPN
admet-496	112	21	ccnu	ccnu	NOUN
admet-496	112	22	(	(	PUNCT
admet-496	112	23	lomustine	lomustine	PROPN
admet-496	112	24	;	;	PUNCT
admet-496	112	25	1-(2	1-(2	PROPN
admet-496	112	26	-	-	PUNCT
admet-496	112	27	chloroethyl)-3	chloroethyl)-3	PROPN
admet-496	112	28	-	-	PUNCT
admet-496	112	29	cyclohexyl-1	cyclohexyl-1	NOUN
admet-496	112	30	-	-	PUNCT
admet-496	112	31	nitrosourea	nitrosourea	NOUN
admet-496	112	32	)	)	PUNCT
admet-496	112	33	being	be	AUX
admet-496	112	34	the	the	DET
admet-496	112	35	highest	high	ADJ
admet-496	112	36	.	.	PUNCT
admet-496	113	1	it	it	PRON
admet-496	113	2	was	be	AUX
admet-496	113	3	insoluble	insoluble	ADJ
admet-496	113	4	and	and	CCONJ
admet-496	113	5	a	a	DET
admet-496	113	6	suspension	suspension	NOUN
admet-496	113	7	could	could	AUX
admet-496	113	8	only	only	ADV
admet-496	113	9	be	be	AUX
admet-496	113	10	obtained	obtain	VERB
admet-496	113	11	in	in	ADP
admet-496	113	12	10	10	NUM
admet-496	113	13	%	%	NOUN
admet-496	113	14	dma	dma	NOUN
admet-496	114	1	+	+	CCONJ
admet-496	114	2	arachis	arachis	PRON
admet-496	114	3	oil	oil	NOUN
admet-496	114	4	(	(	PUNCT
admet-496	114	5	but	but	CCONJ
admet-496	114	6	not	not	PART
admet-496	114	7	in	in	ADP
admet-496	114	8	dmso	dmso	NOUN
admet-496	114	9	or	or	CCONJ
admet-496	114	10	ethanol	ethanol	NOUN
admet-496	114	11	)	)	PUNCT
admet-496	114	12	,	,	PUNCT
admet-496	114	13	which	which	PRON
admet-496	114	14	showed	show	VERB
admet-496	114	15	acceptable	acceptable	ADJ
admet-496	114	16	toxicity	toxicity	NOUN
admet-496	114	17	(	(	PUNCT
admet-496	114	18	<	<	X
admet-496	114	19	10	10	NUM
admet-496	114	20	%	%	NOUN
admet-496	114	21	)	)	PUNCT
admet-496	114	22	.	.	PUNCT
admet-496	115	1	due	due	ADP
admet-496	115	2	to	to	ADP
admet-496	115	3	these	these	DET
admet-496	115	4	properties	property	NOUN
admet-496	115	5	an	an	DET
admet-496	115	6	adequate	adequate	ADJ
admet-496	115	7	hplc	hplc	NOUN
admet-496	115	8	method	method	NOUN
admet-496	115	9	could	could	AUX
admet-496	115	10	not	not	PART
admet-496	115	11	be	be	AUX
admet-496	115	12	established	establish	VERB
admet-496	115	13	and	and	CCONJ
admet-496	115	14	drug	drug	NOUN
admet-496	115	15	sensitivity	sensitivity	NOUN
admet-496	115	16	studies	study	NOUN
admet-496	115	17	could	could	AUX
admet-496	115	18	not	not	PART
admet-496	115	19	be	be	AUX
admet-496	115	20	completed	complete	VERB
admet-496	115	21	.	.	PUNCT
admet-496	116	1	therefore	therefore	ADV
admet-496	116	2	,	,	PUNCT
admet-496	116	3	the	the	DET
admet-496	116	4	development	development	NOUN
admet-496	116	5	of	of	ADP
admet-496	116	6	this	this	DET
admet-496	116	7	compound	compound	NOUN
admet-496	116	8	was	be	AUX
admet-496	116	9	stopped	stop	VERB
admet-496	116	10	.	.	PUNCT
admet-496	117	1	n	n	CCONJ
admet-496	117	2	n	n	PROPN
admet-496	117	3	s	s	NOUN
admet-496	117	4	n	n	PRON
admet-496	117	5	n	n	ADV
admet-496	118	1	o	o	NOUN
admet-496	118	2	o	o	X
admet-496	119	1	ohcl	ohcl	ADV
admet-496	119	2	s	s	VERB
admet-496	119	3	n	n	NOUN
admet-496	119	4	s	s	NOUN
admet-496	119	5	bi	bi	NOUN
admet-496	120	1	3	3	NUM
admet-496	120	2	+	+	SYM
admet-496	120	3	s	s	NOUN
admet-496	120	4	cl	cl	NOUN
admet-496	120	5	cl	cl	NOUN
admet-496	120	6	s	s	NOUN
admet-496	120	7	nr	nr	NOUN
admet-496	120	8	nh2	nh2	PROPN
admet-496	120	9	s	s	PART
admet-496	120	10	nf	nf	NOUN
admet-496	120	11	n	n	PRON
admet-496	120	12	h	h	NOUN
admet-496	120	13	nh2	nh2	PROPN
admet-496	120	14	(	(	PUNCT
admet-496	120	15	ch2)4	ch2)4	X
admet-496	120	16	nh2	nh2	PROPN
admet-496	120	17	o	o	NOUN
admet-496	120	18	n	n	CCONJ
admet-496	120	19	n	n	PRON
admet-496	120	20	o	o	NOUN
admet-496	120	21	on	on	ADP
admet-496	120	22	n	n	PRON
admet-496	120	23	ome	ome	NOUN
admet-496	120	24	meo	meo	NOUN
admet-496	120	25	oo	oo	INTJ
admet-496	120	26	h	h	NOUN
admet-496	120	27	h	h	NOUN
admet-496	120	28	2hcl	2hcl	NUM
admet-496	120	29	nsc-697786	nsc-697786	NOUN
admet-496	120	30	chemical	chemical	NOUN
admet-496	120	31	formula	formula	NOUN
admet-496	120	32	:	:	PUNCT
admet-496	120	33	c14h9cln4o3s2	c14h9cln4o3s2	ADJ
admet-496	120	34	exact	exact	ADJ
admet-496	120	35	mass	mass	NOUN
admet-496	120	36	:	:	PUNCT
admet-496	120	37	379.98	379.98	NUM
admet-496	120	38	molecular	molecular	ADJ
admet-496	120	39	weight	weight	NOUN
admet-496	120	40	:	:	PUNCT
admet-496	120	41	380.83	380.83	NUM
admet-496	120	42	nsc-625492	nsc-625492	NOUN
admet-496	120	43	chemical	chemical	ADJ
admet-496	120	44	formula	formula	NOUN
admet-496	120	45	:	:	PUNCT
admet-496	120	46	c6h10bicl2ns2	c6h10bicl2ns2	DET
admet-496	120	47	exact	exact	ADJ
admet-496	120	48	mass	mass	NOUN
admet-496	120	49	:	:	PUNCT
admet-496	120	50	438.94	438.94	NUM
admet-496	120	51	molecular	molecular	ADJ
admet-496	120	52	weight	weight	NOUN
admet-496	120	53	:	:	PUNCT
admet-496	120	54	440.17	440.17	NUM
admet-496	120	55	df	df	NOUN
admet-496	120	56	203	203	NUM
admet-496	120	57	(	(	PUNCT
admet-496	120	58	nsc	nsc	PROPN
admet-496	120	59	674495	674495	NUM
admet-496	120	60	):	):	PUNCT
admet-496	120	61	r	r	NOUN
admet-496	120	62	=	=	SYM
admet-496	120	63	h	h	NOUN
admet-496	120	64	5f	5f	NOUN
admet-496	120	65	203	203	NUM
admet-496	120	66	(	(	PUNCT
admet-496	120	67	nsc	nsc	PROPN
admet-496	120	68	703786	703786	NUM
admet-496	120	69	):	):	PUNCT
admet-496	120	70	r	r	NOUN
admet-496	120	71	=	=	SYM
admet-496	120	72	f	f	PROPN
admet-496	120	73	chemical	chemical	NOUN
admet-496	120	74	formula	formula	NOUN
admet-496	120	75	5f	5f	NOUN
admet-496	120	76	203	203	NUM
admet-496	120	77	:	:	PUNCT
admet-496	120	78	c14h11fn2s	c14h11fn2s	PROPN
admet-496	120	79	exact	exact	ADJ
admet-496	120	80	mass	mass	NOUN
admet-496	120	81	:	:	PUNCT
admet-496	120	82	258.06	258.06	NUM
admet-496	120	83	molecular	molecular	ADJ
admet-496	120	84	weight	weight	NOUN
admet-496	120	85	:	:	PUNCT
admet-496	120	86	259.31	259.31	NUM
admet-496	120	87	phortress	phortress	NOUN
admet-496	120	88	(	(	PUNCT
admet-496	120	89	nsc	nsc	PROPN
admet-496	120	90	710305	710305	NUM
admet-496	120	91	)	)	PUNCT
admet-496	120	92	chemical	chemical	NOUN
admet-496	120	93	formula	formula	NOUN
admet-496	120	94	:	:	PUNCT
admet-496	120	95	c20h23fn4os	c20h23fn4os	X
admet-496	120	96	exact	exact	ADJ
admet-496	120	97	mass	mass	NOUN
admet-496	120	98	:	:	PUNCT
admet-496	120	99	386.16	386.16	NUM
admet-496	120	100	molecular	molecular	ADJ
admet-496	120	101	weight	weight	NOUN
admet-496	120	102	:	:	PUNCT
admet-496	120	103	386.49	386.49	NUM
admet-496	120	104	sjg-136	sjg-136	ADJ
admet-496	120	105	chemical	chemical	NOUN
admet-496	120	106	formula	formula	NOUN
admet-496	120	107	:	:	PUNCT
admet-496	120	108	c31h32n4o6	c31h32n4o6	NOUN
admet-496	120	109	exact	exact	ADJ
admet-496	120	110	mass	mass	NOUN
admet-496	120	111	:	:	PUNCT
admet-496	120	112	556.23	556.23	NUM
admet-496	120	113	molecular	molecular	ADJ
admet-496	120	114	weight	weight	NOUN
admet-496	120	115	:	:	PUNCT
admet-496	120	116	556.61	556.61	NUM
admet-496	120	117	figure	figure	NOUN
admet-496	120	118	4	4	NUM
admet-496	120	119	.	.	PUNCT
admet-496	120	120	structural	structural	ADJ
admet-496	120	121	formulas	formula	NOUN
admet-496	120	122	and	and	CCONJ
admet-496	120	123	some	some	DET
admet-496	120	124	physico	physico	NOUN
admet-496	120	125	-	-	PUNCT
admet-496	120	126	chemical	chemical	NOUN
admet-496	120	127	properties	property	NOUN
admet-496	120	128	of	of	ADP
admet-496	120	129	several	several	ADJ
admet-496	120	130	of	of	ADP
admet-496	120	131	the	the	DET
admet-496	120	132	investigated	investigate	VERB
admet-496	120	133	compounds	compound	NOUN
admet-496	120	134	.	.	PUNCT
admet-496	121	1	two	two	NUM
admet-496	121	2	examples	example	NOUN
admet-496	121	3	of	of	ADP
admet-496	121	4	drugs	drug	NOUN
admet-496	121	5	with	with	ADP
admet-496	121	6	completely	completely	ADV
admet-496	121	7	different	different	ADJ
admet-496	121	8	mechanisms	mechanism	NOUN
admet-496	121	9	of	of	ADP
admet-496	121	10	action	action	NOUN
admet-496	121	11	are	be	AUX
admet-496	121	12	the	the	DET
admet-496	121	13	combretastatin	combretastatin	NOUN
admet-496	121	14	a-4	a-4	PROPN
admet-496	121	15	analogues	analogue	NOUN
admet-496	121	16	and	and	CCONJ
admet-496	121	17	nsc	nsc	PROPN
admet-496	121	18	734237	734237	NUM
admet-496	121	19	,	,	PUNCT
admet-496	121	20	a	a	DET
admet-496	121	21	paullone	paullone	NOUN
admet-496	121	22	-	-	PUNCT
admet-496	121	23	like	like	ADJ
admet-496	121	24	molecule	molecule	NOUN
admet-496	121	25	.	.	PUNCT
admet-496	122	1	these	these	DET
admet-496	122	2	two	two	NUM
admet-496	122	3	drugs	drug	NOUN
admet-496	122	4	were	be	AUX
admet-496	122	5	investigated	investigate	VERB
admet-496	122	6	in	in	ADP
admet-496	122	7	a	a	DET
admet-496	122	8	collaborative	collaborative	ADJ
admet-496	122	9	effort	effort	NOUN
admet-496	122	10	of	of	ADP
admet-496	122	11	various	various	ADJ
admet-496	122	12	pamm	pamm	NOUN
admet-496	122	13	laboratories	laboratory	NOUN
admet-496	122	14	and	and	CCONJ
admet-496	122	15	the	the	DET
admet-496	122	16	nci	nci	PROPN
admet-496	122	17	drug	drug	PROPN
admet-496	122	18	development	development	PROPN
admet-496	122	19	and	and	CCONJ
admet-496	122	20	target	target	VERB
admet-496	122	21	analysis	analysis	NOUN
admet-496	122	22	branches	branch	NOUN
admet-496	122	23	.	.	PUNCT
admet-496	123	1	combretastatin	combretastatin	PROPN
admet-496	123	2	a-4	a-4	PROPN
admet-496	123	3	is	be	AUX
admet-496	123	4	a	a	DET
admet-496	123	5	poorly	poorly	ADV
admet-496	123	6	soluble	soluble	ADJ
admet-496	123	7	natural	natural	ADJ
admet-496	123	8	product	product	NOUN
admet-496	123	9	and	and	CCONJ
admet-496	123	10	its	its	PRON
admet-496	123	11	more	more	ADV
admet-496	123	12	soluble	soluble	ADJ
admet-496	123	13	metabolite	metabolite	NOUN
admet-496	123	14	combretastatin	combretastatin	NOUN
admet-496	123	15	a-4	a-4	PROPN
admet-496	123	16	phosphate	phosphate	NOUN
admet-496	123	17	disrupts	disrupt	VERB
admet-496	123	18	endothelial	endothelial	ADJ
admet-496	123	19	junctions	junction	NOUN
admet-496	123	20	of	of	ADP
admet-496	123	21	tumour	tumour	NOUN
admet-496	123	22	blood	blood	NOUN
admet-496	123	23	vessels	vessel	NOUN
admet-496	123	24	by	by	ADP
admet-496	123	25	preventing	prevent	VERB
admet-496	123	26	microtubule	microtubule	NOUN
admet-496	123	27	polymerisation	polymerisation	NOUN
admet-496	123	28	in	in	ADP
admet-496	123	29	endothelial	endothelial	ADJ
admet-496	123	30	cells	cell	NOUN
admet-496	123	31	of	of	ADP
admet-496	123	32	tumour	tumour	NOUN
admet-496	123	33	blood	blood	NOUN
admet-496	123	34	vessels	vessel	NOUN
admet-496	123	35	;	;	PUNCT
admet-496	123	36	this	this	PRON
admet-496	123	37	resulted	result	VERB
admet-496	123	38	in	in	ADP
admet-496	123	39	tumour	tumour	NOUN
admet-496	123	40	necrosis	necrosis	NOUN
admet-496	123	41	[	[	X
admet-496	123	42	25,26	25,26	X
admet-496	123	43	]	]	X
admet-496	123	44	.	.	PUNCT
admet-496	124	1	various	various	ADJ
admet-496	124	2	analogues	analogue	NOUN
admet-496	124	3	(	(	PUNCT
admet-496	124	4	nsc736359	nsc736359	NOUN
admet-496	124	5	,	,	PUNCT
admet-496	124	6	nsc736992	nsc736992	ADV
admet-496	124	7	,	,	PUNCT
admet-496	124	8	and	and	CCONJ
admet-496	124	9	nsc733436	nsc733436	NOUN
admet-496	124	10	)	)	PUNCT
admet-496	124	11	with	with	ADP
admet-496	124	12	a	a	DET
admet-496	124	13	high	high	ADJ
admet-496	124	14	potency	potency	NOUN
admet-496	124	15	(	(	PUNCT
admet-496	124	16	nm-µm	nm-µm	INTJ
admet-496	124	17	range	range	NOUN
admet-496	124	18	)	)	PUNCT
admet-496	124	19	were	be	AUX
admet-496	124	20	further	far	ADV
admet-496	124	21	analysed	analyse	VERB
admet-496	124	22	,	,	PUNCT
admet-496	124	23	but	but	CCONJ
admet-496	124	24	moderate	moderate	ADJ
admet-496	124	25	antitumor	antitumor	PROPN
admet-496	124	26	activity	activity	NOUN
admet-496	124	27	was	be	AUX
admet-496	124	28	observed	observe	VERB
admet-496	124	29	[	[	X
admet-496	124	30	27	27	NUM
admet-496	124	31	]	]	PUNCT
admet-496	124	32	,	,	PUNCT
admet-496	124	33	possibly	possibly	ADV
admet-496	124	34	because	because	SCONJ
admet-496	124	35	under	under	ADP
admet-496	124	36	these	these	DET
admet-496	124	37	conditions	condition	NOUN
admet-496	124	38	the	the	DET
admet-496	124	39	density	density	NOUN
admet-496	124	40	(	(	PUNCT
admet-496	124	41	size	size	NOUN
admet-496	124	42	and	and	CCONJ
admet-496	124	43	number	number	NOUN
admet-496	124	44	)	)	PUNCT
admet-496	124	45	of	of	ADP
admet-496	124	46	cd31	cd31	PROPN
admet-496	124	47	+	+	CCONJ
admet-496	124	48	blood	blood	NOUN
admet-496	124	49	vessels	vessel	NOUN
admet-496	124	50	was	be	AUX
admet-496	124	51	not	not	PART
admet-496	124	52	affected	affect	VERB
admet-496	124	53	.	.	PUNCT
admet-496	125	1	the	the	DET
admet-496	125	2	paullone	paullone	NOUN
admet-496	125	3	-	-	PUNCT
admet-496	125	4	like	like	ADJ
admet-496	125	5	molecule	molecule	NOUN
admet-496	125	6	nsc	nsc	PROPN
admet-496	125	7	734237	734237	NUM
admet-496	125	8	is	be	AUX
admet-496	125	9	an	an	DET
admet-496	125	10	isoindoloquinoxaline	isoindoloquinoxaline	NOUN
admet-496	125	11	with	with	ADP
admet-496	125	12	low	low	ADJ
admet-496	125	13	to	to	PART
admet-496	125	14	sub	sub	VERB
admet-496	125	15	µm	µm	ADP
admet-496	125	16	ic50	ic50	PROPN
admet-496	125	17	values	value	NOUN
admet-496	125	18	[	[	X
admet-496	125	19	28	28	NUM
admet-496	125	20	]	]	PUNCT
admet-496	125	21	for	for	ADP
admet-496	125	22	cns	cns	NOUN
admet-496	125	23	,	,	PUNCT
admet-496	125	24	colon	colon	NOUN
admet-496	125	25	,	,	PUNCT
admet-496	125	26	melanoma	melanoma	NOUN
admet-496	125	27	and	and	CCONJ
admet-496	125	28	breast	breast	NOUN
admet-496	125	29	cancer	cancer	NOUN
admet-496	125	30	lines	line	NOUN
admet-496	125	31	.	.	PUNCT
admet-496	126	1	however	however	ADV
admet-496	126	2	,	,	PUNCT
admet-496	126	3	the	the	DET
admet-496	126	4	compound	compound	NOUN
admet-496	126	5	was	be	AUX
admet-496	126	6	quite	quite	ADV
admet-496	126	7	insoluble	insoluble	ADJ
admet-496	126	8	(	(	PUNCT
admet-496	126	9	6	6	NUM
admet-496	126	10	%	%	NOUN
admet-496	126	11	active	active	ADJ
admet-496	126	12	drug	drug	NOUN
admet-496	126	13	in	in	ADP
admet-496	126	14	a	a	DET
admet-496	126	15	liposomal	liposomal	ADJ
admet-496	126	16	formulation	formulation	NOUN
admet-496	126	17	)	)	PUNCT
admet-496	126	18	,	,	PUNCT
admet-496	126	19	but	but	CCONJ
admet-496	126	20	showed	show	VERB
admet-496	126	21	antitumor	antitumor	PROPN
admet-496	126	22	activity	activity	NOUN
admet-496	126	23	against	against	ADP
admet-496	126	24	a	a	DET
admet-496	126	25	doxorubicin	doxorubicin	NOUN
admet-496	126	26	-	-	PUNCT
admet-496	126	27	resistant	resistant	ADJ
admet-496	126	28	,	,	PUNCT
admet-496	126	29	oestrogen	oestrogen	NOUN
admet-496	126	30	admet	admet	PROPN
admet-496	126	31	&	&	CCONJ
admet-496	126	32	dmpk	dmpk	PROPN
admet-496	126	33	6(1	6(1	NUM
admet-496	126	34	)	)	PUNCT
admet-496	126	35	(	(	PUNCT
admet-496	126	36	2018	2018	NUM
admet-496	126	37	)	)	PUNCT
admet-496	126	38	4	4	NUM
admet-496	126	39	-	-	SYM
admet-496	126	40	14	14	NUM
admet-496	126	41	the	the	DET
admet-496	126	42	role	role	NOUN
admet-496	126	43	of	of	ADP
admet-496	126	44	pharmacology	pharmacology	NOUN
admet-496	126	45	in	in	ADP
admet-496	126	46	anticancer	anticancer	NOUN
admet-496	126	47	drug	drug	PROPN
admet-496	126	48	development	development	PROPN
admet-496	126	49	doi	doi	PROPN
admet-496	126	50	:	:	PUNCT
admet-496	126	51	10.5599	10.5599	NUM
admet-496	126	52	/	/	SYM
admet-496	126	53	admet.6.1.496	admet.6.1.496	VERB
admet-496	126	54	11	11	NUM
admet-496	126	55	receptor	receptor	NOUN
admet-496	126	56	negative	negative	ADJ
admet-496	126	57	human	human	ADJ
admet-496	126	58	breast	breast	NOUN
admet-496	126	59	cancer	cancer	NOUN
admet-496	126	60	xenograft	xenograft	PROPN
admet-496	126	61	mt-3	mt-3	PROPN
admet-496	126	62	/	/	SYM
admet-496	126	63	adr	adr	PROPN
admet-496	126	64	with	with	ADP
admet-496	126	65	a	a	DET
admet-496	126	66	reduction	reduction	NOUN
admet-496	126	67	in	in	ADP
admet-496	126	68	both	both	PRON
admet-496	126	69	cd31	cd31	PROPN
admet-496	126	70	+	+	CCONJ
admet-496	126	71	microvessel	microvessel	NOUN
admet-496	126	72	density	density	NOUN
admet-496	126	73	and	and	CCONJ
admet-496	126	74	ki-67	ki-67	NOUN
admet-496	126	75	.	.	PUNCT
admet-496	127	1	hence	hence	ADV
admet-496	127	2	the	the	DET
admet-496	127	3	drug	drug	NOUN
admet-496	127	4	showed	show	VERB
admet-496	127	5	antivascular	antivascular	ADJ
admet-496	127	6	effects	effect	NOUN
admet-496	127	7	and	and	CCONJ
admet-496	127	8	cytotoxic	cytotoxic	ADJ
admet-496	127	9	activity	activity	NOUN
admet-496	127	10	,	,	PUNCT
admet-496	127	11	which	which	PRON
admet-496	127	12	are	be	AUX
admet-496	127	13	most	most	ADV
admet-496	127	14	likely	likely	ADJ
admet-496	127	15	due	due	ADJ
admet-496	127	16	to	to	ADP
admet-496	127	17	inhibition	inhibition	NOUN
admet-496	127	18	of	of	ADP
admet-496	127	19	tubulin	tubulin	NOUN
admet-496	127	20	polymerisation	polymerisation	NOUN
admet-496	127	21	and	and	CCONJ
admet-496	127	22	topoisomerase	topoisomerase	NOUN
admet-496	127	23	i	i	PRON
admet-496	127	24	,	,	PUNCT
admet-496	127	25	respectively	respectively	ADV
admet-496	127	26	.	.	PUNCT
admet-496	128	1	more	more	ADJ
admet-496	128	2	water	water	NOUN
admet-496	128	3	soluble	soluble	ADJ
admet-496	128	4	analogues	analogue	NOUN
admet-496	128	5	were	be	AUX
admet-496	128	6	investigated	investigate	VERB
admet-496	128	7	further	far	ADV
admet-496	128	8	,	,	PUNCT
admet-496	128	9	but	but	CCONJ
admet-496	128	10	did	do	AUX
admet-496	128	11	not	not	PART
admet-496	128	12	improve	improve	VERB
admet-496	128	13	the	the	DET
admet-496	128	14	overall	overall	ADJ
admet-496	128	15	result	result	NOUN
admet-496	128	16	.	.	PUNCT
admet-496	129	1	in	in	ADP
admet-496	129	2	the	the	DET
admet-496	129	3	future	future	NOUN
admet-496	129	4	,	,	PUNCT
admet-496	129	5	such	such	ADJ
admet-496	129	6	compounds	compound	NOUN
admet-496	129	7	should	should	AUX
admet-496	129	8	optimally	optimally	ADV
admet-496	129	9	be	be	AUX
admet-496	129	10	investigated	investigate	VERB
admet-496	129	11	more	more	ADV
admet-496	129	12	extensively	extensively	ADV
admet-496	129	13	for	for	ADP
admet-496	129	14	their	their	PRON
admet-496	129	15	oral	oral	ADJ
admet-496	129	16	bioavailability	bioavailability	NOUN
admet-496	129	17	and	and	CCONJ
admet-496	129	18	their	their	PRON
admet-496	129	19	formulation	formulation	NOUN
admet-496	129	20	adapted	adapt	VERB
admet-496	129	21	.	.	PUNCT
admet-496	130	1	figure	figure	NOUN
admet-496	130	2	5	5	NUM
admet-496	130	3	.	.	PUNCT
admet-496	130	4	concentration	concentration	NOUN
admet-496	130	5	time	time	NOUN
admet-496	130	6	curves	curve	NOUN
admet-496	130	7	of	of	ADP
admet-496	130	8	nsc-625492	nsc-625492	NOUN
admet-496	130	9	.	.	PUNCT
admet-496	131	1	mice	mouse	NOUN
admet-496	131	2	were	be	AUX
admet-496	131	3	injected	inject	VERB
admet-496	131	4	with	with	ADP
admet-496	131	5	30	30	NUM
admet-496	131	6	mg	mg	NUM
admet-496	131	7	/	/	SYM
admet-496	131	8	kg	kg	PROPN
admet-496	131	9	nsc-625492	nsc-625492	NOUN
admet-496	131	10	in	in	ADP
admet-496	131	11	10	10	NUM
admet-496	131	12	%	%	NOUN
admet-496	131	13	dma	dma	NOUN
admet-496	131	14	in	in	ADP
admet-496	131	15	arachis	arachis	PRON
admet-496	131	16	oil	oil	NOUN
admet-496	131	17	.	.	PUNCT
admet-496	132	1	for	for	ADP
admet-496	132	2	the	the	DET
admet-496	132	3	pharmacokinetics	pharmacokinetic	NOUN
admet-496	132	4	study	study	NOUN
admet-496	132	5	mice	mouse	NOUN
admet-496	132	6	were	be	AUX
admet-496	132	7	sacrificed	sacrifice	VERB
admet-496	132	8	at	at	ADP
admet-496	132	9	0.25	0.25	NUM
admet-496	132	10	,	,	PUNCT
admet-496	132	11	3	3	NUM
admet-496	132	12	,	,	PUNCT
admet-496	132	13	6	6	NUM
admet-496	132	14	and	and	CCONJ
admet-496	132	15	24	24	NUM
admet-496	132	16	h	h	NOUN
admet-496	132	17	and	and	CCONJ
admet-496	132	18	blood	blood	NOUN
admet-496	132	19	was	be	AUX
admet-496	132	20	collected	collect	VERB
admet-496	132	21	by	by	ADP
admet-496	132	22	heparinization	heparinization	NOUN
admet-496	132	23	to	to	PART
admet-496	132	24	prepare	prepare	VERB
admet-496	132	25	plasma	plasma	NOUN
admet-496	132	26	.	.	PUNCT
admet-496	133	1	total	total	ADJ
admet-496	133	2	bismuth	bismuth	NOUN
admet-496	133	3	was	be	AUX
admet-496	133	4	measured	measure	VERB
admet-496	133	5	by	by	ADP
admet-496	133	6	mixing	mix	VERB
admet-496	133	7	1	1	NUM
admet-496	133	8	volume	volume	NOUN
admet-496	133	9	of	of	ADP
admet-496	133	10	plasma	plasma	NOUN
admet-496	133	11	with	with	ADP
admet-496	133	12	5	5	NUM
admet-496	133	13	volumes	volume	NOUN
admet-496	133	14	of	of	ADP
admet-496	133	15	triton	triton	PROPN
admet-496	133	16	/	/	SYM
admet-496	133	17	antifoam	antifoam	PROPN
admet-496	133	18	(	(	PUNCT
admet-496	133	19	1/1	1/1	NUM
admet-496	133	20	)	)	PUNCT
admet-496	133	21	and	and	CCONJ
admet-496	133	22	4	4	NUM
admet-496	133	23	volumes	volume	NOUN
admet-496	133	24	of	of	ADP
admet-496	133	25	0.4	0.4	NUM
admet-496	133	26	m	m	NOUN
admet-496	133	27	hcl	hcl	PROPN
admet-496	133	28	,	,	PUNCT
admet-496	133	29	which	which	PRON
admet-496	133	30	was	be	AUX
admet-496	133	31	directly	directly	ADV
admet-496	133	32	introduced	introduce	VERB
admet-496	133	33	into	into	ADP
admet-496	133	34	the	the	DET
admet-496	133	35	aas	aas	NOUN
admet-496	133	36	(	(	PUNCT
admet-496	133	37	varian	varian	PROPN
admet-496	133	38	spectraa	spectraa	VERB
admet-496	133	39	300	300	NUM
admet-496	133	40	zeeman	zeeman	NOUN
admet-496	133	41	with	with	ADP
admet-496	133	42	certified	certified	ADJ
admet-496	133	43	bi	bi	NOUN
admet-496	133	44	-	-	NOUN
admet-496	133	45	lamp	lamp	ADJ
admet-496	133	46	;	;	PUNCT
admet-496	133	47	λ=306.8	λ=306.8	PROPN
admet-496	133	48	nm	nm	PROPN
admet-496	133	49	)	)	PUNCT
admet-496	133	50	.	.	PUNCT
admet-496	134	1	calibration	calibration	NOUN
admet-496	134	2	lines	line	NOUN
admet-496	134	3	were	be	AUX
admet-496	134	4	obtained	obtain	VERB
admet-496	134	5	with	with	ADP
admet-496	134	6	bismuth	bismuth	NOUN
admet-496	134	7	nitrate	nitrate	NOUN
admet-496	134	8	from	from	ADP
admet-496	134	9	0.17	0.17	NUM
admet-496	134	10	to	to	ADP
admet-496	134	11	3	3	NUM
admet-496	134	12	μm	μm	NOUN
admet-496	134	13	.	.	PUNCT
admet-496	135	1	free	free	ADJ
admet-496	135	2	bismuth	bismuth	NOUN
admet-496	135	3	(	(	PUNCT
admet-496	135	4	non	non	ADJ
admet-496	135	5	-	-	ADJ
admet-496	135	6	protein	protein	ADJ
admet-496	135	7	bound	bind	VERB
admet-496	135	8	)	)	PUNCT
admet-496	135	9	was	be	AUX
admet-496	135	10	measured	measure	VERB
admet-496	135	11	in	in	ADP
admet-496	135	12	the	the	DET
admet-496	135	13	supernatant	supernatant	NOUN
admet-496	135	14	after	after	ADP
admet-496	135	15	deproteinization	deproteinization	NOUN
admet-496	135	16	(	(	PUNCT
admet-496	135	17	1	1	NUM
admet-496	135	18	volume	volume	NOUN
admet-496	135	19	of	of	ADP
admet-496	135	20	plasma	plasma	NOUN
admet-496	135	21	mixed	mix	VERB
admet-496	135	22	with	with	ADP
admet-496	135	23	2	2	NUM
admet-496	135	24	volumes	volume	NOUN
admet-496	135	25	of	of	ADP
admet-496	135	26	ethanol	ethanol	NOUN
admet-496	135	27	and	and	CCONJ
admet-496	135	28	put	put	VERB
admet-496	135	29	at	at	ADP
admet-496	135	30	-20	-20	NUM
admet-496	135	31	°	°	PROPN
admet-496	135	32	c	c	NOUN
admet-496	135	33	for	for	ADP
admet-496	135	34	2	2	NUM
admet-496	135	35	hr	hr	NOUN
admet-496	135	36	followed	follow	VERB
admet-496	135	37	by	by	ADP
admet-496	135	38	centrifugation	centrifugation	NOUN
admet-496	135	39	for	for	ADP
admet-496	135	40	10	10	NUM
admet-496	135	41	min	min	NOUN
admet-496	135	42	at	at	ADP
admet-496	135	43	4000	4000	NUM
admet-496	135	44	g	g	NOUN
admet-496	135	45	)	)	PUNCT
admet-496	135	46	however	however	ADV
admet-496	135	47	,	,	PUNCT
admet-496	135	48	several	several	ADJ
admet-496	135	49	compounds	compound	NOUN
admet-496	135	50	that	that	PRON
admet-496	135	51	showed	show	VERB
admet-496	135	52	an	an	DET
admet-496	135	53	interesting	interesting	ADJ
admet-496	135	54	profile	profile	NOUN
admet-496	135	55	in	in	ADP
admet-496	135	56	the	the	DET
admet-496	135	57	nci	nci	NOUN
admet-496	135	58	-	-	PUNCT
admet-496	135	59	screen	screen	NOUN
admet-496	135	60	,	,	PUNCT
admet-496	135	61	were	be	AUX
admet-496	135	62	also	also	ADV
admet-496	135	63	successful	successful	ADJ
admet-496	135	64	at	at	ADP
admet-496	135	65	further	further	ADJ
admet-496	135	66	evaluation	evaluation	NOUN
admet-496	135	67	,	,	PUNCT
admet-496	135	68	such	such	ADJ
admet-496	135	69	as	as	ADP
admet-496	135	70	drh-147	drh-147	NOUN
admet-496	135	71	and	and	CCONJ
admet-496	135	72	phortress	phortress	VERB
admet-496	135	73	.	.	PUNCT
admet-496	136	1	drh-417	drh-417	PROPN
admet-496	136	2	,	,	PUNCT
admet-496	136	3	a	a	DET
admet-496	136	4	pyrrolobenzodiazepine	pyrrolobenzodiazepine	NOUN
admet-496	136	5	monomer	monomer	NOUN
admet-496	136	6	acts	act	VERB
admet-496	136	7	by	by	ADP
admet-496	136	8	binding	bind	VERB
admet-496	136	9	into	into	ADP
admet-496	136	10	the	the	DET
admet-496	136	11	minor	minor	ADJ
admet-496	136	12	groove	groove	NOUN
admet-496	136	13	of	of	ADP
admet-496	136	14	dna	dna	NOUN
admet-496	136	15	and	and	CCONJ
admet-496	136	16	was	be	AUX
admet-496	136	17	very	very	ADV
admet-496	136	18	potent	potent	ADJ
admet-496	136	19	in	in	ADP
admet-496	136	20	the	the	DET
admet-496	136	21	nci	nci	PROPN
admet-496	136	22	60	60	NUM
admet-496	136	23	-	-	PUNCT
admet-496	136	24	panel	panel	NOUN
admet-496	136	25	(	(	PUNCT
admet-496	136	26	mean	mean	INTJ
admet-496	136	27	ic50	ic50	PROPN
admet-496	136	28	3	3	NUM
admet-496	136	29	nm	nm	NOUN
admet-496	136	30	)	)	PUNCT
admet-496	136	31	and	and	CCONJ
admet-496	136	32	at	at	ADP
admet-496	136	33	subsequent	subsequent	ADJ
admet-496	136	34	testing	testing	NOUN
admet-496	136	35	by	by	ADP
admet-496	136	36	investigators	investigator	NOUN
admet-496	136	37	of	of	ADP
admet-496	136	38	the	the	DET
admet-496	136	39	european	european	PROPN
admet-496	136	40	nci	nci	PROPN
admet-496	136	41	compounds	compound	VERB
admet-496	136	42	group	group	NOUN
admet-496	137	1	[	[	X
admet-496	137	2	29	29	NUM
admet-496	137	3	]	]	PUNCT
admet-496	137	4	.	.	PUNCT
admet-496	138	1	it	it	PRON
admet-496	138	2	showed	show	VERB
admet-496	138	3	favourable	favourable	ADJ
admet-496	138	4	pharmacokinetics	pharmacokinetic	NOUN
admet-496	138	5	(	(	PUNCT
admet-496	138	6	plasma	plasma	NOUN
admet-496	138	7	peak	peak	NOUN
admet-496	138	8	levels	level	NOUN
admet-496	138	9	of	of	ADP
admet-496	138	10	171	171	NUM
admet-496	138	11	nm	nm	NOUN
admet-496	138	12	,	,	PUNCT
admet-496	138	13	far	far	ADV
admet-496	138	14	above	above	ADP
admet-496	138	15	the	the	DET
admet-496	138	16	gi50	gi50	PROPN
admet-496	138	17	value	value	NOUN
admet-496	138	18	)	)	PUNCT
admet-496	138	19	and	and	CCONJ
admet-496	138	20	interesting	interesting	ADJ
admet-496	138	21	in	in	ADP
admet-496	138	22	vivo	vivo	ADJ
admet-496	138	23	activity	activity	NOUN
admet-496	138	24	against	against	ADP
admet-496	138	25	several	several	ADJ
admet-496	138	26	htx	htx	NOUN
admet-496	138	27	models	model	NOUN
admet-496	138	28	(	(	PUNCT
admet-496	138	29	p<0.01	p<0.01	PROPN
admet-496	138	30	)	)	PUNCT
admet-496	138	31	.	.	PUNCT
admet-496	139	1	these	these	DET
admet-496	139	2	data	datum	NOUN
admet-496	139	3	led	lead	VERB
admet-496	139	4	to	to	ADP
admet-496	139	5	the	the	DET
admet-496	139	6	development	development	NOUN
admet-496	139	7	of	of	ADP
admet-496	139	8	sjg-136	sjg-136	ADJ
admet-496	139	9	,	,	PUNCT
admet-496	139	10	a	a	DET
admet-496	139	11	pyrrolobenzodiazepine	pyrrolobenzodiazepine	NOUN
admet-496	139	12	dimer	dimer	NOUN
admet-496	139	13	that	that	PRON
admet-496	139	14	went	go	VERB
admet-496	139	15	into	into	ADP
admet-496	139	16	a	a	DET
admet-496	139	17	clinical	clinical	ADJ
admet-496	139	18	phase	phase	NOUN
admet-496	139	19	i	i	PRON
admet-496	139	20	study	study	VERB
admet-496	139	21	and	and	CCONJ
admet-496	139	22	phase	phase	NOUN
admet-496	139	23	ii	ii	PROPN
admet-496	139	24	studies	study	NOUN
admet-496	139	25	in	in	ADP
admet-496	139	26	ovarian	ovarian	ADJ
admet-496	139	27	cancer	cancer	NOUN
admet-496	139	28	and	and	CCONJ
admet-496	139	29	leukaemia	leukaemia	NOUN
admet-496	139	30	[	[	X
admet-496	139	31	30	30	NUM
admet-496	139	32	]	]	PUNCT
admet-496	139	33	.	.	PUNCT
admet-496	140	1	phortress	phortress	NOUN
admet-496	140	2	(	(	PUNCT
admet-496	140	3	figure	figure	NOUN
admet-496	140	4	3	3	NUM
admet-496	140	5	)	)	PUNCT
admet-496	140	6	is	be	AUX
admet-496	140	7	a	a	DET
admet-496	140	8	water	water	NOUN
admet-496	140	9	-	-	PUNCT
admet-496	140	10	soluble	soluble	ADJ
admet-496	140	11	benzothiazole	benzothiazole	NOUN
admet-496	140	12	prodrug	prodrug	NOUN
admet-496	140	13	of	of	ADP
admet-496	140	14	5f-203	5f-203	NUM
admet-496	140	15	,	,	PUNCT
admet-496	140	16	that	that	PRON
admet-496	140	17	is	be	AUX
admet-496	140	18	active	active	ADJ
admet-496	140	19	(	(	PUNCT
admet-496	140	20	low	low	ADJ
admet-496	140	21	nanomolar	nanomolar	ADJ
admet-496	140	22	gi50	gi50	PROPN
admet-496	140	23	)	)	PUNCT
admet-496	140	24	,	,	PUNCT
admet-496	140	25	and	and	CCONJ
admet-496	140	26	selective	selective	ADJ
admet-496	140	27	against	against	ADP
admet-496	140	28	breast	breast	NOUN
admet-496	140	29	,	,	PUNCT
admet-496	140	30	ovarian	ovarian	ADJ
admet-496	140	31	and	and	CCONJ
admet-496	140	32	lung	lung	NOUN
admet-496	140	33	cancer	cancer	NOUN
admet-496	140	34	[	[	X
admet-496	140	35	31	31	NUM
admet-496	140	36	]	]	PUNCT
admet-496	140	37	.	.	PUNCT
admet-496	141	1	5f-203	5f-203	NUM
admet-496	141	2	binds	bind	VERB
admet-496	141	3	to	to	ADP
admet-496	141	4	cytoplasmic	cytoplasmic	ADJ
admet-496	141	5	aryl	aryl	NOUN
admet-496	141	6	hydrocarbon	hydrocarbon	NOUN
admet-496	141	7	receptors	receptor	NOUN
admet-496	141	8	,	,	PUNCT
admet-496	141	9	forming	form	VERB
admet-496	141	10	a	a	DET
admet-496	141	11	complex	complex	NOUN
admet-496	141	12	that	that	PRON
admet-496	141	13	is	be	AUX
admet-496	141	14	translocated	translocate	VERB
admet-496	141	15	to	to	ADP
admet-496	141	16	the	the	DET
admet-496	141	17	cellular	cellular	ADJ
admet-496	141	18	nucleus	nucleus	NOUN
admet-496	141	19	,	,	PUNCT
admet-496	141	20	and	and	CCONJ
admet-496	141	21	subsequently	subsequently	ADV
admet-496	141	22	binds	bind	VERB
admet-496	141	23	to	to	ADP
admet-496	141	24	the	the	DET
admet-496	141	25	cyp1a1	cyp1a1	NOUN
admet-496	141	26	promoter	promoter	NOUN
admet-496	141	27	[	[	X
admet-496	141	28	32,33	32,33	NUM
admet-496	141	29	]	]	PUNCT
admet-496	141	30	.	.	PUNCT
admet-496	142	1	this	this	PRON
admet-496	142	2	leads	lead	VERB
admet-496	142	3	to	to	ADP
admet-496	142	4	an	an	DET
admet-496	142	5	induction	induction	NOUN
admet-496	142	6	of	of	ADP
admet-496	142	7	the	the	DET
admet-496	142	8	expression	expression	NOUN
admet-496	142	9	of	of	ADP
admet-496	142	10	cytochrome	cytochrome	ADJ
admet-496	142	11	p450	p450	PROPN
admet-496	142	12	1a1	1a1	NUM
admet-496	142	13	,	,	PUNCT
admet-496	142	14	responsible	responsible	ADJ
admet-496	142	15	for	for	ADP
admet-496	142	16	metabolism	metabolism	NOUN
admet-496	142	17	of	of	ADP
admet-496	142	18	5f-203	5f-203	NUM
admet-496	142	19	to	to	ADP
admet-496	142	20	a	a	DET
admet-496	142	21	bio	bio	ADJ
admet-496	142	22	-	-	ADJ
admet-496	142	23	reactive	reactive	ADJ
admet-496	142	24	species	specie	NOUN
admet-496	142	25	that	that	PRON
admet-496	142	26	forms	form	VERB
admet-496	142	27	dna	dna	NOUN
admet-496	142	28	-	-	PUNCT
admet-496	142	29	adducts	adduct	NOUN
admet-496	142	30	.	.	PUNCT
admet-496	143	1	this	this	DET
admet-496	143	2	unique	unique	ADJ
admet-496	143	3	mechanism	mechanism	NOUN
admet-496	143	4	of	of	ADP
admet-496	143	5	action	action	NOUN
admet-496	143	6	,	,	PUNCT
admet-496	143	7	together	together	ADV
admet-496	143	8	with	with	ADP
admet-496	143	9	a	a	DET
admet-496	143	10	good	good	ADJ
admet-496	143	11	pharmacokinetic	pharmacokinetic	ADJ
admet-496	143	12	profile	profile	NOUN
admet-496	143	13	,	,	PUNCT
admet-496	143	14	led	lead	VERB
admet-496	143	15	to	to	ADP
admet-496	143	16	further	further	ADJ
admet-496	143	17	evaluation	evaluation	NOUN
admet-496	143	18	in	in	ADP
admet-496	143	19	phase	phase	NOUN
admet-496	143	20	i	i	PRON
admet-496	143	21	clinical	clinical	ADJ
admet-496	143	22	study	study	NOUN
admet-496	144	1	[	[	X
admet-496	144	2	34	34	NUM
admet-496	144	3	]	]	PUNCT
admet-496	144	4	,	,	PUNCT
admet-496	144	5	in	in	ADP
admet-496	144	6	which	which	PRON
admet-496	144	7	14	14	NUM
admet-496	144	8	out	out	ADP
admet-496	144	9	of	of	ADP
admet-496	144	10	42	42	NUM
admet-496	144	11	patients	patient	NOUN
admet-496	144	12	had	have	VERB
admet-496	144	13	stable	stable	ADJ
admet-496	144	14	disease	disease	NOUN
admet-496	144	15	.	.	PUNCT
admet-496	145	1	all	all	ADV
admet-496	145	2	together	together	ADV
admet-496	145	3	,	,	PUNCT
admet-496	145	4	these	these	DET
admet-496	145	5	data	datum	NOUN
admet-496	145	6	show	show	VERB
admet-496	145	7	that	that	SCONJ
admet-496	145	8	the	the	DET
admet-496	145	9	approach	approach	NOUN
admet-496	145	10	can	can	AUX
admet-496	145	11	lead	lead	VERB
admet-496	145	12	to	to	ADP
admet-496	145	13	compounds	compound	NOUN
admet-496	145	14	with	with	ADP
admet-496	145	15	clinical	clinical	ADJ
admet-496	145	16	activity	activity	NOUN
admet-496	145	17	.	.	PUNCT
admet-496	146	1	godefridus	godefridus	PROPN
admet-496	146	2	peters	peters	PROPN
admet-496	146	3	et	et	PROPN
admet-496	146	4	al	al	PROPN
admet-496	146	5	.	.	PROPN
admet-496	146	6	admet	admet	PROPN
admet-496	146	7	&	&	CCONJ
admet-496	146	8	dmpk	dmpk	PROPN
admet-496	146	9	6(1	6(1	NUM
admet-496	146	10	)	)	PUNCT
admet-496	146	11	(	(	PUNCT
admet-496	146	12	2018	2018	NUM
admet-496	146	13	)	)	PUNCT
admet-496	146	14	4	4	NUM
admet-496	146	15	-	-	SYM
admet-496	146	16	14	14	NUM
admet-496	146	17	12	12	NUM
admet-496	146	18	figure	figure	NOUN
admet-496	146	19	6	6	NUM
admet-496	146	20	.	.	PUNCT
admet-496	147	1	flow	flow	NOUN
admet-496	147	2	chart	chart	NOUN
admet-496	147	3	showing	show	VERB
admet-496	147	4	the	the	DET
admet-496	147	5	testing	testing	NOUN
admet-496	147	6	procedure	procedure	NOUN
admet-496	147	7	and	and	CCONJ
admet-496	147	8	addition	addition	NOUN
admet-496	147	9	of	of	ADP
admet-496	147	10	novel	novel	ADJ
admet-496	147	11	parameters	parameter	NOUN
admet-496	147	12	as	as	SCONJ
admet-496	147	13	outlined	outline	VERB
admet-496	147	14	in	in	ADP
admet-496	147	15	the	the	DET
admet-496	147	16	text	text	NOUN
admet-496	147	17	.	.	PUNCT
admet-496	148	1	each	each	DET
admet-496	148	2	step	step	NOUN
admet-496	148	3	can	can	AUX
admet-496	148	4	lead	lead	VERB
admet-496	148	5	to	to	ADP
admet-496	148	6	elimination	elimination	NOUN
admet-496	148	7	when	when	SCONJ
admet-496	148	8	not	not	PART
admet-496	148	9	full	full	ADV
admet-496	148	10	-	-	PUNCT
admet-496	148	11	filling	fill	VERB
admet-496	148	12	the	the	DET
admet-496	148	13	criteria	criterion	NOUN
admet-496	148	14	.	.	PUNCT
admet-496	149	1	nce	nce	NOUN
admet-496	149	2	,	,	PUNCT
admet-496	149	3	new	new	ADJ
admet-496	149	4	chemical	chemical	NOUN
admet-496	149	5	entity	entity	NOUN
admet-496	149	6	;	;	PUNCT
admet-496	149	7	mtd	mtd	PROPN
admet-496	149	8	,	,	PUNCT
admet-496	149	9	maximal	maximal	ADJ
admet-496	149	10	tolerated	tolerate	VERB
admet-496	149	11	dose	dose	NOUN
admet-496	149	12	;	;	PUNCT
admet-496	149	13	hfa	hfa	PROPN
admet-496	149	14	,	,	PUNCT
admet-496	149	15	hollow	hollow	ADJ
admet-496	149	16	fiber	fiber	NOUN
admet-496	149	17	assay	assay	VERB
admet-496	149	18	.	.	PUNCT
admet-496	150	1	the	the	DET
admet-496	150	2	first	first	ADJ
admet-496	150	3	three	three	NUM
admet-496	150	4	examples	example	NOUN
admet-496	150	5	show	show	VERB
admet-496	150	6	that	that	SCONJ
admet-496	150	7	despite	despite	SCONJ
admet-496	150	8	initial	initial	ADJ
admet-496	150	9	enthusiasm	enthusiasm	NOUN
admet-496	150	10	about	about	ADP
admet-496	150	11	the	the	DET
admet-496	150	12	drug	drug	NOUN
admet-496	150	13	sensitivity	sensitivity	NOUN
admet-496	150	14	profile	profile	NOUN
admet-496	150	15	and	and	CCONJ
admet-496	150	16	compare	compare	VERB
admet-496	150	17	data	datum	NOUN
admet-496	150	18	,	,	PUNCT
admet-496	150	19	development	development	NOUN
admet-496	150	20	had	have	VERB
admet-496	150	21	to	to	PART
admet-496	150	22	be	be	AUX
admet-496	150	23	discontinued	discontinue	VERB
admet-496	150	24	rapidly	rapidly	ADV
admet-496	150	25	.	.	PUNCT
admet-496	151	1	unfavourable	unfavourable	ADJ
admet-496	151	2	physico	physico	NOUN
admet-496	151	3	-	-	PUNCT
admet-496	151	4	chemical	chemical	NOUN
admet-496	151	5	properties	property	NOUN
admet-496	151	6	,	,	PUNCT
admet-496	151	7	such	such	ADJ
admet-496	151	8	as	as	ADP
admet-496	151	9	insolubility	insolubility	NOUN
admet-496	151	10	,	,	PUNCT
admet-496	151	11	made	make	VERB
admet-496	151	12	it	it	PRON
admet-496	151	13	impossible	impossible	ADJ
admet-496	151	14	to	to	PART
admet-496	151	15	perform	perform	VERB
admet-496	151	16	adequate	adequate	ADJ
admet-496	151	17	in	in	ADP
admet-496	151	18	vitro	vitro	X
admet-496	151	19	and	and	CCONJ
admet-496	151	20	in	in	ADP
admet-496	151	21	vivo	vivo	ADJ
admet-496	151	22	studies	study	NOUN
admet-496	151	23	and	and	CCONJ
admet-496	151	24	to	to	PART
admet-496	151	25	set	set	VERB
admet-496	151	26	up	up	ADP
admet-496	151	27	suitable	suitable	ADJ
admet-496	151	28	analytical	analytical	ADJ
admet-496	151	29	assays	assay	NOUN
admet-496	151	30	.	.	PUNCT
admet-496	152	1	in	in	ADP
admet-496	152	2	addition	addition	NOUN
admet-496	152	3	to	to	ADP
admet-496	152	4	this	this	PRON
admet-496	152	5	and	and	CCONJ
admet-496	152	6	lack	lack	NOUN
admet-496	152	7	of	of	ADP
admet-496	152	8	in	in	ADP
admet-496	152	9	vivo	vivo	NOUN
admet-496	152	10	activity	activity	NOUN
admet-496	152	11	,	,	PUNCT
admet-496	152	12	other	other	ADJ
admet-496	152	13	reasons	reason	NOUN
admet-496	152	14	for	for	ADP
admet-496	152	15	discontinuation	discontinuation	NOUN
admet-496	152	16	included	include	VERB
admet-496	152	17	instability	instability	NOUN
admet-496	152	18	,	,	PUNCT
admet-496	152	19	impurity	impurity	NOUN
admet-496	152	20	,	,	PUNCT
admet-496	152	21	unavailability	unavailability	NOUN
admet-496	152	22	of	of	ADP
admet-496	152	23	material	material	NOUN
admet-496	152	24	and	and	CCONJ
admet-496	152	25	insufficient	insufficient	ADJ
admet-496	152	26	bioavailability	bioavailability	NOUN
admet-496	152	27	.	.	PUNCT
admet-496	153	1	a	a	DET
admet-496	153	2	careful	careful	ADJ
admet-496	153	3	analysis	analysis	NOUN
admet-496	153	4	of	of	ADP
admet-496	153	5	the	the	DET
admet-496	153	6	mechanism	mechanism	NOUN
admet-496	153	7	of	of	ADP
admet-496	153	8	action	action	NOUN
admet-496	153	9	helps	help	VERB
admet-496	153	10	to	to	PART
admet-496	153	11	understand	understand	VERB
admet-496	153	12	the	the	DET
admet-496	153	13	success	success	NOUN
admet-496	153	14	(	(	PUNCT
admet-496	153	15	drh-147	drh-147	NOUN
admet-496	153	16	and	and	CCONJ
admet-496	153	17	phortress	phortress	VERB
admet-496	153	18	)	)	PUNCT
admet-496	153	19	but	but	CCONJ
admet-496	153	20	also	also	ADV
admet-496	153	21	enabled	enable	VERB
admet-496	153	22	a	a	DET
admet-496	153	23	systematic	systematic	ADJ
admet-496	153	24	development	development	NOUN
admet-496	153	25	of	of	ADP
admet-496	153	26	novel	novel	ADJ
admet-496	153	27	analogues	analogue	NOUN
admet-496	153	28	.	.	PUNCT
admet-496	154	1	this	this	PRON
admet-496	154	2	was	be	AUX
admet-496	154	3	due	due	ADJ
admet-496	154	4	to	to	ADP
admet-496	154	5	a	a	DET
admet-496	154	6	successful	successful	ADJ
admet-496	154	7	scientific	scientific	ADJ
admet-496	154	8	collaboration	collaboration	NOUN
admet-496	154	9	between	between	ADP
admet-496	154	10	different	different	ADJ
admet-496	154	11	groups	group	NOUN
admet-496	154	12	that	that	PRON
admet-496	154	13	provides	provide	VERB
admet-496	154	14	a	a	DET
admet-496	154	15	model	model	NOUN
admet-496	154	16	for	for	ADP
admet-496	154	17	future	future	ADJ
admet-496	154	18	drug	drug	NOUN
admet-496	154	19	development	development	NOUN
admet-496	154	20	.	.	PUNCT
admet-496	155	1	importantly	importantly	ADV
admet-496	155	2	the	the	DET
admet-496	155	3	groups	group	NOUN
admet-496	155	4	adhered	adhere	VERB
admet-496	155	5	to	to	ADP
admet-496	155	6	standard	standard	ADJ
admet-496	155	7	cellular	cellular	ADJ
admet-496	155	8	pharmacology	pharmacology	NOUN
admet-496	155	9	tools	tool	NOUN
admet-496	155	10	for	for	ADP
admet-496	155	11	testing	test	VERB
admet-496	155	12	[	[	X
admet-496	155	13	14	14	NUM
admet-496	155	14	]	]	PUNCT
admet-496	155	15	.	.	PUNCT
admet-496	156	1	conclusions	conclusion	NOUN
admet-496	156	2	the	the	DET
admet-496	156	3	results	result	NOUN
admet-496	156	4	of	of	ADP
admet-496	156	5	the	the	DET
admet-496	156	6	pharmacologically	pharmacologically	ADV
admet-496	156	7	directed	direct	VERB
admet-496	156	8	approach	approach	NOUN
admet-496	156	9	clearly	clearly	ADV
admet-496	156	10	showed	show	VERB
admet-496	156	11	that	that	SCONJ
admet-496	156	12	a	a	DET
admet-496	156	13	few	few	ADJ
admet-496	156	14	simple	simple	ADJ
admet-496	156	15	procedures	procedure	NOUN
admet-496	156	16	with	with	ADP
admet-496	156	17	small	small	ADJ
admet-496	156	18	numbers	number	NOUN
admet-496	156	19	of	of	ADP
admet-496	156	20	mice	mouse	NOUN
admet-496	156	21	quickly	quickly	ADV
admet-496	156	22	allow	allow	VERB
admet-496	156	23	discontinuing	discontinuing	NOUN
admet-496	156	24	agents	agent	NOUN
admet-496	156	25	that	that	PRON
admet-496	156	26	were	be	AUX
admet-496	156	27	highly	highly	ADV
admet-496	156	28	unlikely	unlikely	ADJ
admet-496	156	29	to	to	PART
admet-496	156	30	have	have	VERB
admet-496	156	31	any	any	DET
admet-496	156	32	antitumor	antitumor	PROPN
admet-496	156	33	activity	activity	NOUN
admet-496	156	34	.	.	PUNCT
admet-496	157	1	the	the	DET
admet-496	157	2	process	process	NOUN
admet-496	157	3	is	be	AUX
admet-496	157	4	outlined	outline	VERB
admet-496	157	5	in	in	ADP
admet-496	157	6	the	the	DET
admet-496	157	7	flow	flow	NOUN
admet-496	157	8	chart	chart	NOUN
admet-496	157	9	(	(	PUNCT
admet-496	157	10	figure	figure	NOUN
admet-496	157	11	6	6	NUM
admet-496	157	12	)	)	PUNCT
admet-496	157	13	.	.	PUNCT
admet-496	158	1	the	the	DET
admet-496	158	2	chart	chart	NOUN
admet-496	158	3	also	also	ADV
admet-496	158	4	shows	show	VERB
admet-496	158	5	some	some	DET
admet-496	158	6	streamlining	streamlining	NOUN
admet-496	158	7	to	to	PART
admet-496	158	8	optimize	optimize	VERB
admet-496	158	9	the	the	DET
admet-496	158	10	process	process	NOUN
admet-496	158	11	and	and	CCONJ
admet-496	158	12	eliminate	eliminate	VERB
admet-496	158	13	agents	agent	NOUN
admet-496	158	14	with	with	ADP
admet-496	158	15	unsuitable	unsuitable	ADJ
admet-496	158	16	pharmacological	pharmacological	ADJ
admet-496	158	17	parameters	parameter	NOUN
admet-496	158	18	in	in	ADP
admet-496	158	19	less	less	ADJ
admet-496	158	20	than	than	ADP
admet-496	158	21	three	three	NUM
admet-496	158	22	months	month	NOUN
admet-496	158	23	.	.	PUNCT
admet-496	159	1	current	current	ADJ
admet-496	159	2	approaches	approach	NOUN
admet-496	159	3	should	should	AUX
admet-496	159	4	put	put	VERB
admet-496	159	5	much	much	ADV
admet-496	159	6	more	more	ADJ
admet-496	159	7	emphasis	emphasis	NOUN
admet-496	159	8	on	on	ADP
admet-496	159	9	physico	physico	NOUN
admet-496	159	10	-	-	PUNCT
admet-496	159	11	chemical	chemical	NOUN
admet-496	159	12	properties	property	NOUN
admet-496	159	13	such	such	ADJ
admet-496	159	14	as	as	ADP
admet-496	159	15	solubility	solubility	NOUN
admet-496	159	16	,	,	PUNCT
admet-496	159	17	pka	pka	PROPN
admet-496	159	18	values	value	NOUN
admet-496	159	19	,	,	PUNCT
admet-496	159	20	log	log	VERB
admet-496	159	21	p	p	NOUN
admet-496	159	22	and	and	CCONJ
admet-496	159	23	log	log	NOUN
admet-496	159	24	d	d	NOUN
admet-496	159	25	values	value	NOUN
admet-496	159	26	,	,	PUNCT
admet-496	159	27	protein	protein	NOUN
admet-496	159	28	binding	bind	VERB
admet-496	159	29	and	and	CCONJ
admet-496	159	30	drug	drug	NOUN
admet-496	159	31	distribution	distribution	NOUN
admet-496	159	32	.	.	PUNCT
admet-496	160	1	this	this	PRON
admet-496	160	2	serves	serve	VERB
admet-496	160	3	two	two	NUM
admet-496	160	4	purposes	purpose	NOUN
admet-496	160	5	,	,	PUNCT
admet-496	160	6	whether	whether	SCONJ
admet-496	160	7	to	to	PART
admet-496	160	8	discontinue	discontinue	VERB
admet-496	160	9	development	development	NOUN
admet-496	160	10	rapidly	rapidly	ADV
admet-496	160	11	or	or	CCONJ
admet-496	160	12	when	when	SCONJ
admet-496	160	13	promising	promise	VERB
admet-496	160	14	how	how	SCONJ
admet-496	160	15	to	to	PART
admet-496	160	16	design	design	VERB
admet-496	160	17	an	an	DET
admet-496	160	18	analogue	analogue	NOUN
admet-496	160	19	with	with	ADP
admet-496	160	20	better	well	ADJ
admet-496	160	21	properties	property	NOUN
admet-496	160	22	.	.	PUNCT
admet-496	161	1	regarding	regard	VERB
admet-496	161	2	solubility	solubility	NOUN
admet-496	161	3	,	,	PUNCT
admet-496	161	4	there	there	PRON
admet-496	161	5	are	be	VERB
admet-496	161	6	novel	novel	ADJ
admet-496	161	7	possibilities	possibility	NOUN
admet-496	161	8	to	to	PART
admet-496	161	9	use	use	VERB
admet-496	161	10	insoluble	insoluble	ADJ
admet-496	161	11	compounds	compound	NOUN
admet-496	161	12	with	with	ADP
admet-496	161	13	adequate	adequate	ADJ
admet-496	161	14	solvents	solvent	NOUN
admet-496	161	15	[	[	X
admet-496	161	16	35	35	NUM
admet-496	161	17	]	]	PUNCT
admet-496	161	18	.	.	PUNCT
admet-496	162	1	using	use	VERB
admet-496	162	2	biomimetic	biomimetic	ADJ
admet-496	162	3	approaches	approach	NOUN
admet-496	162	4	one	one	PRON
admet-496	162	5	would	would	AUX
admet-496	162	6	be	be	AUX
admet-496	162	7	able	able	ADJ
admet-496	162	8	to	to	PART
admet-496	162	9	gain	gain	VERB
admet-496	162	10	insight	insight	NOUN
admet-496	162	11	in	in	ADP
admet-496	162	12	elimination	elimination	NOUN
admet-496	162	13	constants	constant	NOUN
admet-496	162	14	,	,	PUNCT
admet-496	162	15	and	and	CCONJ
admet-496	162	16	likelihood	likelihood	NOUN
admet-496	162	17	of	of	ADP
admet-496	162	18	brain	brain	NOUN
admet-496	162	19	uptake	uptake	ADJ
admet-496	162	20	[	[	X
admet-496	162	21	36	36	NUM
admet-496	162	22	]	]	PUNCT
admet-496	162	23	.	.	PUNCT
admet-496	163	1	next	next	ADJ
admet-496	163	2	to	to	ADP
admet-496	163	3	that	that	PRON
admet-496	163	4	,	,	PUNCT
admet-496	163	5	pharmacological	pharmacological	ADJ
admet-496	163	6	evaluation	evaluation	NOUN
admet-496	163	7	should	should	AUX
admet-496	163	8	include	include	VERB
admet-496	163	9	phase	phase	NOUN
admet-496	163	10	i	i	PRON
admet-496	163	11	(	(	PUNCT
admet-496	163	12	oxidation	oxidation	NOUN
admet-496	163	13	)	)	PUNCT
admet-496	163	14	and	and	CCONJ
admet-496	163	15	ii	ii	PROPN
admet-496	163	16	(	(	PUNCT
admet-496	163	17	conjugation	conjugation	NOUN
admet-496	163	18	)	)	PUNCT
admet-496	163	19	drug	drug	NOUN
admet-496	163	20	metabolism	metabolism	NOUN
admet-496	163	21	which	which	PRON
admet-496	163	22	can	can	AUX
admet-496	163	23	currently	currently	ADV
admet-496	163	24	easily	easily	ADV
admet-496	163	25	being	be	AUX
admet-496	163	26	studied	study	VERB
admet-496	163	27	using	use	VERB
admet-496	163	28	isolated	isolate	VERB
admet-496	163	29	hepatocytes	hepatocyte	NOUN
admet-496	163	30	.	.	PUNCT
admet-496	164	1	inclusion	inclusion	NOUN
admet-496	164	2	of	of	ADP
admet-496	164	3	such	such	ADJ
admet-496	164	4	novel	novel	ADJ
admet-496	164	5	approaches	approach	NOUN
admet-496	164	6	would	would	AUX
admet-496	164	7	more	more	ADV
admet-496	164	8	rapidly	rapidly	ADV
admet-496	164	9	predict	predict	VERB
admet-496	164	10	whether	whether	SCONJ
admet-496	164	11	a	a	DET
admet-496	164	12	drug	drug	NOUN
admet-496	164	13	will	will	AUX
admet-496	164	14	have	have	VERB
admet-496	164	15	suitable	suitable	ADJ
admet-496	164	16	pharmacological	pharmacological	ADJ
admet-496	164	17	properties	property	NOUN
admet-496	164	18	to	to	PART
admet-496	164	19	proceed	proceed	VERB
admet-496	164	20	to	to	ADP
admet-496	164	21	the	the	DET
admet-496	164	22	next	next	ADJ
admet-496	164	23	step	step	NOUN
admet-496	164	24	in	in	ADP
admet-496	164	25	development	development	NOUN
admet-496	164	26	.	.	PUNCT
admet-496	165	1	admet	admet	PROPN
admet-496	165	2	&	&	CCONJ
admet-496	165	3	dmpk	dmpk	PROPN
admet-496	165	4	6(1	6(1	NUM
admet-496	165	5	)	)	PUNCT
admet-496	165	6	(	(	PUNCT
admet-496	165	7	2018	2018	NUM
admet-496	165	8	)	)	PUNCT
admet-496	165	9	4	4	NUM
admet-496	165	10	-	-	SYM
admet-496	165	11	14	14	NUM
admet-496	165	12	the	the	DET
admet-496	165	13	role	role	NOUN
admet-496	165	14	of	of	ADP
admet-496	165	15	pharmacology	pharmacology	NOUN
admet-496	165	16	in	in	ADP
admet-496	165	17	anticancer	anticancer	NOUN
admet-496	165	18	drug	drug	PROPN
admet-496	165	19	development	development	PROPN
admet-496	165	20	doi	doi	PROPN
admet-496	165	21	:	:	PUNCT
admet-496	165	22	10.5599	10.5599	NUM
admet-496	165	23	/	/	SYM
admet-496	165	24	admet.6.1.496	admet.6.1.496	VERB
admet-496	165	25	13	13	NUM
admet-496	165	26	acknowledgements	acknowledgement	NOUN
admet-496	165	27	:	:	PUNCT
admet-496	165	28	the	the	DET
admet-496	165	29	authors	author	NOUN
admet-496	165	30	thank	thank	VERB
admet-496	165	31	all	all	DET
admet-496	165	32	members	member	NOUN
admet-496	165	33	of	of	ADP
admet-496	165	34	the	the	DET
admet-496	165	35	european	european	PROPN
admet-496	165	36	nci	nci	PROPN
admet-496	165	37	compounds	compound	VERB
admet-496	165	38	group	group	NOUN
admet-496	166	1	[	[	X
admet-496	166	2	10,11	10,11	NOUN
admet-496	166	3	]	]	PUNCT
admet-496	166	4	,	,	PUNCT
admet-496	166	5	consisting	consist	VERB
admet-496	166	6	of	of	ADP
admet-496	166	7	investigators	investigator	NOUN
admet-496	166	8	from	from	ADP
admet-496	166	9	the	the	DET
admet-496	166	10	former	former	ADJ
admet-496	166	11	eortc	eortc	NOUN
admet-496	166	12	-	-	PUNCT
admet-496	166	13	spg	spg	PROPN
admet-496	166	14	and	and	CCONJ
admet-496	166	15	ptmg	ptmg	ADJ
admet-496	166	16	groups	group	NOUN
admet-496	166	17	,	,	PUNCT
admet-496	166	18	the	the	DET
admet-496	166	19	nci	nci	PROPN
admet-496	166	20	,	,	PUNCT
admet-496	166	21	crc	crc	NOUN
admet-496	166	22	and	and	CCONJ
admet-496	166	23	cruk	cruk	NOUN
admet-496	166	24	and	and	CCONJ
admet-496	166	25	the	the	DET
admet-496	166	26	current	current	ADJ
admet-496	166	27	eortc	eortc	VERB
admet-496	166	28	-	-	PUNCT
admet-496	166	29	pamm	pamm	NOUN
admet-496	166	30	group	group	NOUN
admet-496	166	31	and	and	CCONJ
admet-496	166	32	its	its	PRON
admet-496	166	33	ddc	ddc	NOUN
admet-496	166	34	group	group	NOUN
admet-496	166	35	.	.	PUNCT
admet-496	167	1	references	reference	NOUN
admet-496	167	2	[	[	X
admet-496	167	3	1	1	NUM
admet-496	167	4	]	]	PUNCT
admet-496	167	5	k.	k.	PROPN
admet-496	167	6	tam	tam	PROPN
admet-496	167	7	.	.	PUNCT
admet-496	168	1	estimating	estimate	VERB
admet-496	168	2	the	the	DET
admet-496	168	3	“	"	PUNCT
admet-496	168	4	first	first	ADJ
admet-496	168	5	in	in	ADP
admet-496	168	6	human	human	NOUN
admet-496	168	7	”	"	PUNCT
admet-496	168	8	dose	dose	NOUN
admet-496	168	9	–	–	PUNCT
admet-496	168	10	a	a	DET
admet-496	168	11	revisit	revisit	NOUN
admet-496	168	12	with	with	ADP
admet-496	168	13	particular	particular	ADJ
admet-496	168	14	emphases	emphasis	NOUN
admet-496	168	15	in	in	ADP
admet-496	168	16	oncology	oncology	NOUN
admet-496	168	17	drugs	drug	NOUN
admet-496	168	18	.	.	PUNCT
admet-496	169	1	admet	admet	PROPN
admet-496	169	2	&	&	CCONJ
admet-496	169	3	dmpk	dmpk	PROPN
admet-496	169	4	1	1	NUM
admet-496	169	5	(	(	PUNCT
admet-496	169	6	2013	2013	NUM
admet-496	169	7	)	)	PUNCT
admet-496	169	8	63	63	NUM
admet-496	169	9	-	-	SYM
admet-496	169	10	75	75	NUM
admet-496	169	11	.	.	PUNCT
admet-496	170	1	[	[	X
admet-496	170	2	2	2	NUM
admet-496	170	3	]	]	X
admet-496	170	4	m.r	m.r	PROPN
admet-496	170	5	.	.	PROPN
admet-496	170	6	grever	grever	NOUN
admet-496	170	7	.	.	PUNCT
admet-496	171	1	accelerating	accelerate	VERB
admet-496	171	2	safe	safe	ADJ
admet-496	171	3	drug	drug	NOUN
admet-496	171	4	development	development	NOUN
admet-496	171	5	:	:	PUNCT
admet-496	171	6	an	an	DET
admet-496	171	7	ideal	ideal	ADJ
admet-496	171	8	approach	approach	NOUN
admet-496	171	9	to	to	ADP
admet-496	171	10	approval	approval	NOUN
admet-496	171	11	.	.	PUNCT
admet-496	172	1	hematology	hematology	NOUN
admet-496	172	2	am	be	AUX
admet-496	172	3	soc	soc	NOUN
admet-496	172	4	hematol	hematol	NOUN
admet-496	172	5	educ	educ	PROPN
admet-496	172	6	program	program	NOUN
admet-496	172	7	.	.	PUNCT
admet-496	173	1	2013	2013	NUM
admet-496	173	2	(	(	PUNCT
admet-496	173	3	2013	2013	NUM
admet-496	173	4	)	)	PUNCT
admet-496	173	5	24	24	NUM
admet-496	173	6	-	-	SYM
admet-496	173	7	9	9	NUM
admet-496	173	8	.	.	PUNCT
admet-496	174	1	[	[	X
admet-496	174	2	3	3	X
admet-496	174	3	]	]	X
admet-496	174	4	j.m	j.m	PROPN
admet-496	174	5	.	.	PROPN
admet-496	174	6	bullock	bullock	PROPN
admet-496	174	7	,	,	PUNCT
admet-496	174	8	a.	a.	PROPN
admet-496	174	9	rahman	rahman	PROPN
admet-496	174	10	,	,	PUNCT
admet-496	174	11	q.	q.	PROPN
admet-496	174	12	liu	liu	PROPN
admet-496	174	13	.	.	PUNCT
admet-496	174	14	lessons	lesson	NOUN
admet-496	174	15	learned	learn	VERB
admet-496	174	16	:	:	PUNCT
admet-496	174	17	dose	dose	NOUN
admet-496	174	18	selection	selection	NOUN
admet-496	174	19	of	of	ADP
admet-496	174	20	small	small	ADJ
admet-496	174	21	molecule	molecule	NOUN
admet-496	174	22	-	-	PUNCT
admet-496	174	23	targeted	target	VERB
admet-496	174	24	oncology	oncology	NOUN
admet-496	174	25	drugs	drug	NOUN
admet-496	174	26	.	.	PUNCT
admet-496	175	1	clin	clin	PROPN
admet-496	175	2	cancer	cancer	NOUN
admet-496	175	3	res	re	VERB
admet-496	175	4	22	22	NUM
admet-496	175	5	(	(	PUNCT
admet-496	175	6	2016	2016	NUM
admet-496	175	7	)	)	PUNCT
admet-496	175	8	2630	2630	NUM
admet-496	175	9	-	-	SYM
admet-496	175	10	8	8	NUM
admet-496	175	11	.	.	PUNCT
admet-496	176	1	[	[	X
admet-496	176	2	4	4	X
admet-496	176	3	]	]	X
admet-496	176	4	j.w	j.w	PROPN
admet-496	176	5	.	.	PROPN
admet-496	176	6	scannell	scannell	PROPN
admet-496	176	7	,	,	PUNCT
admet-496	176	8	a.	a.	NOUN
admet-496	176	9	blanckley	blanckley	PROPN
admet-496	176	10	,	,	PUNCT
admet-496	176	11	h.	h.	PROPN
admet-496	176	12	boldon	boldon	PROPN
admet-496	176	13	,	,	PUNCT
admet-496	176	14	b.	b.	PROPN
admet-496	176	15	warrington	warrington	PROPN
admet-496	176	16	.	.	PUNCT
admet-496	177	1	diagnosing	diagnose	VERB
admet-496	177	2	the	the	DET
admet-496	177	3	decline	decline	NOUN
admet-496	177	4	in	in	ADP
admet-496	177	5	pharmaceutical	pharmaceutical	ADJ
admet-496	177	6	r&d	r&d	NOUN
admet-496	177	7	efficiency	efficiency	NOUN
admet-496	177	8	.	.	PUNCT
admet-496	178	1	nat	nat	PROPN
admet-496	178	2	rev	rev	PROPN
admet-496	178	3	drug	drug	PROPN
admet-496	178	4	discov	discov	PROPN
admet-496	178	5	11	11	NUM
admet-496	178	6	(	(	PUNCT
admet-496	178	7	2012	2012	NUM
admet-496	178	8	)	)	PUNCT
admet-496	178	9	191	191	NUM
admet-496	178	10	-	-	SYM
admet-496	178	11	200	200	NUM
admet-496	178	12	.	.	PUNCT
admet-496	179	1	[	[	X
admet-496	179	2	5	5	X
admet-496	179	3	]	]	PUNCT
admet-496	179	4	d.	d.	PROPN
admet-496	179	5	buffery	buffery	PROPN
admet-496	179	6	.	.	PUNCT
admet-496	180	1	the	the	DET
admet-496	180	2	2015	2015	NUM
admet-496	180	3	oncology	oncology	NOUN
admet-496	180	4	drug	drug	NOUN
admet-496	180	5	pipeline	pipeline	NOUN
admet-496	180	6	:	:	PUNCT
admet-496	180	7	innovation	innovation	NOUN
admet-496	180	8	drives	drive	VERB
admet-496	180	9	the	the	DET
admet-496	180	10	race	race	NOUN
admet-496	180	11	to	to	PART
admet-496	180	12	cure	cure	VERB
admet-496	180	13	cancer	cancer	NOUN
admet-496	180	14	.	.	PUNCT
admet-496	181	1	am	be	AUX
admet-496	181	2	health	health	NOUN
admet-496	181	3	drug	drug	NOUN
admet-496	181	4	benefits	benefit	NOUN
admet-496	181	5	8	8	NUM
admet-496	181	6	(	(	PUNCT
admet-496	181	7	2015	2015	NUM
admet-496	181	8	)	)	PUNCT
admet-496	181	9	216	216	NUM
admet-496	181	10	-	-	SYM
admet-496	181	11	22	22	NUM
admet-496	181	12	.	.	PUNCT
admet-496	182	1	[	[	X
admet-496	182	2	6	6	NUM
admet-496	182	3	]	]	X
admet-496	182	4	p.b	p.b	PROPN
admet-496	182	5	.	.	PROPN
admet-496	182	6	bach	bach	PROPN
admet-496	182	7	.	.	PUNCT
admet-496	183	1	limits	limit	NOUN
admet-496	183	2	on	on	ADP
admet-496	183	3	medicare	medicare	PROPN
admet-496	183	4	's	's	PART
admet-496	183	5	ability	ability	NOUN
admet-496	183	6	to	to	PART
admet-496	183	7	control	control	VERB
admet-496	183	8	rising	rise	VERB
admet-496	183	9	spending	spending	NOUN
admet-496	183	10	on	on	ADP
admet-496	183	11	cancer	cancer	NOUN
admet-496	183	12	drugs	drug	NOUN
admet-496	183	13	.	.	PUNCT
admet-496	184	1	n	n	PRON
admet-496	184	2	engl	engl	PROPN
admet-496	184	3	j	j	PROPN
admet-496	184	4	med	med	PROPN
admet-496	184	5	.	.	PUNCT
admet-496	185	1	360	360	NUM
admet-496	185	2	(	(	PUNCT
admet-496	185	3	2009	2009	NUM
admet-496	185	4	)	)	PUNCT
admet-496	185	5	626	626	NUM
admet-496	185	6	-	-	SYM
admet-496	185	7	33	33	NUM
admet-496	185	8	.	.	PUNCT
admet-496	186	1	[	[	X
admet-496	186	2	7	7	NUM
admet-496	186	3	]	]	X
admet-496	186	4	i.	i.	PROPN
admet-496	186	5	kola	kola	PROPN
admet-496	186	6	,	,	PUNCT
admet-496	186	7	j.	j.	PROPN
admet-496	186	8	landis	landis	PROPN
admet-496	186	9	.	.	PUNCT
admet-496	187	1	can	can	AUX
admet-496	187	2	the	the	DET
admet-496	187	3	pharmaceutical	pharmaceutical	NOUN
admet-496	187	4	industry	industry	NOUN
admet-496	187	5	reduce	reduce	VERB
admet-496	187	6	attrition	attrition	NOUN
admet-496	187	7	rates	rate	NOUN
admet-496	187	8	?	?	PUNCT
admet-496	188	1	nat	nat	PROPN
admet-496	188	2	rev	rev	VERB
admet-496	188	3	drug	drug	NOUN
admet-496	188	4	discov	discov	NOUN
admet-496	188	5	.	.	PUNCT
admet-496	189	1	3	3	NUM
admet-496	189	2	(	(	PUNCT
admet-496	189	3	2004	2004	NUM
admet-496	189	4	)	)	PUNCT
admet-496	189	5	711	711	NUM
admet-496	189	6	-	-	SYM
admet-496	189	7	5	5	NUM
admet-496	189	8	.	.	PUNCT
admet-496	190	1	[	[	X
admet-496	190	2	8	8	NUM
admet-496	190	3	]	]	X
admet-496	190	4	d.	d.	PROPN
admet-496	190	5	lacombe	lacombe	PROPN
admet-496	190	6	,	,	PUNCT
admet-496	190	7	s.	s.	PROPN
admet-496	190	8	burock	burock	PROPN
admet-496	190	9	,	,	PUNCT
admet-496	190	10	f.	f.	PROPN
admet-496	190	11	meunier	meunier	PROPN
admet-496	190	12	.	.	PUNCT
admet-496	191	1	academia	academia	NOUN
admet-496	191	2	-	-	PUNCT
admet-496	191	3	industry	industry	NOUN
admet-496	191	4	partnerships	partnership	NOUN
admet-496	191	5	:	:	PUNCT
admet-496	191	6	are	be	AUX
admet-496	191	7	we	we	PRON
admet-496	191	8	ready	ready	ADJ
admet-496	191	9	for	for	ADP
admet-496	191	10	new	new	ADJ
admet-496	191	11	models	model	NOUN
admet-496	191	12	of	of	ADP
admet-496	191	13	partnership	partnership	NOUN
admet-496	191	14	?	?	PUNCT
admet-496	191	15	:	:	PUNCT
admet-496	192	1	the	the	DET
admet-496	192	2	point	point	NOUN
admet-496	192	3	of	of	ADP
admet-496	192	4	view	view	NOUN
admet-496	192	5	of	of	ADP
admet-496	192	6	the	the	DET
admet-496	192	7	eortc	eortc	ADJ
admet-496	192	8	,	,	PUNCT
admet-496	192	9	an	an	DET
admet-496	192	10	academic	academic	ADJ
admet-496	192	11	clinical	clinical	ADJ
admet-496	192	12	cancer	cancer	NOUN
admet-496	192	13	research	research	NOUN
admet-496	192	14	organisation	organisation	NOUN
admet-496	192	15	.	.	PUNCT
admet-496	193	1	eur	eur	PROPN
admet-496	193	2	j	j	PROPN
admet-496	193	3	cancer	cancer	NOUN
admet-496	193	4	49	49	NUM
admet-496	193	5	(	(	PUNCT
admet-496	193	6	2013	2013	NUM
admet-496	193	7	)	)	PUNCT
admet-496	193	8	1	1	NUM
admet-496	193	9	-	-	SYM
admet-496	193	10	7	7	NUM
admet-496	193	11	.	.	PUNCT
admet-496	194	1	[	[	X
admet-496	194	2	9	9	NUM
admet-496	194	3	]	]	X
admet-496	194	4	m.r	m.r	PROPN
admet-496	194	5	.	.	PROPN
admet-496	194	6	grever	grever	PROPN
admet-496	194	7	,	,	PUNCT
admet-496	194	8	s.a	s.a	PROPN
admet-496	194	9	.	.	PROPN
admet-496	194	10	schepartz	schepartz	PROPN
admet-496	194	11	,	,	PUNCT
admet-496	194	12	b.a	b.a	PROPN
admet-496	194	13	.	.	PROPN
admet-496	194	14	chabner	chabner	PROPN
admet-496	194	15	.	.	PUNCT
admet-496	195	1	the	the	DET
admet-496	195	2	national	national	PROPN
admet-496	195	3	cancer	cancer	PROPN
admet-496	195	4	institute	institute	PROPN
admet-496	195	5	:	:	PUNCT
admet-496	195	6	cancer	cancer	NOUN
admet-496	195	7	drug	drug	NOUN
admet-496	195	8	discovery	discovery	PROPN
admet-496	195	9	and	and	CCONJ
admet-496	195	10	development	development	NOUN
admet-496	195	11	program	program	NOUN
admet-496	195	12	.	.	PUNCT
admet-496	196	1	semin	semin	PROPN
admet-496	196	2	oncol	oncol	PROPN
admet-496	196	3	19	19	NUM
admet-496	196	4	(	(	PUNCT
admet-496	196	5	1992	1992	NUM
admet-496	196	6	)	)	PUNCT
admet-496	196	7	622	622	NUM
admet-496	196	8	-	-	PUNCT
admet-496	196	9	638	638	NUM
admet-496	196	10	.	.	PUNCT
admet-496	197	1	[	[	X
admet-496	197	2	10	10	NUM
admet-496	197	3	]	]	X
admet-496	197	4	h.r	h.r	PROPN
admet-496	197	5	.	.	PROPN
admet-496	197	6	hendriks	hendriks	PROPN
admet-496	197	7	,	,	PUNCT
admet-496	197	8	a.s	a.s	PROPN
admet-496	197	9	.	.	PROPN
admet-496	197	10	govaerts	govaerts	PROPN
admet-496	197	11	,	,	PUNCT
admet-496	197	12	i.	i.	PROPN
admet-496	197	13	fichtner	fichtner	PROPN
admet-496	197	14	,	,	PUNCT
admet-496	197	15	a.d	a.d	PROPN
admet-496	197	16	.	.	PROPN
admet-496	197	17	westwell	westwell	PROPN
admet-496	197	18	,	,	PUNCT
admet-496	197	19	s.	s.	PROPN
admet-496	197	20	hurtles	hurtles	PROPN
admet-496	197	21	,	,	PUNCT
admet-496	197	22	g.j	g.j	PROPN
admet-496	197	23	.	.	PROPN
admet-496	197	24	peters	peters	PROPN
admet-496	197	25	,	,	PUNCT
admet-496	197	26	for	for	ADP
admet-496	197	27	the	the	DET
admet-496	197	28	eortc	eortc	ADJ
admet-496	197	29	ddc	ddc	PROPN
admet-496	197	30	group	group	NOUN
admet-496	197	31	.	.	PUNCT
admet-496	198	1	pharmacologically	pharmacologically	ADV
admet-496	198	2	directed	direct	VERB
admet-496	198	3	strategies	strategy	NOUN
admet-496	198	4	in	in	ADP
admet-496	198	5	academic	academic	ADJ
admet-496	198	6	anticancer	anticancer	NOUN
admet-496	198	7	drug	drug	NOUN
admet-496	198	8	discovery	discovery	NOUN
admet-496	198	9	based	base	VERB
admet-496	198	10	on	on	ADP
admet-496	198	11	the	the	DET
admet-496	198	12	european	european	PROPN
admet-496	198	13	nci	nci	PROPN
admet-496	198	14	compounds	compound	VERB
admet-496	198	15	initiative	initiative	NOUN
admet-496	198	16	.	.	PUNCT
admet-496	199	1	brit	brit	PROPN
admet-496	199	2	j	j	PROPN
admet-496	199	3	cancer	cancer	NOUN
admet-496	199	4	117	117	NUM
admet-496	199	5	(	(	PUNCT
admet-496	199	6	2017	2017	NUM
admet-496	199	7	)	)	PUNCT
admet-496	199	8	195	195	NUM
admet-496	199	9	-	-	SYM
admet-496	199	10	202	202	NUM
admet-496	199	11	.	.	PUNCT
admet-496	200	1	[	[	X
admet-496	200	2	11	11	NUM
admet-496	200	3	]	]	X
admet-496	200	4	g.j	g.j	PROPN
admet-496	200	5	.	.	PROPN
admet-496	200	6	peters	peters	PROPN
admet-496	200	7	,	,	PUNCT
admet-496	200	8	e.	e.	PROPN
admet-496	200	9	chatelut	chatelut	PROPN
admet-496	200	10	,	,	PUNCT
admet-496	200	11	a.k	a.k	PROPN
admet-496	200	12	.	.	PROPN
admet-496	200	13	larsen	larsen	PROPN
admet-496	200	14	,	,	PUNCT
admet-496	200	15	n.	n.	PROPN
admet-496	200	16	zaffaroni	zaffaroni	PROPN
admet-496	200	17	,	,	PUNCT
admet-496	200	18	on	on	ADP
admet-496	200	19	behalf	behalf	NOUN
admet-496	200	20	of	of	ADP
admet-496	200	21	pamm	pamm	PROPN
admet-496	200	22	.	.	PUNCT
admet-496	201	1	eortc	eortc	VERB
admet-496	201	2	-	-	PUNCT
admet-496	201	3	related	relate	VERB
admet-496	201	4	new	new	ADJ
admet-496	201	5	drug	drug	NOUN
admet-496	201	6	discovery	discovery	NOUN
admet-496	201	7	and	and	CCONJ
admet-496	201	8	development	development	NOUN
admet-496	201	9	activities	activity	NOUN
admet-496	201	10	:	:	PUNCT
admet-496	201	11	role	role	NOUN
admet-496	201	12	of	of	ADP
admet-496	201	13	the	the	DET
admet-496	201	14	pharmacology	pharmacology	NOUN
admet-496	201	15	and	and	CCONJ
admet-496	201	16	molecular	molecular	ADJ
admet-496	201	17	mechanisms	mechanism	NOUN
admet-496	201	18	group	group	NOUN
admet-496	201	19	.	.	PUNCT
admet-496	202	1	eur	eur	PROPN
admet-496	202	2	j	j	PROPN
admet-496	202	3	cancer	cancer	NOUN
admet-496	202	4	suppl	suppl	PROPN
admet-496	202	5	10	10	NUM
admet-496	202	6	(	(	PUNCT
admet-496	202	7	2012	2012	NUM
admet-496	202	8	)	)	PUNCT
admet-496	202	9	128	128	NUM
admet-496	202	10	-	-	SYM
admet-496	202	11	140	140	NUM
admet-496	202	12	.	.	PUNCT
admet-496	203	1	[	[	X
admet-496	203	2	12	12	NUM
admet-496	203	3	]	]	X
admet-496	203	4	k.d	k.d	PROPN
admet-496	203	5	.	.	PROPN
admet-496	203	6	paull	paull	PROPN
admet-496	203	7	,	,	PUNCT
admet-496	203	8	r.h	r.h	PROPN
admet-496	203	9	.	.	PROPN
admet-496	203	10	shoemaker	shoemaker	PROPN
admet-496	203	11	,	,	PUNCT
admet-496	203	12	l.	l.	PROPN
admet-496	203	13	hodes	hodes	PROPN
admet-496	203	14	,	,	PUNCT
admet-496	203	15	a.	a.	NOUN
admet-496	203	16	monks	monk	NOUN
admet-496	203	17	,	,	PUNCT
admet-496	203	18	d.a	d.a	PROPN
admet-496	203	19	.	.	PROPN
admet-496	203	20	scudiero	scudiero	PROPN
admet-496	203	21	,	,	PUNCT
admet-496	203	22	l.	l.	PROPN
admet-496	203	23	rubinstein	rubinstein	PROPN
admet-496	203	24	,	,	PUNCT
admet-496	203	25	j.	j.	PROPN
admet-496	203	26	plowman	plowman	PROPN
admet-496	203	27	,	,	PUNCT
admet-496	203	28	m.r	m.r	PROPN
admet-496	203	29	.	.	PROPN
admet-496	203	30	boyd	boyd	PROPN
admet-496	203	31	.	.	PUNCT
admet-496	203	32	display	display	NOUN
admet-496	203	33	and	and	CCONJ
admet-496	203	34	analysis	analysis	NOUN
admet-496	203	35	of	of	ADP
admet-496	203	36	patterns	pattern	NOUN
admet-496	203	37	of	of	ADP
admet-496	203	38	differential	differential	ADJ
admet-496	203	39	activity	activity	NOUN
admet-496	203	40	of	of	ADP
admet-496	203	41	drugs	drug	NOUN
admet-496	203	42	against	against	ADP
admet-496	203	43	human	human	ADJ
admet-496	203	44	tumour	tumour	NOUN
admet-496	203	45	cell	cell	NOUN
admet-496	203	46	lines	line	NOUN
admet-496	203	47	:	:	PUNCT
admet-496	203	48	development	development	NOUN
admet-496	203	49	of	of	ADP
admet-496	203	50	mean	mean	ADJ
admet-496	203	51	graph	graph	NOUN
admet-496	203	52	and	and	CCONJ
admet-496	203	53	compare	compare	VERB
admet-496	203	54	algorithm	algorithm	NOUN
admet-496	203	55	.	.	PUNCT
admet-496	204	1	j	j	PROPN
admet-496	204	2	natl	natl	PROPN
admet-496	204	3	cancer	cancer	PROPN
admet-496	204	4	inst	inst	PROPN
admet-496	204	5	81	81	NUM
admet-496	204	6	(	(	PUNCT
admet-496	204	7	1989	1989	NUM
admet-496	204	8	)	)	PUNCT
admet-496	204	9	1088	1088	NUM
admet-496	204	10	-	-	SYM
admet-496	204	11	1092	1092	NUM
admet-496	204	12	.	.	PUNCT
admet-496	205	1	[	[	X
admet-496	205	2	13	13	NUM
admet-496	205	3	]	]	X
admet-496	205	4	c.o	c.o	PROPN
admet-496	205	5	.	.	PUNCT
admet-496	205	6	leong	leong	PROPN
admet-496	205	7	,	,	PUNCT
admet-496	205	8	m.	m.	NOUN
admet-496	205	9	suggitt	suggitt	VERB
admet-496	205	10	,	,	PUNCT
admet-496	205	11	d.j	d.j	PROPN
admet-496	205	12	.	.	PROPN
admet-496	205	13	swaine	swaine	PROPN
admet-496	205	14	,	,	PUNCT
admet-496	205	15	m.c	m.c	PROPN
admet-496	205	16	.	.	PROPN
admet-496	205	17	bibby	bibby	PROPN
admet-496	205	18	,	,	PUNCT
admet-496	205	19	m.f.g	m.f.g	PROPN
admet-496	205	20	.	.	PROPN
admet-496	205	21	stevens	stevens	PROPN
admet-496	205	22	,	,	PUNCT
admet-496	205	23	t.d	t.d	PROPN
admet-496	205	24	.	.	PROPN
admet-496	205	25	bradshaw	bradshaw	PROPN
admet-496	205	26	.	.	PUNCT
admet-496	206	1	in	in	ADP
admet-496	206	2	vitro	vitro	X
admet-496	206	3	,	,	PUNCT
admet-496	206	4	in	in	ADP
admet-496	206	5	vivo	vivo	NOUN
admet-496	206	6	,	,	PUNCT
admet-496	206	7	and	and	CCONJ
admet-496	206	8	in	in	ADP
admet-496	206	9	silico	silico	NOUN
admet-496	206	10	analyses	analysis	NOUN
admet-496	206	11	of	of	ADP
admet-496	206	12	the	the	DET
admet-496	206	13	antitumor	antitumor	PROPN
admet-496	206	14	activity	activity	NOUN
admet-496	206	15	of	of	ADP
admet-496	206	16	2-(4	2-(4	PROPN
admet-496	206	17	-	-	PUNCT
admet-496	206	18	amino-3	amino-3	PROPN
admet-496	206	19	-	-	PUNCT
admet-496	206	20	methylpenyl)-5	methylpenyl)-5	NOUN
admet-496	206	21	-	-	PUNCT
admet-496	206	22	fluorobenzothiazoles	fluorobenzothiazole	NOUN
admet-496	206	23	.	.	PUNCT
admet-496	207	1	mol	mol	ADP
admet-496	207	2	cancer	cancer	NOUN
admet-496	207	3	ther	ther	PROPN
admet-496	207	4	3	3	NUM
admet-496	207	5	(	(	PUNCT
admet-496	207	6	2004	2004	NUM
admet-496	207	7	)	)	PUNCT
admet-496	207	8	1565	1565	NUM
admet-496	207	9	-	-	SYM
admet-496	207	10	1575	1575	NUM
admet-496	207	11	.	.	PUNCT
admet-496	208	1	[	[	X
admet-496	208	2	14	14	NUM
admet-496	208	3	]	]	X
admet-496	208	4	p.	p.	NOUN
admet-496	208	5	perego	perego	PROPN
admet-496	208	6	,	,	PUNCT
admet-496	208	7	g.	g.	PROPN
admet-496	208	8	hempel	hempel	PROPN
admet-496	208	9	,	,	PUNCT
admet-496	208	10	s.	s.	PROPN
admet-496	208	11	linder	linder	PROPN
admet-496	208	12	,	,	PUNCT
admet-496	208	13	t.d	t.d	PROPN
admet-496	208	14	.	.	PROPN
admet-496	208	15	bradshaw	bradshaw	PROPN
admet-496	208	16	,	,	PUNCT
admet-496	208	17	a.k	a.k	PROPN
admet-496	208	18	.	.	PROPN
admet-496	208	19	larsen	larsen	PROPN
admet-496	208	20	,	,	PUNCT
admet-496	208	21	g.j	g.j	PROPN
admet-496	208	22	.	.	PROPN
admet-496	208	23	peters	peters	PROPN
admet-496	208	24	,	,	PUNCT
admet-496	208	25	r.m	r.m	PROPN
admet-496	208	26	.	.	PROPN
admet-496	208	27	phillips	phillips	PROPN
admet-496	208	28	on	on	ADP
admet-496	208	29	behalf	behalf	NOUN
admet-496	208	30	of	of	ADP
admet-496	208	31	the	the	DET
admet-496	208	32	eortc	eortc	ADJ
admet-496	208	33	pamm	pamm	PROPN
admet-496	208	34	group	group	NOUN
admet-496	208	35	.	.	PUNCT
admet-496	209	1	cellular	cellular	ADJ
admet-496	209	2	pharmacology	pharmacology	NOUN
admet-496	209	3	studies	study	NOUN
admet-496	209	4	of	of	ADP
admet-496	209	5	anticancer	anticancer	NOUN
admet-496	209	6	agents	agent	NOUN
admet-496	209	7	:	:	PUNCT
admet-496	209	8	recommendations	recommendation	NOUN
admet-496	209	9	from	from	ADP
admet-496	209	10	the	the	DET
admet-496	209	11	eortc	eortc	ADJ
admet-496	209	12	-	-	PUNCT
admet-496	209	13	pamm	pamm	NOUN
admet-496	209	14	group	group	NOUN
admet-496	209	15	.	.	PUNCT
admet-496	210	1	cancer	cancer	NOUN
admet-496	210	2	chemother	chemother	PROPN
admet-496	210	3	pharmacol	pharmacol	PROPN
admet-496	210	4	81	81	NUM
admet-496	210	5	(	(	PUNCT
admet-496	210	6	2018	2018	NUM
admet-496	210	7	)	)	PUNCT
admet-496	210	8	427	427	NUM
admet-496	210	9	-	-	SYM
admet-496	210	10	441	441	NUM
admet-496	210	11	.	.	PUNCT
admet-496	211	1	[	[	X
admet-496	211	2	15	15	NUM
admet-496	211	3	]	]	X
admet-496	211	4	m.g	m.g	PROPN
admet-496	211	5	.	.	PROPN
admet-496	211	6	hollingshead	hollingshead	PROPN
admet-496	211	7	,	,	PUNCT
admet-496	211	8	m.c	m.c	PROPN
admet-496	211	9	.	.	PROPN
admet-496	211	10	alley	alley	PROPN
admet-496	211	11	,	,	PUNCT
admet-496	211	12	r.f	r.f	PROPN
admet-496	211	13	.	.	PROPN
admet-496	211	14	camalier	camalier	NOUN
admet-496	211	15	,	,	PUNCT
admet-496	211	16	b.j	b.j	PROPN
admet-496	211	17	.	.	PROPN
admet-496	211	18	abbott	abbott	PROPN
admet-496	211	19	,	,	PUNCT
admet-496	211	20	j.g	j.g	PROPN
admet-496	211	21	.	.	PROPN
admet-496	211	22	mayo	mayo	PROPN
admet-496	211	23	,	,	PUNCT
admet-496	211	24	l.	l.	PROPN
admet-496	211	25	malspeis	malspeis	PROPN
admet-496	211	26	,	,	PUNCT
admet-496	211	27	m.r	m.r	PROPN
admet-496	211	28	.	.	PROPN
admet-496	211	29	grever	grever	PROPN
admet-496	211	30	.	.	PUNCT
admet-496	212	1	in	in	ADP
admet-496	212	2	vivo	vivo	ADJ
admet-496	212	3	cultivation	cultivation	NOUN
admet-496	212	4	of	of	ADP
admet-496	212	5	tumor	tumor	NOUN
admet-496	212	6	cells	cell	NOUN
admet-496	212	7	in	in	ADP
admet-496	212	8	hollow	hollow	ADJ
admet-496	212	9	fibers	fiber	NOUN
admet-496	212	10	.	.	PUNCT
admet-496	213	1	life	life	NOUN
admet-496	213	2	sci	sci	PROPN
admet-496	213	3	57	57	NUM
admet-496	213	4	(	(	PUNCT
admet-496	213	5	1995	1995	NUM
admet-496	213	6	)	)	PUNCT
admet-496	213	7	131	131	NUM
admet-496	213	8	-	-	SYM
admet-496	213	9	141	141	NUM
admet-496	213	10	.	.	PUNCT
admet-496	214	1	[	[	X
admet-496	214	2	16	16	NUM
admet-496	214	3	]	]	X
admet-496	214	4	m.g	m.g	PROPN
admet-496	214	5	.	.	PROPN
admet-496	214	6	hollingshead	hollingshead	PROPN
admet-496	214	7	,	,	PUNCT
admet-496	214	8	j.	j.	PROPN
admet-496	214	9	plowman	plowman	PROPN
admet-496	214	10	,	,	PUNCT
admet-496	214	11	m.	m.	NOUN
admet-496	214	12	alley	alley	PROPN
admet-496	214	13	,	,	PUNCT
admet-496	214	14	j.	j.	PROPN
admet-496	214	15	mayo	mayo	PROPN
admet-496	214	16	,	,	PUNCT
admet-496	214	17	e.	e.	PROPN
admet-496	214	18	sausville	sausville	PROPN
admet-496	214	19	.	.	PUNCT
admet-496	215	1	the	the	DET
admet-496	215	2	hollow	hollow	ADJ
admet-496	215	3	fiber	fiber	NOUN
admet-496	215	4	assay	assay	VERB
admet-496	215	5	.	.	PUNCT
admet-496	216	1	in	in	ADP
admet-496	216	2	contributions	contribution	NOUN
admet-496	216	3	to	to	ADP
admet-496	216	4	oncology	oncology	NOUN
admet-496	216	5	,	,	PUNCT
admet-496	216	6	vol	vol	NOUN
admet-496	216	7	54	54	NUM
admet-496	216	8	,	,	PUNCT
admet-496	216	9	relevance	relevance	NOUN
admet-496	216	10	of	of	ADP
admet-496	216	11	tumor	tumor	NOUN
admet-496	216	12	models	model	NOUN
admet-496	216	13	for	for	ADP
admet-496	216	14	anticancer	anticancer	NOUN
admet-496	216	15	drug	drug	NOUN
admet-496	216	16	development	development	NOUN
admet-496	216	17	,	,	PUNCT
admet-496	216	18	(	(	PUNCT
admet-496	216	19	1999	1999	NUM
admet-496	216	20	)	)	PUNCT
admet-496	216	21	h.h	h.h	PROPN
admet-496	216	22	.	.	PROPN
admet-496	216	23	fiebig	fiebig	PROPN
admet-496	216	24	,	,	PUNCT
admet-496	216	25	a.m.	a.m.	PROPN
admet-496	216	26	burger	burger	NOUN
admet-496	216	27	(	(	PUNCT
admet-496	216	28	eds),karger	eds),karger	PROPN
admet-496	216	29	:	:	PUNCT
admet-496	216	30	basel	basel	PROPN
admet-496	216	31	pp	pp	PROPN
admet-496	216	32	.	.	PUNCT
admet-496	217	1	109	109	NUM
admet-496	217	2	-	-	SYM
admet-496	217	3	120	120	NUM
admet-496	217	4	.	.	PUNCT
admet-496	218	1	[	[	X
admet-496	218	2	17	17	NUM
admet-496	218	3	]	]	X
admet-496	218	4	r.m	r.m	PROPN
admet-496	218	5	.	.	PROPN
admet-496	218	6	phillips	phillips	PROPN
admet-496	218	7	,	,	PUNCT
admet-496	218	8	m.c	m.c	PROPN
admet-496	218	9	.	.	PROPN
admet-496	218	10	bibby	bibby	PROPN
admet-496	218	11	,	,	PUNCT
admet-496	218	12	j.a	j.a	PROPN
admet-496	218	13	.	.	PROPN
admet-496	218	14	double	double	PROPN
admet-496	218	15	.	.	PUNCT
admet-496	219	1	a	a	DET
admet-496	219	2	critical	critical	ADJ
admet-496	219	3	appraisal	appraisal	NOUN
admet-496	219	4	of	of	ADP
admet-496	219	5	the	the	DET
admet-496	219	6	predictive	predictive	ADJ
admet-496	219	7	value	value	NOUN
admet-496	219	8	of	of	ADP
admet-496	219	9	in	in	ADP
admet-496	219	10	vitro	vitro	X
admet-496	219	11	chemosensitivity	chemosensitivity	NOUN
admet-496	219	12	testing	testing	NOUN
admet-496	219	13	.	.	PUNCT
admet-496	220	1	j	j	PROPN
admet-496	220	2	natl	natl	PROPN
admet-496	220	3	cancer	cancer	PROPN
admet-496	220	4	inst	inst	PROPN
admet-496	220	5	82	82	NUM
admet-496	220	6	(	(	PUNCT
admet-496	220	7	2008	2008	NUM
admet-496	220	8	)	)	PUNCT
admet-496	220	9	1457	1457	NUM
admet-496	220	10	-	-	SYM
admet-496	220	11	1468	1468	NUM
admet-496	220	12	.	.	PUNCT
admet-496	221	1	[	[	X
admet-496	221	2	18	18	NUM
admet-496	221	3	]	]	X
admet-496	221	4	i.v	i.v	PROPN
admet-496	221	5	.	.	PROPN
admet-496	221	6	bijnsdorp	bijnsdorp	PROPN
admet-496	221	7	,	,	PUNCT
admet-496	221	8	g.j	g.j	PROPN
admet-496	221	9	.	.	PROPN
admet-496	221	10	peters	peters	PROPN
admet-496	221	11	.	.	PUNCT
admet-496	222	1	hollow	hollow	ADJ
admet-496	222	2	fiber	fiber	NOUN
admet-496	222	3	assay	assay	VERB
admet-496	222	4	.	.	PUNCT
admet-496	223	1	in	in	ADP
admet-496	223	2	encyclopedia	encyclopedia	NOUN
admet-496	223	3	of	of	ADP
admet-496	223	4	cancer	cancer	NOUN
admet-496	223	5	,	,	PUNCT
admet-496	223	6	(	(	PUNCT
admet-496	223	7	2008	2008	NUM
admet-496	223	8	)	)	PUNCT
admet-496	223	9	m.	m.	NOUN
admet-496	223	10	schwab	schwab	PROPN
admet-496	223	11	(	(	PUNCT
admet-496	223	12	ed	ed	NOUN
admet-496	223	13	)	)	PUNCT
admet-496	223	14	.	.	PUNCT
admet-496	224	1	springer	springer	PROPN
admet-496	224	2	verlag	verlag	PROPN
admet-496	224	3	:	:	PUNCT
admet-496	224	4	berlin	berlin	PROPN
admet-496	224	5	,	,	PUNCT
admet-496	224	6	heidelberg	heidelberg	PROPN
admet-496	224	7	,	,	PUNCT
admet-496	224	8	new	new	PROPN
admet-496	224	9	york	york	PROPN
admet-496	224	10	pp	pp	PROPN
admet-496	224	11	.	.	PUNCT
admet-496	225	1	1404	1404	NUM
admet-496	225	2	-	-	SYM
admet-496	225	3	1406	1406	NUM
admet-496	225	4	.	.	PUNCT
admet-496	226	1	godefridus	godefridus	PROPN
admet-496	226	2	peters	peters	PROPN
admet-496	226	3	et	et	PROPN
admet-496	226	4	al	al	PROPN
admet-496	226	5	.	.	PROPN
admet-496	226	6	admet	admet	PROPN
admet-496	226	7	&	&	CCONJ
admet-496	226	8	dmpk	dmpk	PROPN
admet-496	226	9	6(1	6(1	NUM
admet-496	226	10	)	)	PUNCT
admet-496	226	11	(	(	PUNCT
admet-496	226	12	2018	2018	NUM
admet-496	226	13	)	)	PUNCT
admet-496	226	14	4	4	NUM
admet-496	226	15	-	-	SYM
admet-496	226	16	14	14	NUM
admet-496	226	17	14	14	NUM
admet-496	226	18	[	[	X
admet-496	226	19	19	19	NUM
admet-496	226	20	]	]	X
admet-496	226	21	j.i	j.i	PROPN
admet-496	226	22	.	.	PROPN
admet-496	226	23	johnson	johnson	PROPN
admet-496	226	24	,	,	PUNCT
admet-496	226	25	s.	s.	PROPN
admet-496	226	26	decker	decker	PROPN
admet-496	226	27	,	,	PUNCT
admet-496	226	28	d.	d.	PROPN
admet-496	226	29	zaharevitz	zaharevitz	PROPN
admet-496	226	30	,	,	PUNCT
admet-496	226	31	l.v	l.v	PROPN
admet-496	226	32	.	.	PROPN
admet-496	226	33	rubinstein	rubinstein	PROPN
admet-496	226	34	,	,	PUNCT
admet-496	226	35	j.m	j.m	PROPN
admet-496	226	36	.	.	PROPN
admet-496	226	37	venditti	venditti	PROPN
admet-496	226	38	,	,	PUNCT
admet-496	226	39	s.	s.	PROPN
admet-496	226	40	schepartz	schepartz	PROPN
admet-496	226	41	,	,	PUNCT
admet-496	226	42	s.	s.	PROPN
admet-496	226	43	kalyandrug	kalyandrug	PROPN
admet-496	226	44	,	,	PUNCT
admet-496	226	45	m.	m.	PROPN
admet-496	226	46	christian	christian	PROPN
admet-496	226	47	,	,	PUNCT
admet-496	226	48	s.	s.	PROPN
admet-496	226	49	arbuck	arbuck	PROPN
admet-496	226	50	,	,	PUNCT
admet-496	226	51	m.	m.	NOUN
admet-496	226	52	hollingshead	hollingshead	PROPN
admet-496	226	53	,	,	PUNCT
admet-496	226	54	e.a	e.a	PROPN
admet-496	226	55	.	.	PROPN
admet-496	226	56	sausville	sausville	NOUN
admet-496	226	57	.	.	PUNCT
admet-496	227	1	relationships	relationship	NOUN
admet-496	227	2	between	between	ADP
admet-496	227	3	drug	drug	NOUN
admet-496	227	4	activity	activity	NOUN
admet-496	227	5	in	in	ADP
admet-496	227	6	nci	nci	PROPN
admet-496	227	7	preclinical	preclinical	NOUN
admet-496	227	8	in	in	ADP
admet-496	227	9	vitro	vitro	X
admet-496	227	10	and	and	CCONJ
admet-496	227	11	in	in	ADP
admet-496	227	12	vivo	vivo	NOUN
admet-496	227	13	models	model	NOUN
admet-496	227	14	and	and	CCONJ
admet-496	227	15	early	early	ADJ
admet-496	227	16	clinical	clinical	ADJ
admet-496	227	17	trials	trial	NOUN
admet-496	227	18	.	.	PUNCT
admet-496	228	1	br	br	PROPN
admet-496	228	2	j	j	PROPN
admet-496	228	3	cancer	cancer	NOUN
admet-496	228	4	84	84	NUM
admet-496	228	5	(	(	PUNCT
admet-496	228	6	2001	2001	NUM
admet-496	228	7	)	)	PUNCT
admet-496	228	8	1424	1424	NUM
admet-496	228	9	-	-	SYM
admet-496	228	10	1431	1431	NUM
admet-496	228	11	.	.	PUNCT
admet-496	229	1	[	[	X
admet-496	229	2	20	20	NUM
admet-496	229	3	]	]	X
admet-496	229	4	s.l	s.l	PROPN
admet-496	229	5	.	.	PROPN
admet-496	229	6	holbeck	holbeck	PROPN
admet-496	229	7	.	.	PUNCT
admet-496	230	1	update	update	NOUN
admet-496	230	2	on	on	ADP
admet-496	230	3	nci	nci	PROPN
admet-496	230	4	in	in	ADP
admet-496	230	5	vitro	vitro	X
admet-496	230	6	drug	drug	NOUN
admet-496	230	7	screen	screen	NOUN
admet-496	230	8	utilities	utility	NOUN
admet-496	230	9	.	.	PUNCT
admet-496	231	1	eur	eur	PROPN
admet-496	231	2	j	j	PROPN
admet-496	231	3	cancer	cancer	NOUN
admet-496	231	4	40	40	NUM
admet-496	231	5	(	(	PUNCT
admet-496	231	6	2004	2004	NUM
admet-496	231	7	)	)	PUNCT
admet-496	231	8	785	785	NUM
admet-496	231	9	-	-	SYM
admet-496	231	10	793	793	NUM
admet-496	231	11	.	.	PUNCT
admet-496	232	1	[	[	X
admet-496	232	2	21	21	NUM
admet-496	232	3	]	]	X
admet-496	232	4	h.h.j	h.h.j	PROPN
admet-496	232	5	.	.	PUNCT
admet-496	232	6	backus	backus	PROPN
admet-496	232	7	,	,	PUNCT
admet-496	232	8	h.m	h.m	PROPN
admet-496	232	9	.	.	PROPN
admet-496	232	10	pinedo	pinedo	PROPN
admet-496	232	11	,	,	PUNCT
admet-496	232	12	d.	d.	PROPN
admet-496	232	13	wouters	wouters	PROPN
admet-496	232	14	,	,	PUNCT
admet-496	232	15	j.m	j.m	PROPN
admet-496	232	16	.	.	PROPN
admet-496	232	17	padron	padron	PROPN
admet-496	232	18	,	,	PUNCT
admet-496	232	19	n.	n.	NOUN
admet-496	232	20	molders	molder	NOUN
admet-496	232	21	,	,	PUNCT
admet-496	232	22	c.l	c.l	PROPN
admet-496	232	23	.	.	PROPN
admet-496	232	24	van	van	PROPN
admet-496	232	25	der	der	PROPN
admet-496	232	26	wilt	wilt	NOUN
admet-496	232	27	,	,	PUNCT
admet-496	232	28	c.j	c.j	PROPN
admet-496	232	29	.	.	PROPN
admet-496	232	30	van	van	PROPN
admet-496	232	31	groeningen	groeningen	PROPN
admet-496	232	32	,	,	PUNCT
admet-496	232	33	g.	g.	PROPN
admet-496	232	34	jansen	jansen	PROPN
admet-496	232	35	,	,	PUNCT
admet-496	232	36	g.j	g.j	PROPN
admet-496	232	37	.	.	PROPN
admet-496	232	38	peters	peters	PROPN
admet-496	232	39	.	.	PUNCT
admet-496	233	1	folate	folate	NOUN
admet-496	233	2	depletion	depletion	NOUN
admet-496	233	3	increases	increase	VERB
admet-496	233	4	sensitivity	sensitivity	NOUN
admet-496	233	5	of	of	ADP
admet-496	233	6	solid	solid	ADJ
admet-496	233	7	tumor	tumor	NOUN
admet-496	233	8	cell	cell	NOUN
admet-496	233	9	lines	line	NOUN
admet-496	233	10	to	to	ADP
admet-496	233	11	5fluorouracil	5fluorouracil	NUM
admet-496	233	12	and	and	CCONJ
admet-496	233	13	antifolates	antifolate	NOUN
admet-496	233	14	.	.	PUNCT
admet-496	234	1	int	int	NOUN
admet-496	234	2	.	.	PUNCT
admet-496	235	1	j.	j.	PROPN
admet-496	235	2	cancer	cancer	PROPN
admet-496	235	3	87	87	NUM
admet-496	235	4	(	(	PUNCT
admet-496	235	5	2000	2000	NUM
admet-496	235	6	)	)	PUNCT
admet-496	235	7	771	771	NUM
admet-496	235	8	-	-	SYM
admet-496	235	9	778	778	NUM
admet-496	235	10	.	.	PUNCT
admet-496	236	1	[	[	X
admet-496	236	2	22	22	NUM
admet-496	236	3	]	]	X
admet-496	236	4	g.j	g.j	PROPN
admet-496	236	5	.	.	PROPN
admet-496	236	6	peters	peters	PROPN
admet-496	236	7	,	,	PUNCT
admet-496	236	8	s.l	s.l	PROPN
admet-496	236	9	.	.	PROPN
admet-496	236	10	sharma	sharma	PROPN
admet-496	236	11	,	,	PUNCT
admet-496	236	12	e.	e.	PROPN
admet-496	236	13	laurensse	laurensse	PROPN
admet-496	236	14	,	,	PUNCT
admet-496	236	15	h.m	h.m	PROPN
admet-496	236	16	.	.	PROPN
admet-496	236	17	pinedo	pinedo	PROPN
admet-496	236	18	.	.	PUNCT
admet-496	237	1	inhibition	inhibition	NOUN
admet-496	237	2	of	of	ADP
admet-496	237	3	pyrimidine	pyrimidine	NOUN
admet-496	237	4	de	de	X
admet-496	237	5	novo	novo	NOUN
admet-496	237	6	synthesis	synthesis	NOUN
admet-496	237	7	by	by	ADP
admet-496	237	8	dup-785	dup-785	NOUN
admet-496	237	9	(	(	PUNCT
admet-496	237	10	nsc	nsc	PROPN
admet-496	237	11	368390	368390	NUM
admet-496	237	12	)	)	PUNCT
admet-496	237	13	.	.	PUNCT
admet-496	238	1	invest	invest	VERB
admet-496	238	2	.	.	PUNCT
admet-496	239	1	new	new	ADJ
admet-496	239	2	drugs	drug	NOUN
admet-496	239	3	5	5	NUM
admet-496	239	4	(	(	PUNCT
admet-496	239	5	1987	1987	NUM
admet-496	239	6	)	)	PUNCT
admet-496	239	7	235	235	NUM
admet-496	239	8	-	-	SYM
admet-496	239	9	244	244	NUM
admet-496	239	10	.	.	PUNCT
admet-496	240	1	[	[	X
admet-496	240	2	23	23	NUM
admet-496	240	3	]	]	X
admet-496	240	4	i.v	i.v	PROPN
admet-496	240	5	.	.	PROPN
admet-496	240	6	bijnsdorp	bijnsdorp	PROPN
admet-496	240	7	,	,	PUNCT
admet-496	240	8	e.m	e.m	PROPN
admet-496	240	9	.	.	PROPN
admet-496	240	10	comijn	comijn	PROPN
admet-496	240	11	,	,	PUNCT
admet-496	240	12	j.m	j.m	PROPN
admet-496	240	13	.	.	PROPN
admet-496	240	14	padron	padron	PROPN
admet-496	240	15	,	,	PUNCT
admet-496	240	16	w.h	w.h	PROPN
admet-496	240	17	.	.	PROPN
admet-496	240	18	gmeiner	gmeiner	PROPN
admet-496	240	19	,	,	PUNCT
admet-496	240	20	g.j	g.j	PROPN
admet-496	240	21	.	.	PROPN
admet-496	240	22	peters	peters	PROPN
admet-496	240	23	.	.	PUNCT
admet-496	240	24	mechanisms	mechanism	NOUN
admet-496	240	25	of	of	ADP
admet-496	240	26	action	action	NOUN
admet-496	240	27	of	of	ADP
admet-496	240	28	fdump[10	fdump[10	NOUN
admet-496	240	29	]	]	PUNCT
admet-496	240	30	;	;	PUNCT
admet-496	240	31	metabolite	metabolite	NOUN
admet-496	240	32	activation	activation	NOUN
admet-496	240	33	and	and	CCONJ
admet-496	240	34	thymidylate	thymidylate	NOUN
admet-496	240	35	synthase	synthase	NOUN
admet-496	240	36	inhibition	inhibition	NOUN
admet-496	240	37	.	.	PUNCT
admet-496	241	1	oncol	oncol	PROPN
admet-496	241	2	.	.	PUNCT
admet-496	242	1	rep	rep	PROPN
admet-496	242	2	.	.	PROPN
admet-496	242	3	18	18	NUM
admet-496	242	4	(	(	PUNCT
admet-496	242	5	2007	2007	NUM
admet-496	242	6	)	)	PUNCT
admet-496	242	7	287291	287291	NUM
admet-496	242	8	.	.	PUNCT
admet-496	243	1	[	[	X
admet-496	243	2	24	24	NUM
admet-496	243	3	]	]	X
admet-496	243	4	c.j.a	c.j.a	NOUN
admet-496	243	5	.	.	PUNCT
admet-496	244	1	van	van	PROPN
admet-496	244	2	moorsel	moorsel	PROPN
admet-496	244	3	,	,	PUNCT
admet-496	244	4	h.m	h.m	PROPN
admet-496	244	5	.	.	PROPN
admet-496	244	6	pinedo	pinedo	PROPN
admet-496	244	7	,	,	PUNCT
admet-496	244	8	g.	g.	PROPN
admet-496	244	9	veerman	veerman	PROPN
admet-496	244	10	,	,	PUNCT
admet-496	244	11	a.m.	a.m.	PROPN
admet-496	244	12	bergman	bergman	PROPN
admet-496	244	13	,	,	PUNCT
admet-496	244	14	c.m	c.m	PROPN
admet-496	244	15	.	.	PROPN
admet-496	244	16	kuiper	kuiper	PROPN
admet-496	244	17	,	,	PUNCT
admet-496	244	18	j.b	j.b	PROPN
admet-496	244	19	.	.	PROPN
admet-496	245	1	vermorken	vermorken	VERB
admet-496	245	2	,	,	PUNCT
admet-496	245	3	w.j.f	w.j.f	NOUN
admet-496	245	4	.	.	PUNCT
admet-496	246	1	van	van	PROPN
admet-496	246	2	der	der	PROPN
admet-496	246	3	vijgh	vijgh	ADV
admet-496	246	4	,	,	PUNCT
admet-496	246	5	g.j	g.j	PROPN
admet-496	246	6	.	.	PROPN
admet-496	246	7	peters	peters	PROPN
admet-496	246	8	.	.	PUNCT
admet-496	247	1	mechanisms	mechanism	NOUN
admet-496	247	2	of	of	ADP
admet-496	247	3	synergism	synergism	NOUN
admet-496	247	4	between	between	ADP
admet-496	247	5	cisplatin	cisplatin	NOUN
admet-496	247	6	and	and	CCONJ
admet-496	247	7	gemcitabine	gemcitabine	NOUN
admet-496	247	8	in	in	ADP
admet-496	247	9	ovarian	ovarian	ADJ
admet-496	247	10	and	and	CCONJ
admet-496	247	11	non	non	ADJ
admet-496	247	12	-	-	ADJ
admet-496	247	13	small	small	ADJ
admet-496	247	14	cell	cell	NOUN
admet-496	247	15	lung	lung	NOUN
admet-496	247	16	cancer	cancer	NOUN
admet-496	247	17	cell	cell	NOUN
admet-496	247	18	lines	line	NOUN
admet-496	247	19	.	.	PUNCT
admet-496	248	1	brit	brit	PROPN
admet-496	248	2	.	.	PUNCT
admet-496	249	1	j.	j.	PROPN
admet-496	249	2	cancer	cancer	PROPN
admet-496	249	3	35	35	NUM
admet-496	249	4	(	(	PUNCT
admet-496	249	5	1999	1999	NUM
admet-496	249	6	)	)	PUNCT
admet-496	249	7	808	808	NUM
admet-496	249	8	-	-	SYM
admet-496	249	9	814	814	NUM
admet-496	249	10	.	.	PUNCT
admet-496	250	1	[	[	X
admet-496	250	2	25	25	NUM
admet-496	250	3	]	]	X
admet-496	250	4	g.g	g.g	PROPN
admet-496	250	5	.	.	PROPN
admet-496	250	6	dark	dark	PROPN
admet-496	250	7	,	,	PUNCT
admet-496	250	8	s.a	s.a	PROPN
admet-496	250	9	.	.	PROPN
admet-496	250	10	hill	hill	PROPN
admet-496	250	11	,	,	PUNCT
admet-496	250	12	v.e	v.e	PROPN
admet-496	250	13	.	.	PROPN
admet-496	250	14	prise	prise	PROPN
admet-496	250	15	,	,	PUNCT
admet-496	250	16	g.m	g.m	PROPN
admet-496	250	17	.	.	PROPN
admet-496	250	18	tozer	tozer	PROPN
admet-496	250	19	,	,	PUNCT
admet-496	250	20	g.r	g.r	PROPN
admet-496	250	21	.	.	PROPN
admet-496	250	22	pettit	pettit	PROPN
admet-496	250	23	,	,	PUNCT
admet-496	250	24	d.j	d.j	PROPN
admet-496	250	25	.	.	PROPN
admet-496	250	26	chaplin	chaplin	PROPN
admet-496	250	27	.	.	PUNCT
admet-496	251	1	combretastatin	combretastatin	PROPN
admet-496	251	2	a-4	a-4	PROPN
admet-496	251	3	,	,	PUNCT
admet-496	251	4	an	an	DET
admet-496	251	5	agent	agent	NOUN
admet-496	251	6	that	that	PRON
admet-496	251	7	displays	display	VERB
admet-496	251	8	potent	potent	ADJ
admet-496	251	9	and	and	CCONJ
admet-496	251	10	selective	selective	ADJ
admet-496	251	11	toxicity	toxicity	NOUN
admet-496	251	12	toward	toward	ADP
admet-496	251	13	tumor	tumor	NOUN
admet-496	251	14	vasculature	vasculature	NOUN
admet-496	251	15	.	.	PUNCT
admet-496	252	1	cancer	cancer	NOUN
admet-496	252	2	res	re	NOUN
admet-496	252	3	57	57	NUM
admet-496	252	4	(	(	PUNCT
admet-496	252	5	1997	1997	NUM
admet-496	252	6	)	)	PUNCT
admet-496	252	7	1829–1834	1829–1834	NUM
admet-496	252	8	.	.	PUNCT
admet-496	253	1	[	[	X
admet-496	253	2	26	26	NUM
admet-496	253	3	]	]	X
admet-496	253	4	g.m	g.m	PROPN
admet-496	253	5	.	.	PUNCT
admet-496	253	6	tozer	tozer	PROPN
admet-496	253	7	,	,	PUNCT
admet-496	253	8	c.	c.	PROPN
admet-496	253	9	kanthou	kanthou	PROPN
admet-496	253	10	,	,	PUNCT
admet-496	253	11	c.s	c.s	PROPN
admet-496	253	12	.	.	PROPN
admet-496	253	13	parkins	parkins	PROPN
admet-496	253	14	,	,	PUNCT
admet-496	253	15	s.a	s.a	PROPN
admet-496	253	16	.	.	PROPN
admet-496	253	17	hill	hill	PROPN
admet-496	253	18	.	.	PUNCT
admet-496	254	1	the	the	DET
admet-496	254	2	biology	biology	NOUN
admet-496	254	3	of	of	ADP
admet-496	254	4	the	the	DET
admet-496	254	5	combretastatins	combretastatin	NOUN
admet-496	254	6	as	as	ADP
admet-496	254	7	tumour	tumour	NOUN
admet-496	254	8	vascular	vascular	ADJ
admet-496	254	9	targeting	targeting	NOUN
admet-496	254	10	agents	agent	NOUN
admet-496	254	11	.	.	PUNCT
admet-496	255	1	int	int	NOUN
admet-496	255	2	j	j	PROPN
admet-496	255	3	exp	exp	NOUN
admet-496	255	4	pathol	pathol	NOUN
admet-496	255	5	83	83	NUM
admet-496	255	6	(	(	PUNCT
admet-496	255	7	2002	2002	NUM
admet-496	255	8	)	)	PUNCT
admet-496	255	9	21–38	21–38	NUM
admet-496	255	10	.	.	PUNCT
admet-496	256	1	[	[	X
admet-496	256	2	27	27	NUM
admet-496	256	3	]	]	PUNCT
admet-496	256	4	k.	k.	PROPN
admet-496	256	5	bonezzi	bonezzi	PROPN
admet-496	256	6	,	,	PUNCT
admet-496	256	7	g.	g.	PROPN
admet-496	256	8	taraboletti	taraboletti	PROPN
admet-496	256	9	,	,	PUNCT
admet-496	256	10	p.	p.	PROPN
admet-496	256	11	borsotti	borsotti	PROPN
admet-496	256	12	,	,	PUNCT
admet-496	256	13	f.	f.	PROPN
admet-496	256	14	bellina	bellina	PROPN
admet-496	256	15	,	,	PUNCT
admet-496	256	16	r.	r.	PROPN
admet-496	256	17	rossi	rossi	PROPN
admet-496	256	18	,	,	PUNCT
admet-496	256	19	r.	r.	PROPN
admet-496	256	20	giavazzi	giavazzi	NOUN
admet-496	256	21	.	.	PUNCT
admet-496	257	1	vascular	vascular	ADJ
admet-496	257	2	disrupting	disrupt	VERB
admet-496	257	3	activity	activity	NOUN
admet-496	257	4	of	of	ADP
admet-496	257	5	tubulin	tubulin	NOUN
admet-496	257	6	-	-	PUNCT
admet-496	257	7	binding	bind	VERB
admet-496	257	8	1,5	1,5	NUM
admet-496	257	9	-	-	PUNCT
admet-496	257	10	diaryl-1h	diaryl-1h	NOUN
admet-496	257	11	-	-	PUNCT
admet-496	257	12	imidazoles	imidazole	NOUN
admet-496	257	13	.	.	PUNCT
admet-496	258	1	j	j	PROPN
admet-496	258	2	med	med	PROPN
admet-496	258	3	chem	chem	NOUN
admet-496	258	4	52	52	NUM
admet-496	258	5	(	(	PUNCT
admet-496	258	6	2009	2009	NUM
admet-496	258	7	)	)	PUNCT
admet-496	258	8	7906–7910	7906–7910	NOUN
admet-496	258	9	.	.	PUNCT
admet-496	259	1	[	[	X
admet-496	259	2	28	28	NUM
admet-496	259	3	]	]	X
admet-496	259	4	p.	p.	PROPN
admet-496	259	5	diana	diana	PROPN
admet-496	259	6	,	,	PUNCT
admet-496	259	7	a.	a.	PROPN
admet-496	259	8	martorana	martorana	PROPN
admet-496	259	9	,	,	PUNCT
admet-496	259	10	p.	p.	PROPN
admet-496	259	11	barraja	barraja	PROPN
admet-496	259	12	,	,	PUNCT
admet-496	259	13	a.	a.	NOUN
admet-496	259	14	montalbano	montalbano	PROPN
admet-496	259	15	,	,	PUNCT
admet-496	259	16	g.	g.	PROPN
admet-496	259	17	dattolo	dattolo	PROPN
admet-496	259	18	,	,	PUNCT
admet-496	259	19	g.	g.	PROPN
admet-496	259	20	cirrincione	cirrincione	PROPN
admet-496	259	21	,	,	PUNCT
admet-496	259	22	f.	f.	PROPN
admet-496	259	23	dall'acqua	dall'acqua	PROPN
admet-496	259	24	,	,	PUNCT
admet-496	259	25	a.	a.	NOUN
admet-496	259	26	salvador	salvador	PROPN
admet-496	259	27	,	,	PUNCT
admet-496	259	28	d.	d.	PROPN
admet-496	259	29	vedaldi	vedaldi	PROPN
admet-496	259	30	,	,	PUNCT
admet-496	259	31	g.	g.	PROPN
admet-496	259	32	basso	basso	PROPN
admet-496	259	33	,	,	PUNCT
admet-496	259	34	g.	g.	PROPN
admet-496	259	35	viola	viola	PROPN
admet-496	259	36	.	.	PUNCT
admet-496	260	1	isoindolo[2,1	isoindolo[2,1	PROPN
admet-496	260	2	-	-	PUNCT
admet-496	260	3	a]quinoxaline	a]quinoxaline	PROPN
admet-496	260	4	derivatives	derivative	NOUN
admet-496	260	5	,	,	PUNCT
admet-496	260	6	novel	novel	ADJ
admet-496	260	7	potent	potent	NOUN
admet-496	260	8	antitumor	antitumor	PROPN
admet-496	260	9	agents	agent	NOUN
admet-496	260	10	with	with	ADP
admet-496	260	11	dual	dual	ADJ
admet-496	260	12	inhibition	inhibition	NOUN
admet-496	260	13	of	of	ADP
admet-496	260	14	tubulin	tubulin	NOUN
admet-496	260	15	polymerization	polymerization	NOUN
admet-496	260	16	and	and	CCONJ
admet-496	260	17	topoisomerase	topoisomerase	ADJ
admet-496	260	18	i.	i.	PROPN
admet-496	260	19	j	j	PROPN
admet-496	260	20	med	med	PROPN
admet-496	260	21	chem	chem	NOUN
admet-496	260	22	51	51	NUM
admet-496	260	23	(	(	PUNCT
admet-496	260	24	2008	2008	NUM
admet-496	260	25	)	)	PUNCT
admet-496	260	26	2387	2387	NUM
admet-496	260	27	-	-	SYM
admet-496	260	28	2399	2399	NUM
admet-496	260	29	.	.	PUNCT
admet-496	261	1	[	[	X
admet-496	261	2	29	29	NUM
admet-496	261	3	]	]	PUNCT
admet-496	261	4	a.m.	a.m.	NOUN
admet-496	261	5	burger	burger	PROPN
admet-496	261	6	,	,	PUNCT
admet-496	261	7	p.m.	p.m.	NOUN
admet-496	261	8	loadman	loadman	NOUN
admet-496	261	9	,	,	PUNCT
admet-496	261	10	d.e	d.e	PROPN
admet-496	261	11	.	.	PROPN
admet-496	261	12	thurston	thurston	PROPN
admet-496	261	13	,	,	PUNCT
admet-496	261	14	r.	r.	PROPN
admet-496	261	15	schultz	schultz	PROPN
admet-496	261	16	,	,	PUNCT
admet-496	261	17	h.h	h.h	PROPN
admet-496	261	18	.	.	PROPN
admet-496	261	19	fiebig	fiebig	PROPN
admet-496	261	20	,	,	PUNCT
admet-496	261	21	m.c	m.c	PROPN
admet-496	261	22	.	.	PROPN
admet-496	261	23	bibby	bibby	PROPN
admet-496	261	24	.	.	PUNCT
admet-496	262	1	preclinical	preclinical	ADJ
admet-496	262	2	pharmacology	pharmacology	NOUN
admet-496	262	3	of	of	ADP
admet-496	262	4	the	the	DET
admet-496	262	5	pyrrolobenzodiazepine	pyrrolobenzodiazepine	NOUN
admet-496	262	6	(	(	PUNCT
admet-496	262	7	pbd	pbd	PROPN
admet-496	262	8	)	)	PUNCT
admet-496	262	9	monomer	monomer	NOUN
admet-496	262	10	drh-417	drh-417	NOUN
admet-496	262	11	(	(	PUNCT
admet-496	262	12	nsc	nsc	PROPN
admet-496	262	13	709119	709119	NUM
admet-496	262	14	)	)	PUNCT
admet-496	262	15	.	.	PUNCT
admet-496	263	1	j	j	PROPN
admet-496	263	2	chemother	chemother	PROPN
admet-496	263	3	19	19	NUM
admet-496	263	4	(	(	PUNCT
admet-496	263	5	2007	2007	NUM
admet-496	263	6	)	)	PUNCT
admet-496	263	7	66	66	NUM
admet-496	263	8	-	-	SYM
admet-496	263	9	78	78	NUM
admet-496	263	10	.	.	PUNCT
admet-496	264	1	[	[	X
admet-496	264	2	30	30	NUM
admet-496	264	3	]	]	X
admet-496	264	4	j.	j.	PROPN
admet-496	264	5	mantaj	mantaj	PROPN
admet-496	264	6	,	,	PUNCT
admet-496	264	7	p.j.m	p.j.m	NOUN
admet-496	264	8	.	.	PROPN
admet-496	264	9	jackson	jackson	PROPN
admet-496	264	10	,	,	PUNCT
admet-496	264	11	k.	k.	PROPN
admet-496	264	12	rahman	rahman	PROPN
admet-496	264	13	,	,	PUNCT
admet-496	264	14	d.e	d.e	PROPN
admet-496	264	15	.	.	PROPN
admet-496	264	16	thurston	thurston	PROPN
admet-496	264	17	.	.	PUNCT
admet-496	265	1	from	from	ADP
admet-496	265	2	anthramycin	anthramycin	PROPN
admet-496	265	3	to	to	ADP
admet-496	265	4	pyrrolobenzodiazepines	pyrrolobenzodiazepine	NOUN
admet-496	265	5	(	(	PUNCT
admet-496	265	6	pdb)containing	pdb)containe	VERB
admet-496	265	7	antibody	antibody	NOUN
admet-496	265	8	conjugates	conjugate	NOUN
admet-496	265	9	(	(	PUNCT
admet-496	265	10	adcs	adcs	ADJ
admet-496	265	11	)	)	PUNCT
admet-496	265	12	.	.	PUNCT
admet-496	266	1	angew	angew	PROPN
admet-496	266	2	chem	chem	PROPN
admet-496	266	3	int	int	PROPN
admet-496	266	4	ed	ed	PROPN
admet-496	266	5	engl	engl	PROPN
admet-496	266	6	56	56	NUM
admet-496	266	7	(	(	PUNCT
admet-496	266	8	2017	2017	NUM
admet-496	266	9	)	)	PUNCT
admet-496	266	10	462	462	NUM
admet-496	266	11	-	-	SYM
admet-496	266	12	488	488	NUM
admet-496	266	13	.	.	PUNCT
admet-496	267	1	[	[	X
admet-496	267	2	31	31	NUM
admet-496	267	3	]	]	PUNCT
admet-496	267	4	i.	i.	NOUN
admet-496	267	5	fichtner	fichtner	PROPN
admet-496	267	6	,	,	PUNCT
admet-496	267	7	a.	a.	NOUN
admet-496	267	8	monks	monk	NOUN
admet-496	267	9	,	,	PUNCT
admet-496	267	10	c.	c.	PROPN
admet-496	267	11	hose	hose	PROPN
admet-496	267	12	,	,	PUNCT
admet-496	267	13	m.f	m.f	PROPN
admet-496	267	14	.	.	PROPN
admet-496	267	15	stevens	stevens	PROPN
admet-496	267	16	,	,	PUNCT
admet-496	267	17	t.d	t.d	PROPN
admet-496	267	18	.	.	PROPN
admet-496	267	19	bradshaw	bradshaw	PROPN
admet-496	267	20	.	.	PUNCT
admet-496	268	1	the	the	DET
admet-496	268	2	experimental	experimental	ADJ
admet-496	268	3	antitumor	antitumor	PROPN
admet-496	268	4	agents	agent	NOUN
admet-496	268	5	phortress	phortress	VERB
admet-496	268	6	and	and	CCONJ
admet-496	268	7	doxorubicin	doxorubicin	PROPN
admet-496	268	8	are	be	AUX
admet-496	268	9	equiactive	equiactive	ADJ
admet-496	268	10	against	against	ADP
admet-496	268	11	human	human	NOUN
admet-496	268	12	-	-	PUNCT
admet-496	268	13	derived	derive	VERB
admet-496	268	14	breast	breast	NOUN
admet-496	268	15	carcinoma	carcinoma	NOUN
admet-496	268	16	xenograft	xenograft	NOUN
admet-496	268	17	models	model	NOUN
admet-496	268	18	.	.	PUNCT
admet-496	269	1	breast	breast	NOUN
admet-496	269	2	cancer	cancer	NOUN
admet-496	269	3	res	re	NOUN
admet-496	269	4	treat	treat	VERB
admet-496	269	5	87	87	NUM
admet-496	269	6	(	(	PUNCT
admet-496	269	7	2004	2004	NUM
admet-496	269	8	)	)	PUNCT
admet-496	270	1	97–107	97–107	NOUN
admet-496	270	2	.	.	PUNCT
admet-496	271	1	[	[	X
admet-496	271	2	32	32	NUM
admet-496	271	3	]	]	X
admet-496	271	4	t.d	t.d	PROPN
admet-496	271	5	.	.	PROPN
admet-496	271	6	bradshaw	bradshaw	PROPN
admet-496	271	7	,	,	PUNCT
admet-496	271	8	a.d	a.d	PROPN
admet-496	271	9	.	.	PROPN
admet-496	271	10	westwell	westwell	PROPN
admet-496	271	11	.	.	PUNCT
admet-496	272	1	the	the	DET
admet-496	272	2	development	development	NOUN
admet-496	272	3	of	of	ADP
admet-496	272	4	the	the	DET
admet-496	272	5	antitumour	antitumour	NOUN
admet-496	272	6	benzothiazole	benzothiazole	NOUN
admet-496	272	7	prodrug	prodrug	NOUN
admet-496	272	8	,	,	PUNCT
admet-496	272	9	phortress	phortress	NOUN
admet-496	272	10	,	,	PUNCT
admet-496	272	11	as	as	ADP
admet-496	272	12	a	a	DET
admet-496	272	13	clinical	clinical	ADJ
admet-496	272	14	candidate	candidate	NOUN
admet-496	272	15	.	.	PUNCT
admet-496	273	1	curr	curr	PROPN
admet-496	273	2	med	med	PROPN
admet-496	273	3	chem	chem	NOUN
admet-496	273	4	11	11	NUM
admet-496	273	5	(	(	PUNCT
admet-496	273	6	2004	2004	NUM
admet-496	273	7	)	)	PUNCT
admet-496	273	8	1009	1009	NUM
admet-496	273	9	-	-	SYM
admet-496	273	10	1021	1021	NUM
admet-496	273	11	.	.	PUNCT
admet-496	274	1	[	[	X
admet-496	274	2	33	33	NUM
admet-496	274	3	]	]	X
admet-496	274	4	t.d	t.d	PROPN
admet-496	274	5	.	.	PROPN
admet-496	274	6	bradshaw	bradshaw	PROPN
admet-496	274	7	.	.	PUNCT
admet-496	275	1	phortress	phortress	PROPN
admet-496	275	2	:	:	PUNCT
admet-496	275	3	the	the	DET
admet-496	275	4	smart	smart	ADJ
admet-496	275	5	antitumour	antitumour	NOUN
admet-496	275	6	agent	agent	NOUN
admet-496	275	7	which	which	PRON
admet-496	275	8	induces	induce	VERB
admet-496	275	9	its	its	PRON
admet-496	275	10	own	own	ADJ
admet-496	275	11	metabolism	metabolism	NOUN
admet-496	275	12	.	.	PUNCT
admet-496	276	1	pharm	pharm	NOUN
admet-496	276	2	j	j	PROPN
admet-496	276	3	284	284	NUM
admet-496	276	4	(	(	PUNCT
admet-496	276	5	2010	2010	NUM
admet-496	276	6	)	)	PUNCT
admet-496	276	7	23	23	NUM
admet-496	276	8	-	-	SYM
admet-496	276	9	24	24	NUM
admet-496	276	10	.	.	PUNCT
admet-496	277	1	[	[	X
admet-496	277	2	34	34	NUM
admet-496	277	3	]	]	PUNCT
admet-496	277	4	m.	m.	NOUN
admet-496	277	5	seckl	seckl	NOUN
admet-496	277	6	,	,	PUNCT
admet-496	277	7	n.	n.	NOUN
admet-496	277	8	cresti	cresti	PROPN
admet-496	277	9	,	,	PUNCT
admet-496	277	10	a.	a.	PROPN
admet-496	277	11	boddy	boddy	PROPN
admet-496	277	12	,	,	PUNCT
admet-496	277	13	r.	r.	PROPN
admet-496	277	14	phillips	phillips	PROPN
admet-496	277	15	,	,	PUNCT
admet-496	277	16	f.	f.	PROPN
admet-496	277	17	chapman	chapman	PROPN
admet-496	277	18	,	,	PUNCT
admet-496	277	19	h.	h.	PROPN
admet-496	277	20	calvert	calvert	PROPN
admet-496	277	21	,	,	PUNCT
admet-496	277	22	l.	l.	PROPN
admet-496	277	23	robson	robson	PROPN
admet-496	277	24	,	,	PUNCT
admet-496	277	25	r.	r.	PROPN
admet-496	277	26	plummer	plummer	PROPN
admet-496	277	27	.	.	PUNCT
admet-496	278	1	a	a	DET
admet-496	278	2	cancer	cancer	NOUN
admet-496	278	3	research	research	NOUN
admet-496	278	4	uk	uk	PROPN
admet-496	278	5	phase	phase	NOUN
admet-496	278	6	i	i	PRON
admet-496	278	7	trial	trial	NOUN
admet-496	278	8	of	of	ADP
admet-496	278	9	phortress	phortress	NOUN
admet-496	278	10	(	(	PUNCT
admet-496	278	11	novel	novel	ADJ
admet-496	278	12	antitumour	antitumour	NOUN
admet-496	278	13	benzothiazole	benzothiazole	NOUN
admet-496	278	14	)	)	PUNCT
admet-496	278	15	given	give	VERB
admet-496	278	16	intravenously	intravenously	ADV
admet-496	278	17	in	in	ADP
admet-496	278	18	consecutive	consecutive	ADJ
admet-496	278	19	21	21	NUM
admet-496	278	20	day	day	NOUN
admet-496	278	21	cycles	cycle	NOUN
admet-496	278	22	with	with	ADP
admet-496	278	23	treatment	treatment	NOUN
admet-496	278	24	on	on	ADP
admet-496	278	25	day	day	NOUN
admet-496	278	26	1	1	NUM
admet-496	278	27	of	of	ADP
admet-496	278	28	each	each	DET
admet-496	278	29	cycle	cycle	NOUN
admet-496	278	30	.	.	PUNCT
admet-496	279	1	in	in	ADP
admet-496	279	2	:	:	PUNCT
admet-496	279	3	proc	proc	PROPN
admet-496	279	4	8th	8th	PROPN
admet-496	279	5	ncri	ncri	PROPN
admet-496	279	6	cancer	cancer	NOUN
admet-496	279	7	conference	conference	NOUN
admet-496	279	8	,	,	PUNCT
admet-496	279	9	4	4	NUM
admet-496	279	10	-	-	SYM
admet-496	279	11	7	7	NUM
admet-496	279	12	november	november	PROPN
admet-496	279	13	2012	2012	NUM
admet-496	279	14	,	,	PUNCT
admet-496	279	15	liverpool	liverpool	PROPN
admet-496	279	16	,	,	PUNCT
admet-496	279	17	uk	uk	PROPN
admet-496	279	18	.	.	PROPN
admet-496	279	19	abstract	abstract	PROPN
admet-496	279	20	lb79	lb79	PROPN
admet-496	279	21	.	.	PUNCT
admet-496	280	1	[	[	X
admet-496	280	2	35	35	NUM
admet-496	280	3	]	]	PUNCT
admet-496	280	4	a.	a.	NOUN
admet-496	280	5	avdreef	avdreef	PROPN
admet-496	280	6	.	.	PUNCT
admet-496	281	1	suggested	suggest	VERB
admet-496	281	2	improvements	improvement	NOUN
admet-496	281	3	for	for	ADP
admet-496	281	4	measurement	measurement	NOUN
admet-496	281	5	of	of	ADP
admet-496	281	6	equilibrium	equilibrium	NOUN
admet-496	281	7	solubility	solubility	NOUN
admet-496	281	8	-	-	PUNCT
admet-496	281	9	ph	ph	NOUN
admet-496	281	10	of	of	ADP
admet-496	281	11	ionizable	ionizable	ADJ
admet-496	281	12	drugs	drug	NOUN
admet-496	281	13	.	.	PUNCT
admet-496	282	1	admet	admet	PROPN
admet-496	282	2	&	&	CCONJ
admet-496	282	3	dmpk	dmpk	PROPN
admet-496	282	4	3	3	NUM
admet-496	282	5	(	(	PUNCT
admet-496	282	6	2015	2015	NUM
admet-496	282	7	)	)	PUNCT
admet-496	282	8	84	84	NUM
admet-496	282	9	-	-	SYM
admet-496	282	10	109	109	NUM
admet-496	282	11	.	.	PUNCT
admet-496	283	1	[	[	X
admet-496	283	2	36	36	NUM
admet-496	283	3	]	]	PUNCT
admet-496	283	4	k.	k.	PROPN
admet-496	283	5	valko	valko	PROPN
admet-496	283	6	,	,	PUNCT
admet-496	283	7	s.p	s.p	PROPN
admet-496	283	8	.	.	PROPN
admet-496	283	9	teague	teague	PROPN
admet-496	283	10	,	,	PUNCT
admet-496	283	11	c.	c.	PROPN
admet-496	283	12	pidgeon	pidgeon	PROPN
admet-496	283	13	.	.	PUNCT
admet-496	284	1	in	in	ADP
admet-496	284	2	vitro	vitro	X
admet-496	284	3	membrane	membrane	NOUN
admet-496	284	4	binding	bind	VERB
admet-496	284	5	and	and	CCONJ
admet-496	284	6	protein	protein	NOUN
admet-496	284	7	binding	bind	VERB
admet-496	284	8	(	(	PUNCT
admet-496	284	9	iam	iam	PROPN
admet-496	284	10	mb	mb	PROPN
admet-496	284	11	/	/	SYM
admet-496	284	12	pb	pb	X
admet-496	284	13	technology	technology	NOUN
admet-496	284	14	)	)	PUNCT
admet-496	284	15	to	to	PART
admet-496	284	16	estimate	estimate	VERB
admet-496	284	17	in	in	ADP
admet-496	284	18	vivo	vivo	ADJ
admet-496	284	19	distribution	distribution	NOUN
admet-496	284	20	:	:	PUNCT
admet-496	284	21	applications	application	NOUN
admet-496	284	22	in	in	ADP
admet-496	284	23	early	early	ADJ
admet-496	284	24	drug	drug	NOUN
admet-496	284	25	discovery	discovery	NOUN
admet-496	284	26	.	.	PUNCT
admet-496	285	1	admet	admet	PROPN
admet-496	285	2	&	&	CCONJ
admet-496	285	3	dmpk	dmpk	PROPN
admet-496	285	4	5	5	NUM
admet-496	285	5	(	(	PUNCT
admet-496	285	6	2017	2017	NUM
admet-496	285	7	)	)	PUNCT
admet-496	285	8	14	14	NUM
admet-496	285	9	-	-	SYM
admet-496	285	10	38	38	NUM
admet-496	285	11	.	.	PUNCT
admet-496	286	1	©	©	PROPN
admet-496	286	2	2018	2018	NUM
admet-496	286	3	by	by	ADP
admet-496	286	4	the	the	DET
admet-496	286	5	authors	author	NOUN
admet-496	286	6	;	;	PUNCT
admet-496	287	1	licensee	licensee	PROPN
admet-496	287	2	iapc	iapc	PROPN
admet-496	287	3	,	,	PUNCT
admet-496	287	4	zagreb	zagreb	PROPN
admet-496	287	5	,	,	PUNCT
admet-496	287	6	croatia	croatia	PROPN
admet-496	287	7	.	.	PUNCT
admet-496	288	1	this	this	DET
admet-496	288	2	article	article	NOUN
admet-496	288	3	is	be	AUX
admet-496	288	4	an	an	DET
admet-496	288	5	open	open	ADJ
admet-496	288	6	-	-	PUNCT
admet-496	288	7	access	access	NOUN
admet-496	288	8	article	article	NOUN
admet-496	288	9	distributed	distribute	VERB
admet-496	288	10	under	under	ADP
admet-496	288	11	the	the	DET
admet-496	288	12	terms	term	NOUN
admet-496	288	13	and	and	CCONJ
admet-496	288	14	conditions	condition	NOUN
admet-496	288	15	of	of	ADP
admet-496	288	16	the	the	DET
admet-496	288	17	creative	creative	ADJ
admet-496	288	18	commons	common	NOUN
admet-496	288	19	attribution	attribution	NOUN
admet-496	288	20	license	license	NOUN
admet-496	288	21	(	(	PUNCT
admet-496	288	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-496	288	23	)	)	PUNCT
admet-496	288	24	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN